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Glycosylation is the most widely form of protein post-translational modification and is 
involved in many physiological and pathological processes. Specifically, certain patterns 
of glycosylation are associated with determined stages of cell differentiation and can 
modulate processes like cell-signaling and migration and host-pathogen interactions. As 
such, glycosylation plays a crucial role in the modulation of several immune events. 
However, how glycans execute this immune-modulation and, therefore, influence 
immunity is still poorly unknown. Specifically, some terminal sialic acid-modified 
determinants are known to be involved in several physiological immune processes, 
including leukocyte trafficking into sites of inflammation and cell immune activation. 
Therefore, in this work, we sought to investigate more deeply how the expression of these 
glycosidic structures affects events form both innate and adaptive immune responses. 
To this end, we divided our work into three main parts: 
1) Immunity critically depends on the ability of sentinel circulating cells to infiltrate 
injured sites, of which leukocyte binding to endothelial E-selectin is the critical 
first step. Thus, we first analyzed the structure and function of the E-selectin 
ligands expressed on native human peripheral blood mononuclear cells (PBMCs), 
providing novel insights into the molecular effectors governing adhesion of 
circulating monocytes, and of circulating CD4+T, CD8+T and B cells, to vascular 
endothelium under hemodynamic shear conditions. Strikingly, monocytes show a 
higher ability to tether and roll on endothelial cells than lymphocyte subsets. This 
is due to the fact that human circulating monocytes uniformly display a wide 
repertoire of E-selectin binding glycoproteins, namely the E-selectin-binding 
glycoforms of CD43 (CD43E) and CD44 (HCELL), in addition to the previously 
described E-selectin-binding glycoform of PSGL-1 (CLA). In addition, we also 
observed a differential ability of the different lymphocyte subsets to bind to E-
selectin under hemodynamic shear stress conditions, and these differences were 
highly correlated with their individual expression of E-selectin binding 





CD8+T and B cells show little to no E-selectin reactivity. CD4+T cell potent E-
selectin rolling activity is conferred by HCELL expression, in addition to the 
previously reported E-selectin-binding glycoproteins CD43E and CLA. CD8+T 
cells display no HCELL and low amounts of CLA and CD43E, whereas B cells 
lack E-selectin ligand expression. Moreover, enforced exofucosylation of cell 
surface of these cells noticeably increases expression of functional E-selectin 
ligands among all leukocytes subsets, with cell type-dependent specificity in the 
protein scaffolds that are modified. Taken together, these findings redefine our 
understanding of the molecular mechanisms governing the trafficking patterns of 
PBMCs that are relevant in the context of acute or chronic inflammatory 
conditions. 
 
2) The ability of circulating dendritic cells (DCs) to extravasate at inflammatory 
sites is critical to the success of DC-based therapies. Therefore, we assessed the 
structure and function of adhesion molecules mediating the transendothelial 
migration (TEM) of human monocyte derived-DCs (mo-DCs), obtained either by 
CD14 positive immune-magnetic selection (CD14-S) or by plastic adherence of 
blood monocytes (PA-S). We report for the first time that the E-selectin binding 
glycoforms of PSGL-1, CD43 and CD44 are all expressed on CD14-S mo-DCs, in 
contrast to PA-S mo-DCs that express only CLA. Importantly, CD44 engagement 
on CD14-S mo-DCs, but not on PA-S mo-DCs, triggers VLA-4-dependent 
adhesiveness and programs TEM in absence of chemokine gradient.  We also 
analyzed the E-selectin ligands expressed on mo-DCs generated from umbilical 
cord blood (UCB) monocytes, and unexpectedly, UCB mo-DCs do not express 
any glycoprotein with E-selectin reactivity. Furthermore, exoglycosylation of 
human mo-DCs using an α(1,3)-fucosyltransferase significantly increases 
expression of HCELL, and therefore  exofucosylated mo-DCs exhibit an 
augmented ability to bind to E-selectin under hemodynamic shear stress 
conditions.  These findings highlight a role for HCELL engagement in priming 
TEM of CD14-S mo-DCs, and suggest that strategies to enforce HCELL 






3) Another obstacle to achieve the promising success of DC-based vaccines is the 
establishment of efficient approaches that could successfully enhance maturation 
and cross-presentation ability of DCs. Therefore, we investigated an alternative 
approach that can overcome this problem. Through removal of sialic acid content 
from DC cell surface we are able to elicit maturation of both human and mouse 
DCs. Notably, desialylated human and murine DCs showed enhanced ability to 
induce autologous T cell to proliferate, to secrete Th1 cytokines and to kill tumor 
cells. Moreover, desialylated DCs display enhanced cross-presentation of tumor 
antigens to cytotoxic CD8+ T cells. Collectively, this study offers key insight to 
optimize the ability of DCs to boost anti-tumor immune responses, and indicates 
that the treatment with an exogenous sialidase is a powerful new technology to 
improve the efficacy and applicability of DC-based vaccines.   
Overall, our findings show how glycosylation and its manipulation can modulate 
immunity. Concretely, through an exofucosylation reaction we are able to greatly 
augment the ability of leukocytes to extravasate into injured tissues, while removal of 
sialic acid moieties from cell surface of DCs, significantly potentiate their ability to 






















O processo de glicosilação é a modificação pós-traducional de proteínas mais comum e 
está envolvido em vários processos fisiológicos e patológicos. Especificamente, certos 
perfis glicosídeos estão correlacionados a estados específicos de diferenciação celular, e 
podem modular  vários eventos celulares, como sinalização celular, migração celular e 
interações hospedeiro-patogénio. Assim sendo, a glicosilação desempenha um papel 
crucial na modulação de vários processos imunológicos. No entanto, permanece por 
esclarecer como as estruturas glicosídicas influenciam a imunidade. Especificamente, 
algumas estruturas glicosídicas terminais que estão modificadas pela ligação de ácido 
siálico desempenham um papel importante em várias funções do sistema imune, 
nomeadamente migração leucocitária em contexto de inflamação e ativação de células 
imunes. 
Como tal, este trabalho teve como objectivo investigar como a expressão de certos 
glicanos influencia componentes importantes da resposta imune inata e adaptativa.  
Este trabalho está dividido em três componentes principais: 
1) A imunidade está amplamente dependente da habilidade das células circulantes 
migrarem para os tecidos inflamados,  sendo que a ligação de leucócitos à E-
selectina endotelial é o primeiro passo. Assim, nós analisámos a estrutura e 
função dos ligandos de E-selectina que são expressos pelas  células humanas 
mononucleares de sangue periférico (PBMCs), fornecendo novos conhecimentos 
para a compreensão dos intervenientes moleculares que mediam a ligação dos 
monócitos, células CD4+ e CD8+T e células B ao endotélio vascular. 
Surpreendentemente, os monócitos apresentaram maior capacidade de ligação à 
E-selectina comparativamente aos linfócitos. Esta observação pode ser explicada 
pelo facto de os monócitos humanos expressarem, uniformemente, um vasto 
reportório de glicoproteínas que exibem afinidade de ligação à E-selectina, 
nomeadamente: as glicoformas do CD43 (CD43E) e do CD44 (HCELL),  em 





Consistentemente, a diferente capacidade  que as diversas populações linfocitárias 
apresentam de se ligar à E-selectina, está integralmente relacionada com a sua 
expressão de glicoproteínas com afinidade de ligação à E-selectina. Enquanto  que 
as células CD4+T apresentam uma elevada reatividade à E-selectina, as células 
CD8+T e B demonstram pouca ou nenhuma capacidade de ligação à E-selectina. 
Esta atividade de ligação à E-selectina das células CD4+T é conferida pela 
expressão de HCELL, em adição às já previamente reportadas CLA e CD43E. As 
células CD8+ T não expressam HCELL e apenas expressam pequenas quantidades 
de CLA e CD43E, enquanto que as células B não expressam ligandos de E-
selectina. Mais, a exofucosilação da superfície destas células, levou ao dramático 
aumento da expressão dos ligandos de E-selectina em todos as populações 
leucocitárias,  verificando-se que a criação de certos ligandos de E-selectina está 
dependente do tipo de célula, após fucosilação. Colectivamente, estes resultados 
redefinem o nosso conhecimento acerca dos mecanismos moleculares que 
governam o tráfico das células mononucleares de sangue periférico em contexto 
de inflamação. 
 
2) A habilidade das células dendríticas (DCs) para extravasarem em locais de 
inflamação é crucial para o sucesso da terapia com DCs. Assim, analisámos a 
estrutura e função das moléculas de adesão que mediam a migração 
transendotelial (TEM) das DCs. Para isso, foram usadas DCs geradas a partir da 
diferenciação de monócitos (mo-DCS), obtidos quer pelo métodos de separação 
imuno-magnética de células CD14+ (CD14-S) ou por isolamento por aderência ao 
plástico (PA-S). Os resultados obtidos indicam que as glicoformas de ligação à E-
selectina de PSGL-1, CD43 e CD44 são expressas pelas CD14-S mo-DCs, 
enquanto  que as PA-S mo-DCs expressam apenas CLA. É importante notar que a 
ligação do CD44 nas mo-DCs, mas não nas PA-S mo-DCs, desencadeia a 
ativação e consequente adesão da VLA-4 ao endotélio na ausência de um 
gradiente de quimiocinas. Procedeu-se também à análise dos ligandos E-selectina 
expressos em mo-DCs geradas a partir de monócitos do sangue do cordão 





glicoproteína com reatividade à E-selectina. Além disso, a exofucosilação das mo-
DCs humanas utilizando uma α(1,3)-fucosiltransferase aumenta 
significativamente a expressão de HCELL e, portanto, estas células apresentam 
uma capacidade aumentada para se ligarem à E-selectina em condições de fluxo 
hemodinâmico. Estes resultados destacam o papel do HCELL no 
desencadeamento do TEM das CD14-S mo-DCs e sugerem que estratégias para 
potenciar a expressão de HCELL poderão impulsionar o recrutamento de mo-DCs 
para locais de inflamação. 
 
3) Outro obstáculo para alcançar o sucesso promissor de vacinas baseadas em DCs é 
o estabelecimento de abordagens eficientes que poderão melhorar o estado de 
maturação e apresentação antigénica das DCs. Por conseguinte, foram 
investigadas abordagens alternativas que podem superar este obstáculo. Através 
da remoção de ácido siálico de superfície celular das DCs, conseguiu-se induzir a 
maturação de DC humanas e de ratinhos. Notavelmente, tanto as DCs humanas 
como as de ratinho, ao serem  desialiladas mostraram uma capacidade aumentada 
para induzir a proliferação de células T, para secretar citocinas Th1 e para induzir 
a morte específica de células tumorais. Em adição, as DCs desialiladas 
apresentam uma maior capacidade de apresentação cruzada de antigénios 
tumorais  às células T citotóxicas. Colectivamente, o presente estudo oferece uma 
visão chave para optimizar a capacidade das DCs em induzir respostas imunitárias 
anti-tumorais, e indica que o tratamento com sialidase é uma nova tecnologia para 
melhorar a eficácia e aplicabilidade das vacinas baseadas em DCs. 
Coletivamente, os nossos resultados demostram como a glicosilação e a sua manipulação 
podem modular a imunidade. Concretamente, através de uma reação de exofucosilação 
conseguimos aumentar fortemente a capacidade de os leucócitos extravasarem  para os 
tecidos afectados, enquanto que a remoção dos níveis de ácido siálico da superfície 
celular das DCs, induz potentes respostas anti-tumorais mediadas por células T 
citotóxicas.	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1.1 The Immune System- an overview 
The functional integrity of our body and its protection from environmental agents are 
mediated by the immune system. The immune system can be defined as a set of integrated 
and complex mechanisms to protect our body against invading pathogens or foreign 
material.1 This is done by the constant recognition of self from non-self determinants, which 
allows an effective immunity to any harmful aggressor but prevents destructive immune 
responses to our own body.2,3 The immune system can be divided into two inter-related and 
functionally defined components: the innate immune response and the adaptive or 
acquired immune response.1 
 
1.1.1 Innate Immune Response 
The innate immune response corresponds to the first line of host defense against infection, 
i.e. comprises physical and physiological barriers, innate immune cells and soluble factors 
that are present and ready to mobilize and combat invading microorganisms. These protection 
mechanisms occur immediately after infection, are not specific to the invading agents, and do 
not present immunological memory.1,2   
A variety of immune cells are responsible for cellular innate immunity. These include the 
cells that are capable of phagocytosis, a process by which ingestion of particulate material 
occurs – neutrophils and mononuclear phagocytes (monocytes, macrophages and dendritic 
cells) –, the cells that are capable of cytotoxicity – Natural killer (NK) cells and eosinophils – 
and the cells mostly dedicated to immune-modulation – basophils and mast cells.2,4,5  
The cellular components of the innate immune system recognize a limited number of 
structures that are characteristic of microbial agents and that are not present in mammal cells. 
These structures are referred to as "Pathogen-associated molecular patterns" (PAMPs). These 
highly conserved structures are recognized and bind to receptors present in the innate immune 
cells, designated as "pattern recognition receptors" (PRR), which include the Toll-like 
receptors (TLRs). These receptors can transduce intracellular signals that will activate anti-
microbial and pro-inflammatory mechanisms in innate immune cells and can also accelerate 




The first step in the phagocytosis process is the recognition of the PAMPs by the PRRs 
expressed on phagocytes, followed by internalization of the pathogens into phagosomes and 
fusion of phagosomes with lysosomes, to form a phagolysosome. Finally, the destruction of 
the external agents is mediated within the phagolysosome by hydrolytic enzymes, with nitric 
oxide and reactive oxygen species (ROS) production. The phagocyte cells include 
monocytes, macrophages, dendritic cells (DCs) and neutrophils.4,10-12 
Monocytes constitute a heterogeneous peripheral blood leukocyte population, comprising 
approximately 5-10% of total peripheral blood leukocytes. These cells are originated from a 
common myeloid-erythroid progenitor (CMP) in the bone marrow and subsequently released 
into the peripheral blood. In case of inflammation, monocytes leave the blood stream and 
migrate to peripheral tissues, where depending on the local chemical environment can further 
differentiate into DCs or macrophages.13,14 Monocytes have thus an essential role in anti-
microbial immunity, due to their phagocytic capacity and ability to differentiate into 
macrophages or DCs, which are professional antigen presenting cells (APCs). Nevertheless, 
monocyte recruitment into tissue is also associated with several pathological inflammatory 
processes, including atherosclerosis.15 
Macrophages and DCs exist virtually in every tissue throughout the body, where they 
survey for potential signs of infection/danger.16 After pathogen phagocytosis, the foreign 
antigens are broken down into smaller fragments and then presented at the cell surface of the 
phagocytes via the Major Histocompatibility Complex (MHC) to lymphocytes.12 Even 
though both cells are able to present antigens, macrophages are less efficient compared to 
DCs. DCs are the most potent APCs. Moreover, after engulfing and processing antigens, DCs 
migrate to the lymphoid organs where they prime T cells.17,18 In contrast, macrophages do not 
leave from the site of injury and their major function is to kill the pathogen, via lysosomal 
proteolitic activity.13,19 In addition to the destructive capacity of invading agents, 
macrophages play other roles in innate immunity through the production of cytokines, in 
particular tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1), which promotes 
inflammation. Macrophages also influence the adaptive immunity via the secretion of IL-12 
that affects polarization of naïve T cells.1,20 
A more accurate and complete description of DC biology and functionality is described in: 




Neutrophils are the first cells to arrive to the inflammation/infection sites and are the most 
abundant white blood cells in the peripheral blood. These cells differentiate in the bone 
marrow from CMP and then are released into bloodstream, where they circulate before 
migrate into the tissue spaces.   Similar to macrophages, neutrophils are involved in 
immediate removal of pathogens via intracellular death mechanisms and also by the 
formation of neutrophil extracellular traps.4,9 Neutrophil granules contain a range of lethal 
substances that destroy or inhibit expansion of several pathogens, including toxic free oxygen 
radicals, chloride derivates, and a wide range of hydrolytic enzymes.21  
NK cells can be cytotoxic against autologous cells when infected by viruses or intracellular 
bacteria, or when they become malignant. These cells arise from a common lymphoid 
progenitor (CLP) within the bone marrow and account for about 15% of total lymphocyte 
population.1 The cytotoxic activity of NK is mediated by cytotoxic proteins contained in 
granules, perforin (a pore-forming protein) and granzyme that when released induce apoptosis 
of target cells.22,23 In addition, NK cells secrete several cytokines, including IL-2, interferon-γ 
(IFN-γ), TNF-β and TNF-α, which have an adjuvant role in NK cytotoxic action.1  The 
eosinophils and basophils develop from a bone marrow CMP and are the rarest of the white 
blood cells in peripheral bloodstream. These cells are mainly involved in allergic and 
inflammatory reactions. Eosinophils are the principal innate immune cells involved in 
parasitic infections, secreting chemical molecules that kill these microorganisms.1 Basophils 
are the cells responsible for secreting histamine, a chemical substance that elicits vasodilation 
and increases vascular permeability to the sites of injury/inflammation.1,24  
The innate and adaptive immunity do not act fully independent of each other. They cooperate 
with each other to produce a more effective immunity. The innate immune response 
stimulates the establishment of the adaptive immunity and influences its nature. Thus, when 
inflammation is not sufficient to remove the invading agent, its perpetuity increases the 
number of APCs in the lymphoid tissue, inducing the activation and migration of T cells, 
while certain complement proteins stimulate the activation of B lymphocytes, developing, 





Figure 1- Integration of innate and adaptive immune response. The body has an integrated and complex 
defense mechanism in which several cells and tissues act in coordination to protect the host. When the innate 
effectors are not able to circumvent the infection/ injury, an appropriate acquired response is mounted, leading to 
a highly effective recognition and destruction of pathogens. In Cellular and Molecular Immunology. 6th edition. 
Abbas k., et al., Philadelphia. Saunders/Elsevier.2010  
 
1.1.2 Adaptive Immune response 
The adaptive immunity is able to specifically recognize and eliminate microorganisms and 
foreign molecules. Unlike the innate immune response, the adaptive response is a delayed 
response and presents antigen specificity, clonal proliferation of effector cells, diversity and 
immunological memory. There are two types of adaptive immune response: cell-mediated 
immunity, performed by T lymphocytes, and humoral immunity, mediated by antibodies 
produced by B lymphocytes.1,25  
 
1.1.2.1 Cellular adaptive immunity 
T cells arise from a CLP within the bone marrow, but unlike B cells, their maturation process 
proceeds within the thymus. Inside the thymus, T cell-precursors (also called thymocytes) 
undergo a set of positive and negative selection stages and as they advance throughout their 
development, they become mature T cells. Typically, mature T cells are tolerant to self 
antigens, single positive for either CD8 or CD4 glycoproteins and express a functional T-cell 
Receptor (TCR) that recognizes a specific antigen bound to the host MHC-Class I (CD8+T 
cells) or MHC-class II (CD4+T cells) molecules. Finally, mature lymphocytes egress the 




organs, where they search for their cognate antigen bearing-APCs. After antigen encounter, T 
cells become activated and undergo clonal expansion and further differentiation into effector 
T cells that migrate to the sites of inflammation or infection.1,26,27  
Mature T cells can be typically categorized into two main subsets, that differ in their cell 
surface CD4 or CD8 expression and immunological functions: helper and cytotoxic T cells, 
respectively. 
1.1.2.1.1 Helper T cells  
Helper T cells (Th), also called CD4+ T cells, play a crucial role in immune system by 
assisting other leukocytes in their immunological roles (see Figure 2). Their main functions 
include: help B cells to differentiate into antibody-secreting cells, elicit activation, 
proliferation and maintenance of CD8+ T cell response, regulate macrophages function and 
regulate/suppress immune responses in cases of auto-immunity or exacerbated immune 
reactions. These cells become activated after recognizing extracellular antigens that, 
following lysossomal-degradation, are bound to MHC-class II molecules and exposed on cell 
surface of APCs. Subsequently to activation, CD4+ T cells are further stimulated to 
differentiate into effector or regulatory CD4+ T cells. Depending on the type of cytokines 
secreted, effector CD4+ T cells can be additionally subdivided into several subtypes, including 
Th1, Th2 and Th17.27,28 
 
Figure 2- Role of CD4+ T cells in immunity. CD4+ T cells recognize, via their T cell receptors, their cognate 
antigens bound to MHC-Class II on APCs. Follow antigen encounter, CD4+ T cells become activated, proliferate 
and depending on local cytokine milieu differentiate into different subsets of effector T cells. CD4+ T cells 
orchestrate several immune responses, including help B cells to produce antibodies, enhance macrophage anti-
microbicidal activity, granulocytes recruitment and activation of CD8+ T cytotoxic activity. In Cellular and 





Th1 cells are essential in promoting cellular immunity against intracellular pathogens, via 
activation of CD8+ T cell response and phagocytes stimulation. Th1 CD4+ T cells secrete high 
levels of IFN-γ, TNF-α and IL-2, which are pro-inflammatory cytokines. IL-12 secretion by 
activated DCs plays a crucial role in the naïve CD4+ T cells polarization into Th1.27-30    
Th2 cells are important in promoting humoral immune response, via production of 
antibodies; they stimulate the activation and accumulation of eosinophilis, contributing thus 
to host defense against helminthes, but are also involved in acute and chronic inflammation in 
allergic reactions. These cells produce several anti-inflammatory cytokines, including IL-4, 
IL-5, IL-6, IL-10 and IL-13, which tend to inhibit Th1 response. The major cytokines 
responsible for naïve CD4+ T cells polarization into Th2 are IL-4 and IL-10.27-30 
Th17 cells are critical to combat extracellular bacteria and fungi, given their ability to prompt 
recruitment and activation of neutrophils, via the induction of IL-8 production. Th17 cells 
secrete large amounts of IL-17, which has been correlated with several autoimmune and 
inflammatory diseases. Secretion of IL-23 and IL-1β has been involved in polarization of 
CD4+ T into Th17.27-31 
1.1.2.1.2 Cytotoxic T cells 
Cytotoxic T cells (Tc), also known as CD8+ T cells, provide defense against intracellular 
pathogens, including virus and some intracellular bacteria, and tumor cells. In contrast to 
CD4+ T cells, CD8+ T cells execute their immunological role by directly killing the infected 
or cancer cells, as shown in Figure 3. Within the lymph nodes, CD8+ T cells recognize, 
typically, intracellular antigens that are processed and presented on the cell surface of 
infected or tumor cells via MHC-class I. After antigen encounter in lymphoid tissues, CD8+ T 
cells undergo through clonal expansion and differentiate into memory or effector CD8+T 
cells. Effector CD8+ T cells migrate then to sites of infection/inflammation, where they exert 
their cytotoxic role.1,25  
 
Figure 3- Effector cytotoxic T cell functions. When recognize their cognate antigen-MHC-class I complexes 
on the target cells, CD8+ T cells become activated, proliferate and differentiate into effector T cells, which are 





At sites of injury and when exposed to their target cells, effector CD8+ T cells can employ 
different mechanisms to induce apoptosis of the target cells, as shown in Figure 4. Firstly, 
effector CD8+ T cells are able to release perforin and serine proteases, including granzyme. 
Perforin induces transmembrane channels on plasma membrane of the target cells, allowing 
proteases to enter into the cytosol and, thereby, trigger caspase cascade, leading subsequently 
to programmed cell death of the target cell.  A second mechanism to induce target cell 
apoptosis is through the engagement of the cell death surface receptor Fas, expressed on 
target cells, by Fas ligand (FasL) binding, expressed on cell surface of effector CD8+T cells. 
Activation of Fas-FasL pathway triggers caspase cascade activation that leads to target cell 
apoptosis.1,32 
 
Figure 4- CD8+ T cells exert their cytotoxic activity via two apoptosis-inducing mechanisms. A) When 
cytotoxic CD8+ T cells bind to the target cells, they can release perforin molecules, which create transmembrane 
pores on the infected cells.  This allows the entrance of granzyme into the cytosol, inducing the activation of the 
caspase cascade and culminating in target cell apoptosis. B) Apoptotic cell death of target cells can also be 
induced via engagement of cell death receptor Fas by Fas ligand binding, expressed by effector cytotoxic T 
cells. In Molecular Biology of the cell. 4th edition. Alberts B, et al. New York. Garland Science.2002 
 
Importantly and identical to CD4+ T cells, effector CD8+ T cells are also prompted to 
differentiate into different subsets of effector cells, depending on the type of cytokines they 
express: Tc1 or Tc2. 
Similar to Th1, Tc1 cells are also important in cell-mediated immunity against intracellular 
pathogens and are great producers of IFN-γ. Like Th1 cells, secretion of IL-12 by DCs 




Tc2 cells are mainly committed to protect the host against helminthes and produce mostly IL-
3, IL-5 and IL-13. These cells do not secrete IFN-γ and their cytotoxic activity is significant 
reduced compared to Tc1.30 
Importantly and in addition to endogenous antigens, exogenous antigens can also be 
presented to CD8+ T cells by APCs (mainly DCs) via MHC-Class I in a process called cross-
presentation. This is how our immune system is able to induce CD8+ T cell cytotoxic 
responses against solid tumors or virus that do not infect APCs, or whose antigens are not 
expressed by the target cells due to defects in the antigen presenting machinery.33,34 
 
1.1.2.2 Humoral Immune Response 
B cells differentiate from a CLP and when developed, immature B cells egress the bone 
marrow and migrate via bloodstream to spleen where they differentiate into mature naïve B 
cells. Those naïve mature B cells will then continuously recirculate between secondary 
lymphoid organs (lymph nodes, spleen and mucosa-associated lymphoid tissues (MALT)), 
until they recognize an antigen. At this point, each naïve B cell must express a fully 
functional cell surface receptor (known as B cell Receptor (BCR)) that will bind to one 
specific antigen. Following the initial contact with its cognate antigen, naïve mature B cell 
will initiate clonal expansion and further differentiation into memory B cells or pre-effector B 
cells (plasmablasts), which, thereafter, will differentiate into antibody-secreting plasma B 
cells within the bone marrow or MALT. These effector plasma B cells produce and release 
large amounts of antibodies in the blood, which will bind to their respective antigens and 
promote the destruction of the pathogens via several immune-related mechanisms (Figure 5). 
The antibodies and the membrane-bound BCR will have the same antigen binding sites, i.e. 
the antibodies will have the same specificity to the antigen that caused initial B cell clonal 
expansion. In case of secondary encounter with the same antigen, peripheral blood circulating 
memory B cells are primed to generate a faster and more efficient antibody-mediated 
response.1,35-38  
Antibodies provide immunity in four major ways: neutralization, opsonization, activation of 
the complement cascade and cell-induced apoptosis. Neutralizing antibodies bind to specific 
surface receptors on pathogens, preventing these from entering host cells. The opsonization 




recognized by phagocytes, eliciting pathogen phagocytosis.  Phagocytes express antibody 
receptors, known as Fc receptors, which recognize and bind to the constant region (Fc) of the 
antibody bound to the pathogen, thus facilitating the phagocytosis process. In alternative, 
antibodies bound to the pathogen can activate the complement system pathway, which can 
either result in enhanced pathogen phagocytosis or lead to direct microbe cytolysis by the 
complement cascade components (C7, C8, and C9). Finally, the innate immune cells that 
express Fc receptors and that exert immediate cytotoxic functions (e.g., NK cells or 
eosinophils) can bind to the antibody-pathogen complexes and target their apoptotic activity 
to infected cells, tumor cells, or pathogens.1,25,39 
 
Figure 5- The humoral immune response. After encounter with its cognate antigen, the activated B cell begins 
to differentiate into plasma B cells and release large amounts of antibodies into the blood. In Cellular and 
Molecular Immunology. 6th edition. Abbas k., et al., Philadelphia. Saunders/Elsevier.2010   
 
In addition to being antibody-secreting cells, B cells play also a critical role in regulating 
other immune mechanisms and are important links between innate and acquired immunity. 
After BCR engagement by antigen binding, B cells are stimulated to capture the antigen and 
to present it via MHC-II molecules, after antigenic degradation into smaller peptides. 
Therefore, B cells can also function as professional antigen-presenting cells, presenting the 
antigenic-peptides to CD4+ T cells in a process called T-B cells cooperation.40  Similarly to 
other immune cells, activated B cells (via BCR engagement) can produce cytokines, such as 
the pro-inflammatory cytokines IL-6 and TNF-α, playing an important role in T cell 






1.2 DC-based Immunotherapy 
The concept of anti-tumor immune surveillance was first introduced by Thomas and Burnett, 
proposing that the immune system is able to identify tumor cells as "foreign” with regard to 
normal cells, and thereby trigger the effector mechanisms capable of eliminate tumor 
cells.42,43 However, there are many cases where the immune system does not develop an 
effective response against the tumor cells.44 Therefore, new strategies to boost, reinforce, and 
maintain long lasting anti-cancer immune responses are needed. DCs constitute one of the 
effector components of the immune system involved in the elimination of tumor cells. These 
cells are the antigen-presenting cells par excellence, showing a unique capacity to initiate 
immune response. DCs play a key role in the activation of T and B cells, as well as in the 
activation of NK cells and consequently in the secretion of cytokines by these effectors.1,45,46 
Moreover, DCs have the single ability to cross-present exogenous antigens to CD8+ T cells 
via MHC-Class I. This process is crucial for the generation of cytotoxic CD8+ T mediated 
immune response, and thereby for the generation of anti-tumor immune responses.47 Due to 
their crucial role in boosting innate and adaptive immune responses, immunization of cancer 
patients with autologous tumor-antigen-loaded DCs has been explored in order to generate 
more effective and long-lasting anti-cancer immune responses. 48  
 
1.2.1 Biology of dendritic cells 
1.2.1.1 Origin and DC subsets  
DCs are a rare leukocyte population that displays high structural heterogeneity and 
functionality. Cellular origin, anatomical location, maturation state and T cell activation 
ability are some of the factors that contribute to DC heterogeneity.49 Human DC precursors 
arise from a bone marrow CMP and, classically, are categorized into two major cell lineages: 
myeloid/conventional (CD11c+/CD123-) and lymphoid/plasmacytoid (CD11c-/CD123+).  
In the blood, human myeloid DCs (mDCs) can be further divided into CD141+ (BDCA-3) or 
CD1c+ (BDCA-1) DCs and CD14+ or CD16+ monocyte subsets, as shown in Figure 6. 
CD141+ DCs are specialized in cross-presenting antigens, via MHC class-I molecules, to 
CD8+ T cells, thereby, eliciting CD8+ T cell-mediated immune responses. CD141+ DCs have 




DCs secrete high amounts of IL-12, having an active role in the induction and expansion of 
IFN-γ producing CD4+ and CD8+ T cells, and improving anti-bacterial and antitumor immune 
responses.48,50-54  
In non-lymphoid tissues, mDCs are typically distinguished by cutaneous lymphocyte antigen 
(CLA) and myeloid makers expression and by compartment localization. These include the 
CD141+ DCs (CLA+, known as Langerhans cells in skin tissue) and interstitial DCs (CLA-, 
known as dermal DCs in skin tissue).  The interstitial DCs can be further divided into 
CD1a+DCs and CD14+DCs. Similar to the blood CD141+ DCs, non-lymphoid CD141+ DCs 
are highly efficient in cross-presenting exogenous antigens to CD8+ T cells and priming 
cytotoxic effector CD8+ T cell differentiation. Human interstitial CD14+ DCs are unique in 
their capacity to induce differentiation of naïve B cells into IgM plasma cells, thus being 
crucial for the development of humoral immune responses. On the other hand, interstitial 
CD1a+DCs strongly prompt both CD4+ and CD8+ T cell proliferation, and favours CD4+ T 
cell polarization towards Th2 phenotype.53-57 
pDCs are described as the natural IFN-producing cells. This subset of DCs is characterized by 
CD123, BDCA-2 (CD303) and BDCA-4 expression and is found mostly in blood and 
lymphoid organs. pDCs also seem to play a dual role in anti-tumoral immunity. While some 
reports indicate that pDCs prime specific cytotoxic CD8+ T and CD4+ T polarization into Th1, 
the opposite tolerogenic role has also been observed, predominantly related with the 






Figure 6- Subsets of human DCs. Classically, DCs are classified into two major cell lineages: myeloid (mDCs) 
or plasmacytoid (pDCs) DCs. pDCs are found mostly in the blood and lymphoid tissues, whereas mDCs 
(CD141+ and CD1c/a+ DCs) are found virtually in every tissue. Adapted from Human tissues contain CD141hi 
cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. 
Haniffa M et al., Immunity. 2012  
 
1.2.1.2 Maturation 
DCs are potentially in all tissues where they capture antigens, migrate to secondary lymphoid 
organs and become competent to activate naïve T cells. Notably, a particular characteristic of 
DCs is to comprise a process of differentiation depending on their local chemical milieu. In 
brief, DC precursors circulate in peripheral blood and subsequently penetrate into peripheral 
tissues, where they originate immature DCs. In their immature state, DCs are characterized by 
a high phagocytic and endocytic capacity and a low expression of MHC and co-stimulatory 
molecules. Yet, after antigen recognition, capture and processing, immature DCs differentiate 
into mature DCs, characterized by a reduced endocytic capacity, high expression of antigenic 
peptide-MHC complexes and co-stimulatory molecules (CD40, CD80 and CD86), secretion 
of pro-inflammatory cytokines, such as IL-12, and an increased expression of the C-C 
chemokine receptor type 7 (CCR7) molecule (Figure 7). After differentiation, mature DCs 













Figure 7- Schematic representation of a mature DC. After antigen phagocytosis, DCs increase expression of 
maturation markers, such as antigen-MHC complexes and the co-stimulatory molecules CD40, CD80 and 
CD86. Increased secretion of the Th1-inducing cytokine IL-12 and expression of CCR7, critical for DC 
migration to lymph nodes, are also features of mature DCs. Adapted from Directing dendritic cell 
immunotherapy towards successful cancer treatment. Sabado RL and Bhardwaj N.  Immunotherapy. 2010. 
 
1.2.1.3 DCs and T cell activation 
Upon arrival to the lymph nodes, mature DCs initiate the contacts with T cells via three 
cooperative signals. Firstly, through their MHC molecules, DCs bind to TCR expressed on 
cell surface of naïve T cells. The second signal comes from the interaction of B7 co-
stimulatory molecules, such as CD80 and CD86, on the surface of DCs with the CD28 co-
stimulatory receptor on the T cell surface.48,59 Finally, the third signal results from cytokine 
secretion by DCs and will define which type of Th or Tc response will occur. As mentioned 
previously, secretion of IL-12 is crucial for the induction of Th1 and Tc1 responses.60 On the 
other hand, IL-4 and IL-10 are implicated in Th2 and Tc2 immune responses, whereas IL-23 
and IL-1β promotes differentiation of T cells into Th17. Secretion of IL-10 by activated DCs 
is also highly correlated with tolerance inducement via polarization of naïve Th cells into 
Tregs.28,61-63 
 
1.2.2 DCs in tumor microenvironment  
Many studies have demonstrated that a defect in DC functionality is a key factor that may 
lead to immune escape of tumors. The failure of DC activity is often caused by factors 
secreted by tumors that possess immunosuppressive activity, thus affecting the process of 
maturation and differentiation of DCs.64 IL-6 and macrophage colony stimulating factor (M-
GSF) secretion by tumors inhibits differentiation of monocytes into mature DCs; IL-10 




of IL-12 by DCs and therefore, blocks the maturation of DCs.65,66 DC maturation status is, 
therefore, a central point in anti-tumor immune response initiation. In their immature state, 
DCs exhibit a low expression of MHC and co-stimulatory molecules and consequently, are 
not able to stimulate the activation and differentiation of T cells.49,67 Moreover, immature 
DCs can internalize apoptotic tumor cells and promote activation of Tregs, leading to an 
immunological tolerance and, consequently, to the failure of an effective anti-tumor 
response.48,49 
Unlike the immature DCs, mature DCs play a crucial role in the initiation of the innate and 
adaptive anti-tumor immune responses. Hence, the efficiency and the ultimate success of anti-
tumor immunity are dependent on proper maturation and activation of DCs.  
 
1.2.3 DC-based vaccination procedures 
1.2.3.1 DC precursor isolation  
The development of cytokine-driven methods for expanding and differentiating DCs ex vivo 
has been explored in order to optimized DC-based immunotherapy. These methods include 
DC in vitro differentiation from monocytes, from CD34+ hematopoietic stem cell progenitors 
or in vivo expansion of blood DCs.  
The most common methodology used involves the ex vivo generation of DC from peripheral 
blood monocytes (CD14+ cells), which are isolated from the patient. This method creates 
large amounts of immature monocyte-derived-DCs (mo-DCs) that are functionally similar to 
blood immature DCs. Moreover, in contrast to CD34+ derived DCs, there is no need for 
granulocyte colony-stimulating-factor (G-CSF) or FMS-like tyrosine kinase 3 ligand (Flt3L) 
administration to the patient, in order to mobilized CD34+ cells.  First, peripheral blood 
mononuclear cells (PBMCs) are obtained from leukapheresis procedure and then monocytes 
are isolated, typically, either by CD14+ positive immune-magnetic selection (CD14-S) or by 
plastic adherence selection (PA-S). Monocytes are then cultured for 5-7 days in the presence 
of IL-4 and granulocyte macrophage colony-stimulating factor (GM-CSF) to differentiate 
into immature DCs.48,68-70  
Although both CD14-S and PA-S are two well-established and efficient enrichment-




functional differences between each other.71 CD14-S is a faster method and originates higher 
yields of pure CD14+ cell population.71 On the other hand, Elkord and co-workers72 reported 
that mo-DCs generated by the PA-S method exhibit a higher IL-12, IL-10 and TNF-
α secretion and, consequently, a higher ability to induce cytotoxic Tc1 and Th1 subsets, than 
CD14-S mo-DCs. While both CD14-S and PA-S methods have been employed in several 
DC-based vaccine clinical trials, administered mo-DCs generated by PA-S method show a 
poor capacity to transmigrate to the target tissues.73,74  
1.2.3.2 Maturation of the ex vivo generated DCs 
The ex vivo generated immature DCs are further stimulated to become mature, by culturing 
for an additional 1-2 days in the presence of maturation stimuli. The most common 
maturation stimulus used in DC-immunotherapy is a mixture of pro-inflammatory cytokines 
(TNF-α, IL-1β, IL-6 and Prostaglandin E2 (PGE2)), which induces increased expression of 
MHC-class I/II, CD40, CD80 and CD86 molecules, coherent with the DC mature phenotype, 
as well as the expression of CCR7, necessary for DCs migration to lymph tissues.68,75 In 
addition to this approach, agonists of TLRs or CD40 ligands can also be used, although these 
approaches are not as effective to induce DC maturation as the pro-inflammatory cytokine 
cocktails.48 
1.2.3.3 Tumor-antigen loading of the ex vivo generated DCs 
In order to produce a long lasting and specific anti-tumor response, DCs have to be able to 
present tumor antigens to CD4+ and CD8+T cells.  To date, several approaches to pulse DCs 
with tumor antigens have been explored. These include the use of patient’s tumor-
peptides/proteins or irradiated/lysed whole tumor cells. Another approach involves the use of 
bacterial or viral vectors or DC transfection with mRNA containing genes encoding tumor 
antigens. These tumor antigens after internalization and processing are presented via MHC-
Class I/II, and ideally are able to induce the activation of a cytotoxic CD8+ T cell response. 
During the immunotherapy procedure, the DC tumor-antigen-loading step can occur before or 
after the DC maturation step.48,69  
Finally, the mature and tumor-antigen pulsed-DCs are re-administered to the patient, 
migrating subsequently to the lymph nodes, where they stimulate the patient's T cells and 





Figura 8- Dendritic cell immunotherapy: (1) DC precursors are isolated from the patient. (2) Incubation of 
DC precursors with cytokines induces their differentiation into immature DCs. (3) A maturation stimuli is 
applied to induce DCs to become mature. (4) Loading of DCs with tumor antigens from the patient is performed 
either before or after the maturation process. (5) The antigen-pulsed and mature DCs are injected back into the 
patient, (6) migrating subsequently to the lymphoid tissues, where they activate T cells. (7) Activated T cells 
egress the lymphoid tissue and transmigrate to the tumor site, (8) where they will stop tumor growth. In 
Directing dendritic cell immunotherapy towards successful cancer treatment. Sabado RL and Bhardwaj N.  
Immunotherapy. 2010. 
 
To date, several clinical trials involving DC-based vaccines have been conducted in patients 
with different types cancer.48 Although these vaccines have been proven to be feasible, safe 
and to generate tumor-specific immune responses, the success of this immunotherapy has 
been limited.76 Indeed, only one anti-cancer DC-based vaccine has been approved by Food 
and Drug Administration (FDA), the Provenge (Sipuleucel-T) from Dendreon pharmaceutical 
company, specific for advanced prostate cancer treatment.77 The success of DC-based 
vaccination depends on a large number of variables that need to be optimized, namely the 
source of DC precursors, appropriate maturation stimuli, strategy for tumor-antigen loading 
and application route.48 Importantly, the elimination of the tumor mainly depends on the type 
of cellular immunity elicited by DCs, i.e. generation of Th1/Tc1 vs Th2/Tc2 response. It is 
crucial that the ex vivo expanded DCs used in this type of therapy are fully mature and able to 
induce a Th1 response, needed for the activation of cytotoxic CD8+ T cell activity, and 
therefore, vital for tumor clearance.69 Equally important is the ability of these DCs to reach 
the target tissues from the vasculature, after administration into the patient. Thus, an 
immediate prerequisite to accomplish the enormous promise of DC-based vaccines in cancer 
treatment is to develop methodologies to optimize DC maturation status and their ability to 
elicit Th1 responses, as well as to understand the effectors mediating physiologic trafficking 




1.3 Glycobiology and its effect on the immune response  
All cells in nature present a vast repertoire of glycan structures at their cell surface. Indeed, 
glycosylation of cell surface or of intracellular structures is involved in several physiological 
and pathological processes, including the modulation of innate and adaptive immune 
responses.78 Glycans are involved in processes such as the recognition of self-molecules, 
host-pathogen interactions, leukocyte trafficking, humoral immunity and activation of 
immune cells.78,79 
1.3.1 Glycosylation 
Glycan structures that are found in eukaryotic cells are defined based on the nature of the 
glycan binding to the target scaffold (lipid or protein), leading to the formation of many types 
of glycoconjugates. Thus, glycoconjugates can be classified into four main groups: 
proteoglycans, glycosphingolipids (glycolipids), glycosylphosphatidylinositol (GPI)-linked 
proteins and glycoproteins. 80 Additionally, glycoproteins can be further divided into N- or O-
glycosylated proteins, based on the amino acid residue that binds to the glycan determinant. 
Therefore, an O-glycoprotein consists of a glycan covalently attached to the oxygen atom of a 
serine (Ser) or threonine (Thr) residue, within an amino acid sequence; whereas in N-
glycosylation, the glycan is covalently bonded to the nitrogen atom of an asparagine (Asn) 
residue within the amino acid sequence Asn-X-Ser / Thr (where X represents any amino acid 
except proline (Pro)).80,81 
1.3.1.1 O-Glycans Biosynthesis 
The O-glycosylation process is characterized by a stepwise sugar addition that occurs in the 
Golgi apparatus and involves a broad array of enzymes (Figure 9). There are different classes 
of O-glycans, but the most ubiquitous type of initial O-glycosylation involves the addition of 
an N-acetylgalactosamine (O-GalNAc) to a Ser or Thr residues, known as mucin type O-
glycans.82 This synthesis is initiated by one of the N-acetylgalactosaminyltransferase family 
members (ppGalNAcTs), forming the Tn antigen. The Tn antigen can be sialylated by the 
action of the α(2,6)sialyltransferases ST6GalNAc-I/II, yielding sialyl-Tn antigen (sTn) and 
inhibiting further sugar addition. More frequently, the GalNAc residue of Tn can be 
elongated by core 1 β(1,3)galactosyltransferase (Core1GalT or T synthase) or by core 3 




T antigen (Galβ1-3GalNAc-Ser/Thr), or core 3 structure (GlcNAcβ1-3GalNAc-Ser/Thr), 
respectively. Core 1 can be further lengthened by the addition of an N-acetylglucosamine 
(GlcNAc) through core 2 β(1,6)N-acetylglucosaminyltransferase (C2GnT-1), forming core 2 
structure. On the other hand, T antigen (core 1 structure) sialylation, by the 
α(2,3)sialyltransferases ST3GalI/IV or α(2,6)ST6GalNAc II (forming sialyl-T (sT) or sialyl-
6T (s6T) antigens, respectively), stops core 2 formation. In contrast, repetitive additions of 
galactose (Gal) and GlcNAc by β(1,3/4)GalT and β(1,3/4)GnT enzymes, respectively, can 
further elongate core 2 structures, leading to type 1 (Gal linked to GlcNAc through a β(1,3) 
linkage) and type 2 (Gal linked to GlcNAc through a β(1,4) linkage) lactosamine chain 
formation. 81-85 
 
Figure 9- Schematic representation of O-linked glycoprotein synthesis pathway.  O-glycan synthesis is 
initiated by an N-acetylgalactosaminyltransferase that transfers an N-acetylgalactosamine residue (GalNac) to a 
serine or threonine, forming the Tn antigen. Tn antigen can be sialylated by the activity of the α(2,6)-
sialyltransferase ST6GalNAc-II, yielding the sialyl-Tn antigen (sTn),  which ceases further sugar modification.  
Alternatively, the transfer of galactose (Gal) to Tn antigen leads to the formation of T antigen (core 1) by Core 
1GalT.  T antigen sialylation can be catalyzed by α(2,3)-sialyltransferase ST3GalI/IV or α(2,6)-sialyltransferase 
ST6GalNac-II, forming sialyl-T (sT) or sialyl-6T (s6T) antigens, respectively.  In absence of sialylation, core 1 
can be modified by the addition of an N-acetylglucosamine (GlcNAc) by C2GnT1, forming the “core-2” 
structure.  Repetitive sequential and alternating additions of Gal and GlcNAc, respectively, create the 
lactosaminyl glycan chain that serves as an acceptor for terminal sialofucosylations. In Mucin-type O-glycans in 








1.3.1.2 N-Glycans Biosynthesis 
In contrast to O-glycosylation, the N-glycosylation process requires the production of an 
oligosaccharide precursor (GlcNAc2Man5) in the cytoplasmic phase of the endoplasmic 
reticulum (ER) membrane. This glycan is transferred en block from a lipid donor (Dolichol-
phosphate (Dol-P)) to the Asn residue of a newly synthesized protein in the lumen of the ER 
and further processed in the Golgi compartment (Figure 10).86  Briefly, N-glycan synthesis is 
initiated on the cytoplasmatic side of ER by the transfer of a GlcNAc-1-P to Dol-P, 
generating Dol-P-P-GlcNAc that is further elongated, by the addtition of GlcNac and 
mannose (Man) residues, into Dol-P-P-GlcNAc2Man5. This glycan precursor is flipped across 
the ER membrane to luminal side, where Man and glucose (Glc) residues are added, forming 
the mature N-glycan precursor Glc3Man9GlcNAc2-P-P-Dol. The mature N-glycan precursor is 
then transferred to an Asn residue (Asn-X-Ser/Thr sequon) on a newly synthetized protein by 
the multi-subunit protein complex, oligosaccharyltransferase (OST), as the protein is 
translocated into the ER. After this transfer, the N-glycan precursor goes through Glc and 
Man removal cycles by glucosidases and mannosidases in both ER and cis Golgi 
compartment until Man5GlcNAc2Asn structure is generated. For the biosynthesis of hybrid 
and complex N-glycans, further reactions are initiated in the medial-Golgi by the action of an 
N-acetylglucosaminyltransferase-1 (GlcNAcT-I/MgaT1), which adds an GlcNAc residue to 
the α(1,3)Man on the core of Man5GlcNAc2. The resulting structure may be elongated, giving 
rise to hybrid N-Glycans; or lose the two terminal Man units by mannosidase II, forming the 
GlcNAcMan3GlcNAc2 core. A second GlcNac residue is then added to the α(1,6)Man in the 







Figure 10- Schematic representation of N-linked glycoprotein synthesis pathway. The biosynthesis of N-
glycoproteins is initiated within the endoplasmatic reticulum (ER) with the synthesis of a dolichol-linked 
precursor oligossaccharide that is transferred en block to a newly synthetized protein by the multi-subunit 
protein complex, oligosaccharyltransferase (OST). Subsequent N-glycan processing is carried out in the ER and 
then within Golgi apparatus. Biosynthesis of hybrid and complex glycans is initiated by the action of MgaT1, 
which adds a GlcNAc residue to the mannose (Man) present on the α(1,3)-arm of the Man5GlcNAc2 structure.  
The resulting structure can either lose two mannose units off the α(1,6)-arm of the core mannose, leading to the 
formation of complex N-glycans, or not lose these mannoses, generating hybrid N-glycans.	  In The regulatory 
power of glycans and their binding partners in immunity. Johnson JL et al.,Trends Immunol. 2013.  
 
As mentioned previously, glycosylation modulates several immune events. Specifically, in 
this PhD thesis we investigated the glycoconjugate structures that mediate leukocyte 
extravasation to sites of inflammation and the modulation of DC functionality by sialylated 
glycans. 
 
1.3.2 Leukocyte recruitment to sites of inflammation 
To exert their effector immune functions, circulating leukocytes have to migrate from the 
vasculature to injured sites.  Therefore, the mechanisms involving leukocyte migration are a 








1.3.2.1 Leukocyte transmigration: The Multi-step Model 
Leukocyte recruitment involves a sequential and coordinated series of molecular actions 
mediated by adhesive interactions between circulating leukocytes and endothelial cells in 
post-capillary venules (Figure 11). To initiate the extravasation process, circulating 
leukocytes have to establish low-affinity and reversible interactions (tethering) with 
endothelial cells to roll on venular endothelium (step 1). These interactions allow leukocyte 
velocity to decrease in areas of high fluid shear stress. Leukocyte rolling allows the cells to 
become exposed to chemokines immobilized by glycosaminoglycans on the endothelial 
surface, leading to engagement of chemokine G-protein-coupled receptors (GPCRs) on 
leukocyte cell surface (step 2), thereby triggering G-protein-coupled integrin activation. This 
leads to subsequent firm adhesion of leukocytes to the endothelium (step 3), mediated by the 
binding of leukocyte integrins, as the very late activation protein 4 (VLA-4) and lymphocyte 
function-associated antigen 1 (LFA-1), to their respective endothelial adhesion receptors, the 
vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-
1).92,93 Tight binding by activated integrins allows the leukocytes to extravasate across the 
endothelium (step 4), which can occur via migration between adjacent endothelial cells, 
involving the transient dismantling of endothelial junctions (paracellular migration), or via 












Figure 11– Multi-step model of leukocyte adhesion and migration along the vascular endothelium. 
Leukocytes engage in adhesive contacts with endothelial cells, through the binding of their sialofucosylated 
determinants to E-selectin expressed by endothelial cells (Step 1- Tethering and rolling). Engagement of 
chemokine receptors leads to integrin activation (Step 2) and subsequent firm adhesion of leukocytes to 
endothelium (Step 3), allowing their transmigration (Step 4). In CD44 and HCELL: Preventing hematogenous 





Although several cell-associated proteins are capable of mediating the first step of cell 
migration, the selectins are the most potent effectors of rolling and tethering interactions.91,96 
 
1.3.2.2 Selectins and their carbohydrate ligands 
1.3.2.2.1 The selectin family 
The selectins are a family of three carbohydrate-binding proteins expressed on endothelial 
cells, leukocytes and platelets. Due to their requirement of calcium ions for binding, all three 
selectins, E-, P- and L-selectin, belong to the C-type lectins family (Figure 12).97 Selectins 
share a common structure of five different domains: an N-terminal carbohydrate recognition 
domain (CRD), an epidermal growth factor like domain (EGF), a varying number of short 
consensus repeats (CR) (3, 6, and 9 for L-, E-, and P-selectin, respectively), a transmembrane 
region and a C-terminal cytoplasmatic domain (Figure 12).98 While the CRD and EGF 
domains are highly homologous between the three selectins, the structure of the 
transmembrane and cytoplasmic portions, as well as the extracellular CR domain are not 
conserved across the selectins, resulting in significant different molecular weights between 
selectins (L-selectin, 42 kDa; E-selectin, 64 kDa; P-selectin 86 kDa).99,100  
 
Figure 12- The selectin family. Selectins are a family of three carbohydrate binding proteins: P-selectin, 
expressed on activated platelets and endothelial cells, E-selectin expressed on activated endothelial cells and L-
selectin expressed on leukocytes. The figure shows the five domains shared by selectins: C-type lectin domain, 
epidermal growth factor like domain (EGF), a varying number of short consensus repeats, a transmembrane 
region and a cytoplasmatic domain. In Varki A et al. (Ed.), “Essentials of Glycobiology”, Cold Spring Harbor 





Despite sharing common elements, the three selectins have different functions in diverse 
pathological and physiological processes and vary in their distribution and binding kinetics.  
L-selectin (also known as CD62 antigen-like family member L (CD62L), leukocyte adhesion 
molecule 1 (LAM-1), leukocyte-endothelial cell adhesion molecule 1 (LECAM-1), DREG-
56, Ly-22, Leu8, TQ1 and Mel-14 antigen) was first described by Gallatin and co-workers101 
in 1983 as a lymphocyte homing receptor. This molecule is found to be upregulated on 
hematopoietic stem cells and mature leukocytes, including all myeloid cells, subsets of 
natural killer cells, naïve T and B cells and central memory T cells.97 However, its expression 
decreases on effector T cells after encountering antigen.102 When leukocytes are activated, 
cell surface levels of L-selectin are regulated by proteolytic cleavage by metalloprotease-
dependent shedding of the extracelulluar domain.97  
P-selectin (also known as CD62P, platelet activation-dependent granule to external 
membrane protein (PADGEM), leukocyte-cell adhesion molecule 3 (LCAM-3), granule 
membrane protein 140 (GMP-140)) was discovered in 1984 by McEver and co-workers 103,104 
and Furie and co-workers 105 as a glycoprotein expressed on the cell surface of activated 
platelets. P-selectin is constitutively expressed by megakaryocytes and endothelial cells, 
where it is stored in α-granules of circulating platelets and Weibel-Palade bodies, 
respectively. Following pro-inflammatory stimulus, by molecules such as thrombin or 
histamine, P-selectin is translocated from the granules to the cell surface by fusion of 
intracellular storage compartments with the plasma membrane. In murine endothelial cells, 
but not human, inflammatory mediators such as TNF-α, IL-1β and lipopolysaccharide (LPS) 
induce P-selectin mRNA transcription. 80,97,106 In these murine endothelial cells, TNF-α and 
IL-1β activation of P-selectin is mediated by the binding of the nuclear factor κ-light chain-
enhancer of activated B cells (NF-κB) and activating transcription factor-2 (ATF-2) to the 
their response elements in the P-selectin promoter.107 However, the promoter of P-selectin in 
primates lacks binding sites for NF-κB and ATF-2108. For this reason, in human endothelial 
cells, the only vascular selectin expressed post- TNF-α and IL-1β activation is E-selectin.109  
E-selectin (also known CD62E, endothelial-leukocyte adhesion molecule 1 (ELAM-1) or 
LECAM2) was discovered by Bevilacqua and co-workers110,111 in the 1980´s as a leukocyte 
adhesion molecule on activated endothelial cells. In the majority of tissues, endothelial cells 
do not constitutively express E-selectin, being the expression of this protein strongly 




cytokines induce transient transcription (maximal expression at about 4 hours) of E-selectin 
mRNA in both human and mouse endothelial cells.112 Cytokine-dependent activation of E-
selectin is mediated by NF-κB binding to positive regulatory domains in the E-selectin 
promoter.113 In contrast, skin and bone marrow microvessels express E-selectin 
constitutively.114 Functionally, E-selectin slows leukocyte rolling to much lower velocities 
than either L- or P-selectin, favoring subsequent leukocyte arrest.115 This capacity, along with 
the inability of human endothelial cells to upregulate P-selectin in the presence of IL-1β and 
TNF-α, is why E-selectin is considered to be the most important selectin for cell trafficking to 
sites of inflammation, as it plays a critical role in the recruitment of immune effectors to 
target inflammatory sites. 
 
1.3.2.2.2 The carbohydrate E-selectin ligands 
E-selectin recognizes a broad range of structurally diverse glycan epitopes that typically 
contain an α(1,3/4)-fucose (Fuc) and/or α(2,3)-sialic acid (Sia) modification(s), as shown in 
Figure 13.114 The isomeric tetrassacharides sialyl Lewisx (sLex - Siaα2-3Galβ1-4GlcNAcα1-
3Fuc) and sialyl Lewisa (sLea - Siaα2-3Galβ1-3GlcNAcα1-4Fuc) are the most common 
terminal epitopes present in E-selectin-binding determinants, however, structures related to 
sLex/sLea can also exhibit E-selectin binding activity.116,117 Some sulfated derivates of Lex 
and Lea (3’-Sulfo-Lewisx (3’-Sulfo-LeX) and 3’-Sulfo-Lewisa (3’-Sulfo-Lea), respectively) 
were shown to bind to E-selectin, as well as an internally fucosylated sLex isomer, VIM-2. 
Core-2 based lactosamine structures, such as GalNAc-Lewisx, or polylactosamine chains, in 
which fucose modifications occur at more than one GlcNAc residues (Tri-fucosyl-sialyl 
Lewisx and Di-fucosyl-sialyl Lewisx) can also support E-selectin-dependent 
adhesion.97,98,118,119 However, it is important to point out that sLea and the sulfated derivates 
of Lex and Lea are not natively expressed in leukocytes, and therefore are not involved in 
leukocyte trafficking; although they have been shown to present E-selectin binding activity in 
the laboratory.118,119 The sulfated derivates of Lex and Lea and sLea antigens are mostly 






Figure 13- E-selectin reactive glycan structures. Sialofucosylated and fucosylated glycan structures that 
terminate O-linked, N-linked or lipid-linked glycoconjugate structures, and that have been shown to display E-
selectin biding activity. Adapted from Varki A et al. (Ed.), “Essentials of Glycobiology”, Cold Spring Harbor 
Laboratory Press, 2nd Edition, 2009.  
 
1.3.2.2.3. Glycosyltransferases associated with biosynthesis of selectin carbohydrate-
binding determinants  
E-selectin binding epitopes are regulated by enzymes that directly alter sialylation and 
fucosylation of terminal lactosamines. These determinants are typically displayed at the end 
of O-glycans, N-glycans or glycolipid precursor structures. The synthesis of sialofucosyltated 
epitopes requires the coordinated and sequential action of specific glycosyltransferases 
localized in the lumen of the Golgi apparatus. Complete formation of E-selectin binding 
determinants is catalyzed by the addition of Fuc through α(1,3/4)fucosyltransferases and of 
Sia by α(2,3)sialyltransferases on type 1 (Gal linked to GlcNAc through a β(1,3) linkage – 
(s)Lea structures) or type 2 (Gal linked to GlcNAc through a β(1,4) linkage – (s)Lex 
structures) lactosamine chains (Figure 14).123,124 So far, six human fucosyltransferases (FT) 
have been found to catalyze the addition of Fuc in an α(1,3/4) linkage to GlcNAc - FTIII, 
FTIV, FTV, FTVI, FTVII and FTIX. Each enzyme exhibits specificity for acceptor substrates 
and, therefore, have the ability to generate distinct fucosylated structures.125 Specifically, 
FTIII and FTV are unique in that they exhibit both α(1,3/4) fucosyltransferase activity on 
both sialylated and unsialylated lactosamines. Both enzymes can synthesize sLex and sLea 
structures, as well as the unsialylated forms, Lex and Lea.  FTVI has been reported to 




fucosyltransferases FTIV and FTIX are known to only synthesize Lex.125 The sialylated forms 
of Lewis antigens are synthesized by the action of the α(2,3) sialyltransferases. These 
enzymes transfer sialic acid residues to the Gal on the lactosamine chain, exclusively acting 
prior to fucosylation of the lactosamine chains.83,126 There are 6 members of α(2,3) 
sialyltransferase family- ST3Gal I to ST3Gal VI – but only ST3GalIII, ST3GalIV, and 
ST3GalVI are reported to contribute to the creation of sLex/a.127 Importantly, ST3GalVI 
exclusively catalyzes the formation of sLex, while ST3GalIII and ST3GalIV can additionally 
synthesize sLea. 128-130 The sialyltransferase ST3GalIII exhibits preference for type 1 
lactosamine chain receptors whereas ST3GalIV preferentially acts on type 2 oligosaccharides.  
 
Figure 14- Sialyl LewisX synthesis. The α(2,3)-sialyltransferases, ST3GalIII, IV and VI, terminate the 
elongation of both O- and N-Glycans by creating sialylated lactosamine chains that can be further fucosylated by 
the action of the fucosyltransferases FTIII, V, VI and VII, creating sLex. 
 
Of the six α(1,3/4)fucosyltransferases, only three are thought to be expressed in human 
leukocytes, FTIV, FTVII and FTIX.125,131 Studies have shown that leukocytes from mice 
lacking FTVII have deficient adhesive interactions with E- and P-selectin, suggesting this 
fucosyltransferase plays a predominate role in E-selectin ligand biosynthesis.132,133 However, 
similar studies using mice deficient in both FTVII and FTIV have indicated that FTIV also 
contributes to leukocyte E- and P-selectin ligand expression, being crucial for slow leukocyte 
rolling velocity.134,135 Importantly, in contrast to FTVII, E-selectin binding activity conferred 
by FTIV fucosylation occurs mainly on glycolipids, rather than glycoproteins.136 
Interestingly, a recent study suggested that, unlike murine leukocytes, FTIX plays a 
significant a role in E-selectin dependent interactions in human myeloid cells, where FTVII 
and FTIV contribute to a lesser extent.131  
For the α(2,3) sialyltransferases, studies indicated that leukocytes from mice deficient in 
ST3GalIII preserved E- and P-selectin binding activity.137 However, leukocytes from 
ST3GalIV null-mice show a partial loss of the ability to bind to both E- and P-selectin in 




with ST3GalIV in the selectin ligand biosynthesis process.137 In agreement with murine 
studies, ST3GalIV also plays an important role in the biosynthesis of E- and P-selectin 
ligands in human leukocytes.138 
Glycosyltransferases involved in biosynthesis of O-glycans have also been studied for their 
contributions in the generation of functional selectin ligands using knockout mouse models.  
One study reported that neutrophils from mice deficient in ppGalNAcT-1 showed impaired 
recruitment during inflammation, due to a significant reduction in E- and P-selectin ligand 
levels.139 Mice deficient in C2GnT-1 showed reduced E-selectin and P-selectin binding 
activity of neutrophils under static and shear-based rolling assays.140-142 β(1,4)GalT-I- 
deficient mice showed reduced inflammatory responses and impaired neutrophil P-selectin 
binding activity, however the contribution of this enzyme in the synthesis of E-selectin 
counter-receptors remains to be elucidated.143 
 
1.3.2.3 Glycoconjugates structures for E-selectin ligands 
Several glycostructures with E-selectin binding activity have been identified on various 
hematopoietic cells. Here, we review the glycoconjugates that act as scaffolds for functional 
E-selectin ligands on human and mouse leukocytes. 
Cutaneous lymphocyte antigen (CLA) 
CLA is the E-selectin reactive glycoform of P-selectin glycoprotein ligand-1 (PSGL-1). 
PSGL-1 is a transmembrane 240-kDa homodimeric, mucin-like glycoprotein expressed on 
leukocytes and some activated endothelial cells that plays a crucial role in the homing of 
leukocytes into inflamed tissue.144,145 E-selectin binding activity of PSGL-1 is conferred by 
sialylated and fucosylated core 2 based O-glycans that are distributed along the extracellular 
domain.146 Several studies have identified PSGL-1 as one of several scaffolds displaying 
glycan epitopes with E-selectin ligand activity on different human and mouse blood cell 
subsets, including human and mouse CD34+ cells, human monocytes and DCs, and human 
and mouse neutrophilis and T cells.145,147-151 PSGL-1 is also the dominant ligand for P- and L- 





Hematopoietic cell E- and L- selectin ligand (HCELL)  
HCELL is the sialofucosylated glycoform of CD44 that exhibits E-selectin binding activity. 
CD44, itself, is an 80-200 kDa transmembrane glycoprotein expressed by the majority of 
mammalian cells. It serves as receptor for hyaloronic acid (HA) and participates in a broad 
range of cellular activities, including lymphocyte activation, leukocyte trafficking, 
hematopoiesis, cell growth and survival, and tumor dissemination.154 The CD44 protein 
family displays high structural heterogeneity as a result of both alternative splicing of CD44 
gene transcripts and post-translational modifications of the protein. The standard isoform of 
CD44 (CD44s or CD44H) is encoded by mRNA transcripts comprising exons 1–5 and 16–20 
("s1–s5 and s6–s10") and is ubiquitously expressed in mammalians cells. On the other hand, 
CD44 variant isoforms (CD44v) contain peptide products of variant exons (exons "v2–v10") 
in addition to standard exon peptide products. Post-translation modifications along with 
extensive alternative splicing allow the formation of multiple protein isoforms, expressed in a 
tissue-specific manner.155,156 The standard CD44 molecule ranges in molecular weight from 
80 to 110 kDa, whereas alternative splicing of variant exons produces CD44 isoforms ranging 
from 90 to ~200 kDa. Post-translation modifications include the addition of different glycan 
structures, namely glycosaminoglycans, N- and O-glycan structures.157 The sialofucosylated 
glycoform of CD44 was first described on human hematopoietic stem and progenitor cells 
(HSPCs) by Dimitroff and colleagues158, but not on mouse HSPCs.149  Subsequently, HCELL 
was described to be highly expressed in hematologic158,159 and solid malignancies,160 as well 
as a potential E-selectin binding glycoprotein on human and murine neutrophils.161 
Importantly, for all human HSPCs and blast cells, sLex epitopes are exclusively displayed on 
N-glycan lactosamine structures on CD44s molecule; while, HCELL expressed by solid 
tumors displays E-selectin reactive carbohydrate epitopes on O-glycans of CD44 variant 
isoforms.159,160 Because of its potent capacity to bind to selectins in high shear conditions, 
HCELL has been designated as the most potent L- and E-selectin ligand described on human 
cells. 158,162 
CD43E  
CD43, also known as sialophorin or leukosialin, is a cell surface glycoprotein expressed by 
the majority of hematopoietic cells that is involved in several important processes, including  
cell development, activation, survival, and migration.163-167 Glycosylation of CD43 molecules 




respectively.168 E-selectin binding activity of CD43 was first reported on mouse Th1 cells by 
Matsumoto and colleagues 169 and on human T cells by Fuhlbrigge and colleagues.170 
Subsequently, murine neutrophils,171 human and mouse CD34+ cells149 were also shown to 
express the E-selectin-reactive CD43 glycoform, CD43E. CD43 aberrantly decorated with 
sLex/a determinants was also reported in colon cancer cells.172 Importantly, the sLex epitopes 
that contain E-selectin binding activity of the CD43E glycoprotein are displayed on O-
glycans.149  
E-selectin ligand -1 (ESL-1) 
ESL-1, also called MGF-160 or cysteine-rich fibroblast growth factor receptor 1 (CFR-1) is a 
150 kDa transmembrane glycoprotein widely expressed and is well known for functioning as 
a fibroblast growth factor receptor, contributing to several cellular operations such as 
embryonic development, leukocyte migration, cell division and bone morphogenesis.173,174 
ESL-1 was identified as the chief E-selectin binding glycoprotein on murine myeloid cells175 
and on human metastatic prostate cancer cells.176 Removal of N-glycans from this fibroblast 
growth factor receptor abolishes its E-selectin ligand activity.177  
β2 integrins  
β2 integrins (CD11/CD18) are a family of leukocyte adhesion molecules that mediate cell-cell 
and cell-substrate interactions, playing a critical role during inflammatory events. β2 integrin 
proteins are heterodimers composed of a β2 chain (CD18 (~90 kDa)) and a variable α-subunit 
(CD11a (~177 kDa), CD11b (~165 kDa) or CD11c (~150 kDa)178-182 The first evidence that 
CD11a/CD18 and CD11b/CD18 expressed by human neutrophils could act as ligand for the 
vascular E-selectin was reported by Kotovuori and colleagues,183 and confirmed some years 
later by Crutchfield and colleagues.184 Importantly, the E-selectin reactive sialofucosylated 
epitopes present in β2 integrins are displayed on N-glycans.184 Zen and colleagues reported 
evidences that the CD11b and CD18 subunits are both decorated with sLex epitopes.185 
MPO-EL 
Myeloperoxidase (MPO) is a 150 kDa lysosomal peroxidase enzyme that is expressed in 
neutrophil and monocyte granules (azurophil granules). MPO is a dimeric protein consisting 
of two light chains (~12kda) and two heavy chains (~65 kDa) bound to a prosthetic heme 
group.21,186 Recent studies have shown that MPO-EL, a glycoform of the heavy chain of 




myeloid cells in febrile leukocytosis patients.  E-selectin binding activity of MPO-EL is 
conferred by sLex epitopes displayed on N-glycan structures on the heavy chain of MPO.187 
Basigin (bsg)/CD147 
Bsg is a ~40-70 kDa membrane immunoglobulin (Ig)-like glycoprotein ubiquitously 
expressed.188 Recently, Noritoshi Kato and colleagues reported that murine neutrophils and 
HL-60 cells express a glycoform of bsg that contains E-selectin reactive sialofucosylated N-
linked polylactosamine chains.189 
L-selectin 
As mentioned previously, L-selectin is a crucial player in lymphocyte homing to lymph 
nodes. This selectin can also function as an E-selectin ligand on human neutrophils 190 and 
cultured T lymphobasts191, but not mouse neutrophils.192 E-selectin binding activity of L-
selectin is dependent on sLeX bearing O-glycan structures. 192 
Glycolipids  
Prior studies have suggested that sialofucosylated determinants displayed in lipid backbones 
can mediate adhesion to E-selectin.  Tiemeyer and colleagues reported that leukocyte 
sialylated lactosylceramides decorated with internally fucosylated GlcNAc structures display 
ability to bind to E-selectin.193 Studies focused on the digestion of surface proteins have 
supported this claim and indicate that extensive proteolytic cleavage of NK cells, eosinophils 
and neutrophils does not affect sLex expression and has no effect on E-selectin adhesion.194,195 
Moreover, sLex and sLea synthetic glycolipids were shown to mediate tethering and rolling of 
E-selectin–expressing cells in shear flow,196 while abolishment of glycosphingolipid synthesis 
inhibited E-selectin binding to some extent.197 More recently, sialylated lipid scaffolds 
extracted from breast cancer cells were described to also support binding of E-selectin-
expressing cells under shear stress.198 
 
1.3.3 DCs and glycosylation 
DCs show a specific glycan profile at cell surface that can be modulated during development, 
maturation and immune regulation.199 Typically, the terminal positions of eukaryotic cell 




monosaccharide sialic acid.200 Sialic acid content depends on the expression of a set of 
different sialyltransferases, localized at Golgi and/or sialidases (enzymes that cleave sialic 
acid linkages), located in the cytoplasm, membrane or lysosomes. These sialyltransferases 
transfer sialic acid from a donor substrate, N-acetylneuraminic cytidine monophosphate 
(CMP-Neu5Ac), to the terminal positions of the oligosaccharide chains and depending on 
their nature can catalyze different linkages, in particular α(2,3) or α(2,6) linkage to galactose 
residues and α(2,6) linked to GalNAc or GlcNAc residues.127,201 These terminal sugars are 
involved in many cellular functions, both in physiological and pathological processes, 
including the regulation of the immune system and triggering progression of certain 
infections and diseases.200,202 They can mask underlying structures, preventing cell-to-cell 
interactions through non-specific repulsive effects or preventing recognition by other 
molecules such as lectins.126,203,204  
Besides the crucial role of sialic acids in migration of leukocytes, they play an important role 
in DC-pathogen interaction and recognition and are a key determinant in DC differentiation 
from monocyte precursors.  Specifically, human mo-DCs display a high content of α(2,6) and 
α(2,3)sialic acid linked to carbohydrate moieties compared to their monocyte precursors. 
Furthermore, this increased sialylation is due to an upregulation of the sialyltransferases 
ST3Gal-I and ST6Gal-I.205-207 Interestingly, DC maturation is also affected by sialic acid 
levels. Jenner and co-workers reported that mo-DCs with a higher α(2,6)sialic acid linked 
content exhibit a more tolerogenic and immature phenotype.206 Consistently, removal of sialic 
acid from cell-surface of mo-DCs cells improves their maturation status and the  inactivation 
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2. Rationale and specific objectives 
Glycosylation is the most common and multifaceted form of protein post-translational 
modification. It has been shown that protein glycosylation interferes with different 
immunological mechanisms and proper glycosylation may be a requisite for normal immune 
function. Therefore, understating of how glycosylation influences immunity is actually 
crucial for the complete comprehension of some immune related-functions and may provide 
key insights for the development of novel immunotherapeutic approaches in the future. 
Specifically, in the present work we have been focused mainly in two immune events that are 
strongly modulated by glycosylation: leukocyte extravasation to sites of inflammation that is 
modulated by E-selectin reactive glycoproteins; and dendritic cell (DC) ability to prime T cell 
mediated-immune responses modulated by sialylated glycans. 
Specific objectives 
2.1. To identify the nature and structure of the E-selectin reactive glycoproteins that are 
expressed on human peripheral mononuclear blood cells (PBMCs) 
The vascular E-selectin and its carbohydrate-ligands are one of the key mediators for 
leukocyte trafficking during inflammation. Although several glycoproteins have been shown 
to bind to E-selectin, the majority of the reports have focused on results obtained uniquely 
from studies of mouse leukocytes or hematopoietic cell lines. Therefore, mouse E-selectin 
ligands have generally been presumed to be reflective of human E-selectin ligands, and 
usually not confirmed. However, it has been reported significant differences between mice 
and human leukocyte migration. As such, a complete and detailed identification of the 
physiological ligands for E-selectin expressed on human leukocyte is vital for the 
understanding of leukocyte extravasation process during inflammation. In chapter 3, we 
aimed to identify and characterize the nature of E-selectin ligands expressed by human 
primary peripheral blood mononuclear cells: monocytes, CD4+ and CD8+ T cells, and B cells. 
Specifically, we intended to gain mechanistic and molecular insights into the differential 
ability of these cells to traffic into inflamed tissues during acute or chronic inflammatory 
conditions. To this end, we performed functional assays to analyze the ability of these cells to 






2.2. To elucidate the E-selectin ligands expressed by human and mouse DCs obtained 
using different methodologies, or isolated from different cellular sources 
DCs are professional antigen-presenting cells, which are specialized in the initiation and 
regulation of immune response. Due to their capacity to elicit robust antitumor responses, 
DC-based therapy represents a powerful and promising approach for treatment of cancer. Yet, 
the suboptimal capability of DCs to reach the target tissue from the vasculature has 
contributed to the limited success of this immunotherapy. The most common source of DCs 
used in immune-therapeutics has been the ex vivo generation of DC from monocyte 
precursors. Therefore, in chapter 4, we addressed the nature and the biological function of 
the E-selectin ligands involved in transendothelial migration of human blood monocyte-
derived DCs (mo-DCs), using mo-DCs generated by two well-established enrichment-
monocyte methods employed for clinical DCs applications: monocyte enrichment via CD14-
selection (CD14-S) and those generated following plastic adherence-selection (PA-S). 
Moreover, we intended to augment the expression of E-selectin ligands on human mo-DCs, 
via enforced exofucosylation reaction, and assessed the impact of this glycoengineering on 
their capacity to bind to E-selectin and to transmigrate. 
Although human monocytes are generally obtained from peripheral blood, there has been an 
increasing clinical interest in monocytes obtained from umbilical cord blood source. 
Therefore, in chapter 5, we aimed to perform a comparative study about the E-selectin ligand 
expression on adult peripheral blood (APB) and umbilical cord blood (UCB) monocyte-
derived DCs. To identify the species-specific diversity among DC-E-selectin ligands, we also 
characterized the E-selectin reactive glycoproteins expressed by murine DCs. To achieve the 
appointed goals, we performed several functional assays (Transendothelial migration and 
parallel-plate flow chamber assays), coupled with biochemical studies, including western 
blot, immunoprecipitation, and flow cytometry methodologies. Collectively, in both chapter 
4 and 5, we aimed to provide fundamental findings for the creation of strategies to improve 





2.3. To assess whether sialic acid removal from DC surface improves DC-mediated anti-
tumor immune responses 
Another obstacle to achieve the promising success of DC-based vaccines is establishment of 
efficient approaches that could successfully enhance maturation and cross-presentation ability 
of DCs to trigger specific cytotoxic T cell responses. Notably, it is now well known that high 
expression of cell surface sialic acid is tightly linked to an immature and tolerogenic 
phenotype of DCs.  Therefore, in chapter 6 we aimed to assess whether removal of sialic 
acid from human and mouse DC surface would result in improved ability of DCs to elicit 
tumor-specific immune responses. To this end, we assessed several features of DC 
immunobiology after sialic acid removal, including: DC maturation, direct and cross-
presentation ability, secretion of Th1-inducing cytokines, activation of CD4+ and CD8+T cells 
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Immunity to incipient infection critically depends on the ability of sentinel circulating cells to 
infiltrate affected sites, a process which is initiated by leukocyte binding to E-selectin at 
inflamed endothelial beds.  To evaluate the capacity of human peripheral blood mononuclear 
cells (PBMCs) to engage E-selectin, we performed E-selectin adherence assays under 
hemodynamic flow conditions coupled with flow cytometry assessment of E-selectin binding 
and western blot analysis of glycoprotein E-selectin ligands.  Circulating monocytes 
uniformly displayed high expression of the canonical sialofucosylated E-selectin binding 
determinant sLeX and markedly greater adhesive interactions with E-selectin than did 
lymphocytes, and although CD4+T-cells exhibited significant E-selectin binding, CD8+T and 
B-cells each showed minimal E-selectin engagement.  Western blot analysis of monocytes 
revealed sLeX determinants prominently on proteins PSGL-1, CD43, and CD44 (rendering 
the E-selectin ligands CLA, CD43E, and HCELL, respectively), whereas CD4+T-cells 
expressed lower levels of CLA, CD43E, and HCELL, and CD8+T-cells displayed no HCELL 
and very low amounts of CLA and CD43E.  In contrast, circulating B-cells lacked E-selectin 
ligands, and quantitative PCR gene expression studies of enzymes that regulate display of 
sialofucosylated glycans showed correspondingly high transcript levels among monocytes 
and low levels among B-cells.  Notably, α-(1,3)-exofucosylation markedly increased 
expression of functional E-selectin ligands among all PBMC subsets, most extensively on 
monocytes, with cell type-dependent specificity in the protein scaffolds that are targeted to 
create E-selectin ligands.  Collectively, these findings unveil distinct patterns of E-selectin 
binding activity among PBMCs and provide key mechanistic insights into the molecular basis 






Under physiologic blood flow conditions, circulating immune cells extravasate at sites of 
inflammation via a multistep cascade of events.  This process typically occurs at post-
capillary venules, initiated by leukocyte tethering and rolling contacts on endothelium, 
followed by engagement of chemokine receptor(s) and G-protein-coupled integrin activation 
with subsequent firm adhesion, culminating in extravasation.  The initial adhesive 
interactions are largely dictated by leukocyte binding to the vascular selectins, E- and P-
selectin, causing leukocyte tethering and rolling on target tissue endothelial cells.1  In 
humans, E-selectin is the only selectin inducible by the inflammatory cytokines TNF-α and 
IL-1β,2 thus playing a key role in the recruitment of cells at inflammatory sites.  As such, 
those circulating leukocytes specialized to display high avidity E-selectin ligands serve as 
primary sentinels of host defense. 
E-selectin binds to sialofucosylated glycan determinants decorating specific glycoproteins 
and glycolipids.  These glycans contain an α(2,3)-linked sialic acid substitution on galactose 
and an α(1,3)-linked fucose modification on N-acetylglucosamine, prototypically displayed as 
the terminal lactosaminyl tetrasacharide known as sialyl Lewis X (sLeX).1  Although both 
glycoproteins and glycolipids can display sLeX, glycoproteins play a predominant role in 
initial binding to endothelial E-selectin under hemodynamic shear stress due to their extended 
membrane structure which yields more efficient primary contacts between flowing cells and 
the endothelium.3   
To date, the vast majority of studies of E-selectin ligands have focused on neutrophils, 
particularly mouse neutrophils.4  Among native human cells, the expression of E-selectin 
ligands has been most extensively characterized in  hematopoietic stem and progenitor cells 
(HSPCs).  Human HSPCs express three distinct glycoprotein E-selectin ligands: Cutaneous 
Lymphocyte Antigen (CLA), Hematopoietic Cell E-/L-selectin ligand (HCELL), and CD43-
E, which are heavily sLeX-decorated glycoforms of P-selectin Glycoprotein Ligand-1 (PSGL-
1), CD44, and CD43, respectively.5  Various studies of human neutrophils have shown a 
prominent role for CLA in E-selectin binding6, however, our knowledge of the E-selectin 
ligands expressed by human peripheral blood mononuclear cells (PBMCs) is grossly 
incomplete. In particular, our lack of understanding regarding the function and structural 




selectin is an essential prerequisite for inflammatory site recruitment and, subsequently, 
differentiation into pertinent macrophages or dendritic cells that shape the immune response. 
In this study, we analyzed the E-selectin-dependent binding interactions of  subsets of 
primary human  peripheral blood mononuclear cells (PBMCs) with human endothelial cells 
under physiologic flow conditions.  We found that human monocytes possess profound E-
selectin binding activity and that CD4+T-cells exhibit significant E-selectin binding, but 
CD8+T-cells and B-cells have low/absent E-selectin binding activity.  To elucidate the 
molecular basis of the observed marked differences in E-selectin binding activities, we 
performed complementary biochemical and functional studies of the E-selectin ligands 
expressed by these cells, as well as quantitative PCR gene expression studies of 
glycosyltransferases that mediate expression of sLeX.   Our studies reveal remarkable 
diversity in the structural biology of E-selectin ligands expressed on human leukocytes,  
provide key mechanistic insights on the function and formation of these structures, and 
broaden our understanding of the molecular effectors conferring immunosurveillance 
capabilities upon circulating human monocytes.  
 
 
Materials and Methods 
Isolation of blood cell subsets and cell culture 
Human peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood 
from healthy donors under protocols approved by the Institutional Review Board of Brigham 
& Women’s Hospital (BWH), with informed consent provided as per the Declaration of 
Helsinki.  To isolate monocytes, PBMCs were obtained by Ficoll-Paque (Sigma-Aldrich) 
density gradient centrifugation followed by positive selection using anti-CD14 coated 
magnetic beads (Miltenyi).7  CD4+ and CD8+T-cells and B-cells were isolated by negative 
selection using RosetteSep Human CD4+, CD8+, and B-cell enrichment cocktail, according to 
the manufacturer's instructions (StemCell Technologies).  Cell suspensions were evaluated by 
flow cytometry for purity, which was routinely >90%. 
Human umbilical vein endothelial cells (HUVECs) were obtained from the BWH Pathology 




with full-length human E-selectin cDNA (CHO-E) and mock-transfected CHO cells (CHO-
M) were cultured in modified Eagle’s medium (MEM) supplemented with 10% FBS, 1% 
non-essential amino acids, 1% sodium pyruvate and 1% penicillin-streptomycin.  
 
Antibodies and reagents used for flow cytometry 
Cell surface expression of sLeX, CD44, PSGL-1/CD162, and CD43 was assessed using mAbs 
HECA-452 (Biolegend), clone 2C5 (R&D Systems), KPL-1 and 1G10 (BD Biosciences), 
respectively.  To evaluate post-selection cell purity, PBMC subsets were stained with FITC-
conjugated-anti-human CD14 (Southern Biotech), APC-conjugated-anti-human CD4, FITC-
conjugated-anti-human CD8 and cychrome-conjugated-anti-human CD19 mAbs 
(Pharmingen).  
E-selectin reactivity was determined using recombinant mouse E-selectin-human Fc Ig 
chimera (E-Ig) (R&D Systems), in DPBS containing Ca2+/Mg2+, as previously described5, 
with 5mM EDTA addition (calcium chelation) serving as staining control.  Flow cytometry 
was performed using Cytomics FC 500 MPL flow cytometer (Beckman Coulter), with data 
analysis using FlowJo version 10.0.6 (TreeStar). 
 
Preparation of whole cell lysates 
Cells were suspended in 150mM NaCl, 50mM Tris-HCI (pH 7.4), 0.02% NaN3, 20 µg/mL 
PMSF and protease inhibitor cocktail (Roche), sonicated, and then solubilized in 2% Nonidet 
P-40 (NP-40).  For lysates undergoing immunoprecipitation with E-Ig, 2mM CaCl2 was 
added.   
 
Western blot analysis 
Protein samples were boiled for 7 minutes in reducing Laemmli loading buffer (Boston 
BioProducts) and then resolved on 7.5% SDS-PAGE electrophoresis gels (Bio-Rad).  
Resolved proteins were transferred to PVDF membranes (Bio-Rad) and blocked with 10% 
milk and 0.1% Tween20 in TBS.  Western blots were probed with primary antibodies 




Biotech).  For E-Ig blotting, membranes were incubated with E-Ig suspended in TBS 0.1% 
Tween20 containing 2mM CaCl2 (1µg/mL), followed by staining with rat anti-mouse CD62E 
mAb (R&D Systems) and then goat anti-rat IgG-HRP (Southern Biotech).  Antigens were 
detected by chemiluminescence using Lumi-Light Western blotting substrate (Roche).  
 
Immunoprecipitation studies 
Cell lysates were precleared with protein G-agarose (Invitrogen), followed by incubation with 
antibodies (anti-PSGL-1, anti-CD44, anti-CD43 (each from BD Biosciences)), anti-
myeloperoxidase mAb (clone 03D03, Abcam), or E-Ig.  Immunoprecipitates were then 
collected with protein G beads, beads were boiled, and released proteins were subjected to 
SDS-PAGE and western blotting. 
 
Cell Surface biotinylation 
Cells were incubated with Sulfo-NHS-SS-Biotin according to the manufacturer's instructions 
(Pierce Biotechnology).  After cell lysis, biotinylated proteins were isolated with streptavidin 
beads (Invitrogen).   
 
Blot rolling assay 
The blot rolling assay was performed as described previously.10  Briefly, western blots of 
CD44 immunoprecipitates were stained using HECA-452 mAb and rendered translucent by 
immersion in HBSS with 10% glycerol, 10 mM HEPES (pH 7.4) and 5 mM CaCl2.  Blots 
were then placed in a parallel-plate flow chamber, and CHO-E cells were perfused over blots 
at shear stress of 0.17 dynes/cm2.  Perfusion of CHO-M cells served as control to assess 
binding specificity. 
 
Microfluidic adhesion assay 
HUVEC monolayers were grown to confluence in microfluidic channels (Bioflux, Fluxion 
Biosciences).  To stimulate expression of E-selectin, HUVECs were incubated with 40 ng/mL 




initial shear rate of 0.5 dynes/cm2, with step-wise increments to 8 dynes/cm2.  Rolling and 
arrested cells were counted.  Binding specificity was assessed by treating PBMCs with 
sialidase or incubating HUVECs with function-blocking anti-E-selectin mAb.  
 
Enzymatic treatments  
To remove N-glycans, CD44 immunoprecipitates were treated with Peptide-N-Glycosidase 
(PNGase-F, New England Biolabs) according to the manufacturer's instructions.  Sialic acid 
residues were removed by treatment with 200 mU/mL Vibrio Cholerae sialidase (Roche 
Molecular Biochemicals) at 37°C for 1 hour.  Cell surface proteins were cleaved with 0.1% 
bromelain (Sigma-Aldrich) for 1 hour at 37°C, and efficiency assessed by flow cytometry 
staining for residual CD44 expression.  For α-(1,3)-exofucosylation, cells were treated with 
0.07 mg/mL of fucosyltransferase VII (FTVII) (R&D systems) in HBSS containing 10 mM 
HEPES, 0.1% human serum albumin and 1 mM GDP-fucose (Sigma-Aldrich), for 60 minutes 
at 37ºC.  As controls, cells were suspended in buffer without FTVII (buffer-treated).  
 
Isolation of RNA and Real-Time PCR 
Total RNA from each sample was isolated using the RNeasy Micro Kit (Qiagen) and reverse-
transcribed using the SuperScript VILO cDNA Synthesis kit and Master Mix (Applied 
Biosystems).  Real-time PCR (RT-PCR) reaction was performed using SYBR Select Master 
Mix (Applied Biosystems).  Primer sequences used for real-time PCR are listed in 
Supplemental Table 1 and gene expression was normalized to GAPDH (endogenous control) 






Native human monocytes display high E-selectin binding activity 
To assess engagement of human PBMCs to vascular E-selectin under hemodynamic flow 
conditions, tethering/rolling adhesive interactions of monocytes, CD4+ and CD8+T-cells and 
B-cells were examined on TNF-α-stimulated HUVEC monolayers using a parallel-plate flow 
chamber (Figure 1a).  Within the physiologic shear stress range of 1-4 dynes/cm2, monocytes 
uniformly exhibited the highest tethering/rolling capacity, followed by CD4+T-cells.  
Notably, monocyte adherence to HUVEC was maintained at steady levels at upwards of 7 
dynes/cm2.  CD8+T-cells showed minimal endothelial interactions that peaked at 1-2 
dynes/cm2, whereas B-cells did not exhibit rolling interactions (Figure 1a).  Pretreatment of 
PBMC subsets with sialidase or pre-incubating HUVECs with function blocking antibody 
against E-selectin each abrogated tethering/rolling interations of all PBMCs, confirming the 
specificity of E-selectin receptor/ligand interactions. 
To determine whether the observed variations in tethering/rolling capacity correlated with 
differential expression of E-selectin ligands, flow cytometry was performed using E-Ig 
chimera to measure E-selectin binding activity and mAb HECA-452 to measure expression 
levels of the canonical selectin-binding determinant sLeX.  All blood monocytes exhibited 
robust reactivity with E-Ig and HECA-452 mAb (Figure 1b).  Among lymphocytes, CD4+T-
cells exhibited greater E-Ig and HECA-452 reactivity than CD8+T-cells, whereas B-cells 
showed minimal reactivity (Figure 1b). 
To assess the relative contribution of glycoproteins versus glycolipids as E-selectin ligands, 
cells were treated with bromelain.  All PBMC subsets showed a substantial reduction of 
HECA-452 reactivity after bromelain treatment (Figure 1c), indicating that E-selectin 





Figure 1.  Human monocytes exhibit greater E-selectin binding activity compared to lymphocytes.  (a) 
Parallel-plate flow chamber analysis of tethering and rolling interactions of PBMCs on E-selectin-expressing 
endothelial cells.  Freshly isolated monocytes, CD4+ and CD8+T-cells, and B-cells were perfused over TNF-α-
stimulated HUVECs in flow with shear stress ranging from 0.5 to 8 dynes/cm2.  Cell tethering and rolling was 
observed and video-recorded for analysis.  The number of cells rolling on the HUVEC monolayer, as a fraction 
of total number of perfused cells, was quantified and averaged across three different fields of view at shear stress 
of 0.5, 1, 2, 4 and 8 dynes/cm2.  Monocytes and CD4+T-cells engaged in rolling and adhesive interactions at a 
shear stress of up to 8 dynes/cm2, whereas CD8+ and B-cells only engaged in minimal shear-resistant adhesive 
interactions.  The number of rolling cells for monocytes was three-fold greater than for CD4+T-cells.  Values are 
mean ± SEM; Data shown are from 5 independent experiments.  (b) Representative flow cytometry histograms 
of E-Ig (left) and HECA-452 (right) staining of monocytes, CD4+ and CD8+T-cells and B-cells.  Filled 
histograms represent incubation with isotype control or with E-selectin-Ig in the absence of Ca2+ (EDTA), and 
open histograms represent incubation with HECA-452 or E-Ig.  As shown, human monocytes express the 
highest levels of E-selectin ligands, followed by CD4+ and CD8+T-cells, whereas B-cells lack E-Ig and HECA-
452 reactivity.  (c) Bromelain treatment of PBMCs.  Untreated (black bars) or bromelain-treated (white bars) 
cells were stained with HECA-452 mAb and analyzed by flow cytometry.  Bromelain digestion decreased 





Glycoforms of CD43, CD44, PSGL-1 and a 70 kDa protein are E-selectin ligands on 
human monocytes 
To identify the molecular effectors of E-selectin binding by monocytes, E-Ig was used as 
probe in Western blot analysis.  As shown in Figure 2a, under reduced SDS-PAGE 
conditions, three prominent E-Ig-reactive bands were observed at ~120-130 kDa, ~80-90 kDa 
and ~70 kDa.  The monomer (i.e., reduced homodimer) of CLA migrates at  ~120-130 kDa: 
CLA has been reported to be an E-selectin ligand on human monocytes12,13 and flow 
cytometry confirmed surface expression of PSGL-1 on monocytes (Figure 2b).  E-selectin 
ligands were then immunoprecipitated from monocyte lysates using E-selectin-Ig chimera, 
and analyzed by Western blot using anti-PSGL-1 antibody as a probe.  As shown in Figure 
2c, staining with anti-PSGL-1 mAb was observed at ~120-130 kDa, providing direct evidence 
of CLA expression.  
Although not previously reported in monocytes, the sialofucosylated CD43 isoform - CD43E 
- has a molecular mass similar to CLA (~130 kDa) and functions as an E-selectin ligand in 
some human blood cells.5,14  Flow cytometry confirmed the surface expression of CD43 on 
human monocytes (Figure 2b).  The E-Ig immunoprecipitate also stained positive with anti-
CD43 antibody, confirming that the ~120-130 kDa E-Ig-reactive band corresponds to both 
CD43E and CLA (Figure 2c). 
HCELL, the E-selectin-binding glycovariant of CD44, migrates in reduced SDS-PAGE 
conditions as an ~80-90 kDa band.15  We observed high CD44 expression on monocytes by 
flow cytometry (Figure 2b).  Accordingly, E-Ig-immunoprecipitates of monocyte lysates 
were probed with anti-CD44 antibody on Western blots, and anti-CD44 mAb staining showed 
that the ~80-90 kDa band is HCELL (Figure 2c).   
The E-Ig-reactive ~70 kDa glycoprotein did not stain with anti-PSGL-1, anti-CD43 or anti-
CD44 mAbs and it is expressed on the cell surface of monocytes, as assessed by monocyte 
surface-biotinylation, followed by streptavidin pull-down of cell lysate material 
(Supplementary Figure 1).  A recent report suggested that G-CSF induces expression of an 
E-selectin-reactive glycoform of myeloperoxidase (designated “MPO-EL”) with molecular 
mass ~65 kDa16, however, MPO-immunoprecipitates from monocyte lysates did not stain 





Figure 2.  Identification of glycoprotein E-selectin ligands on human monocytes.  (a) Western blot analysis 
of whole cell lysate of human monocytes stained with E-Ig.  E-Ig staining of monocyte lysates resolved under 
reduced SDS-PAGE conditions revealed three principal bands at ~120-130 kDa, ~80-90 kDa, and ~70 kDa.  (b) 
Representative flow cytometry histograms of CD44, PSGL-1 and CD43 expression on human monocytes.  Filled 
histograms represent incubation with isotype control and open histograms represent incubation with specific 
antibodies.  As shown, human monocytes uniformly express CD44, PSGL-1 and CD43.  (c) Western blot 
analysis of glycoprotein E-selectin ligands of human monocytes.  E-Ig-immunoprecipitated  (E-Ig IP) proteins 
from cell lysates of human monocytes were resolved by SDS-PAGE, blotted, and stained with anti-PSGL-1 and 
anti-CD43 antibodies (Left panel) or with anti-CD44 antibody (Right panel).  In addition, CD44 was 
immunoprecipitated (CD44 IP) from cell lysates of human monocytes, resolved by SDS-PAGE, blotted, and 
stained with E-Ig (Right panel).  Human monocytes express PSGL-1, CD43 and CD44 scaffolds that display E-
selectin reactive epitopes.  (d) Western blot analysis of E-Ig-reactivity of human monocyte myeloperoxidase 
(MPO).  MPO was immunoprecipitated from monocyte lysates, resolved by SDS-PAGE, blotted, and stained 
with anti-MPO mAb (right) or E-Ig (left).  “Total” represents whole lysate and “Supn” corresponds to the 
cleared lysate, i.e., following MPO immunoprecipitation (“MPO IP”).  As shown, MPO is not an E-selectin 





Human CD4+T-cells natively express CLA, CD43E and HCELL, whereas CD8+T-cells 
express only CLA and CD43E, and B-cells lack E-selectin ligands 
To identify E-selectin ligands expressed on subsets of circulating lymphocytes, Western blot 
of CD4+, CD8+T-cell and B-cell lysates was performed using E-Ig as a probe.  As shown in 
Figure 3a, E-Ig staining of CD4+T-cell lysates revealed two distinct bands at ~120-130 kDa 
and ~80-90kDa, whereas staining of CD8+T-cell lysates showed one band at ~120-130 kDa, 
and B-cell lysates lack E-Ig reactivity (Figure 3a).  
Given the characteristic molecular weight of E-selectin-binding glycoforms of PSGL-1 and 
CD43 at ~120-130 kDa, and of CD44 at ~80-90 kDa, we performed flow cytometry to assess 
whether the relevant differences in E-Ig reactivity could reflect differential expression of 
these proteins among CD4+T-cells, CD8+T-cells, and B-cells.  As shown in Figure 3b, all 
CD4+ and CD8+T-cells express, at similar levels, PSGL-1, CD43, and CD44.  In contrast, B-
cells lack expression of PSGL-1, only a small proportion (~5%) of cells express CD43, and 
CD44 is uniformly expressed but at levels lower than that of T cells (Figure 3b). 
As shown in Figure 3c, in CD4+T-cells, PSGL-1 and CD43 immunoprecipitated from whole 
cell lysates showed robust staining with E-Ig, thus indicating expression of both CLA and 
CD43E.  Immunoprecipitated CD44 was also slightly reactive with E-Ig, revealing a low 
level of HCELL expression in CD4+T-cells.  In lysates of CD8+T-cells, PSGL-1- and CD43-
immunoprecipitates each showed reactivity with E-Ig, however, in contrast to CD4+T-cells, 
CD44-immunoprecipitates were not E-Ig reactive, indicating absence of HCELL expression 





Figure 3.  Identification of E-selectin ligands expressed on different subsets of lymphocytes.  (a) Western 
blot analysis of E-Ig-reactive proteins of human CD4+ and CD8+T-cells and B-cells.  Lysates were resolved by 
SDS-PAGE electrophoresis, and immunoblotted with E-Ig chimera.  CD4+ and CD8+ T-cells show two and one 
E-Ig reactive band, respectively, whereas B-cells lack E-Ig staining.  (b) Flow cytometry analysis of PSGL-1, 
CD43 and CD44 expression on human lymphocytes.  Filled histograms represent incubation with isotype control 
and opened histograms represent incubation with specific antibodies.  CD4+ and CD8+T-cells express high levels 
of PSGL-1, CD44 and CD43, whereas B-cells only express CD44 and a small amount of CD43.  (c) 
Identification of glycoprotein E-selectin ligands expressed on human T lymphocytes.  PSGL-1, CD43 and CD44 
were immunoprecipitated from whole cell lysates of human CD4+ and CD8+T-cells.  Immunoprecipitates were 
then resolved by SDS-PAGE, blotted and stained with E-selectin-Ig chimera (E-Ig).  Western blots reveal 
expression of E-selectin ligands CLA, CD43E and HCELL on human CD4+T-cells, and CLA and CD43E on 
human CD8+T-cells. 
 
E-selectin binding determinants on HCELL are displayed on O-glycans on monocytes 
and N-glycans on CD4+T-cells 
HCELL expression has previously been reported only in human hematopoietic stem and 
progenitors cells (HSPCs)15 and in certain types of tumors.17  Structurally, the HCELL 
glycoform identified on human HSPCs consists of sialofucosylated determinants decorating 
N-glycans of standard CD44.18  In contrast, tumors bearing HCELL glycoform display the 
relevant sialofucosylations on O-glycans.17,19  To determine whether the E-selectin binding 
determinants of HCELL on human monocytes and CD4+T-cells are displayed on N- or O-




from the protein backbone.  HCELL on KG1a cells presents its sLeX determinants solely on 
N-glycans, and, as control for efficiency of N-glycan cleavage, CD44-immunoprecipitates 
from KG1a lysates were treated with PNGase-F; the characteristic loss of E-Ig reactivity was 
observed on western blot (Figure 4a, left panel).  As expected from loss of sLeX expression, 
sialidase digestion resulted in abrogation of E-Ig-reactivity in both monocytes and CD4+T-
cells (Figure 4a). Notably, although PNGase-F treatment reduced the molecular weight of 
monocyte CD44, the intensity of E-Ig reactivity by western blot was not decreased, indicating 
that sLeX determinants are not displayed on N-glycans of monocyte CD44 (Figure 4a, 
middle panel).  However, in contrast, CD44-immunoprecipitates from CD4+T-cells 
completely lost E-Ig reactivity following PNGase-F treatment, indicating that HCELL in 
these cells exclusively displays sLeX on N-glycans (Figure 4a, right panel).    
 
HCELL is a functional E-selectin ligand on both human monocytes and CD4+T-cells  
To further assess the capacity of HCELL of human monocytes and CD4+T-cells to support E-
selectin-dependent cell rolling under physiological shear conditions, blot-rolling assays were 
performed.10,20  As shown in Figure 4b, CHO-E cells, but not CHO-M cells, exhibited rolling 
interactions on HCELL immunoprecipitated from monocytes and CD4+T-cells.  Taken 
together, these data confirm that HCELL is a functional E-selectin ligand in both monocytes 
and CD4+T-cells.  Importantly, although sLeX epitopes are displayed on O-glycans of CD44 






Figure 4.  HCELL is a functional E-selectin ligand on human monocytes and CD4+T-cells.  (a) CD44 
expressed by monocytes displays sLex E-selectin binding determinants on O-glycans.  CD44 was 
immunoprecipitated from whole cell lysates of KG1a cells (control) (left panel), monocytes (middle panel) and 
CD4+T-cells (right panel).  CD44 immunoprecipitates were left untreated, or treated with PNGase-F or sialidase.  
Samples were resolved by SDS-PAGE, blotted and stained with E-Ig.  In contrast to results obtained from 
PNGase-F digestion of HCELL of KG1a cells and CD4+T-cells, the persistence of E-Ig staining after PNGase-F 
digestion of HCELL from monocytes shows that CD44 displays sLeX O-glycans;  results are representative of a 
minimum of three separate experiments.  (b) Blot rolling assay of HCELL from monocytes and CD4+T-cells.  
CD44 was immunoprecipitated from cell lysates of monocytes (upper) and CD4+T-cells (lower).  
Immunoprecipitates were resolved by SDS-PAGE, blotted and stained with HECA-452 mAb.  Monocyte and 
CD4+T-cell lysates express the ~80-90kDa CD44 glycoform bearing sLeX (i.e., HCELL), and functional E-
selectin ligand activity was assessed by perfusion of E-selectin-transfected CHO cells (CHO-E) over blots at 
0.17 dynes/cm2.  Non-specific adhesion was assessed by perfusing mock-transfected CHO cells (CHO-M) over 





B-cells express low levels of α(1,3)-Fucosyltransferases  
To gain mechanistic insight into the observed absence of E-selectin ligand expression on B-
cells, we evaluated, by RT-PCR, the principal glycosyltransferases and glycosidases that 
mediate display of sLeX in monocytes and B-cells, which express the highest and lowest 
levels of E-selectin ligands, respectively (Figure 5).  There are 6 fucosyltransferases - FTIII-
VII and FTIX - that add α(1,3)-fucose to N-acetylglucosamine (GlcNac) within a type-2 
lactosamine (i.e., galactose-β(1,4)-N-acetylglucosamine).  FTIII/V-VII modify a sialylated-
lactosamine chain to create sLeX, whereas FTIV/IX only modify the core-lactosamine to 
make LeX.21  α(2,3)-sialylation to create sLeX is programmed by three α(2,3)-
sialyltransferases, ST3GalIII/IV/VI.22-24  However, it is important to distinguish between sLeX 
as displayed on relevant O- and N-linked glycans.  On O-glycans, sLeX is presented on a 
glycan-structure called “type-2 core extension”.  This core-2 structure is produced by core-2-
synthase, C2GnT1, which catalyzes the addition of GlcNac to an acceptor glycan known as a 
“core-1” structure.25  This process is abrogated by sialylation of the core-1 structure by 
ST3GalI or ST6GalNacII.25,26  On N-glycans, the initiation of lactosamine chains requires 
addition of the first GlcNac residue, catalyzed by the enzyme α(1,3)-mannosyl glycoprotein 
2-β-acetylglucosaminyltransferase (GlcNacT1/MGAT-1).27  GDP-Fucose Transporter-1 
(GDP-FucT1) is required for the uptake of GDP-fucose into Golgi-apparatus, where 
fucosylation of glycans and therefore formation of sLeX takes palce.28  In addition, fucosidase 
Fuc129 and sialidases Neu1 and Neu330,31 are responsible for cleaving fucose and sialic acid 
moieties from sLeX glycan structures, respectively.  The structural biology and enzyme 
mediators of sLeX displayed on glycoproteins are summarized in Figure 5a. 
As shown in Figure 5b, monocytes highly express all the α(1,3)-fucosyltransferases with the 
exception of FTV, whereas B-cells only express FTIV and FTVII.  Interestingly, FTVII 
transcript levels were similar between B-cells and monocytes, whereas FTIV expression was 
increased in monocytes.  Among the α(2,3)-sialyltransferases, ST3GalIII and ST3GalIV were 
expressed by both monocytes and B-cells, whereas ST3GalVI transcripts were only observed 
in monocytes.  The transcript levels of glycosyltransferase ST6GalNacII and the glycosidases 
Neu3 and Fuc1 were found to be expressed at low levels in both monocytes and B-cells 
(Figure 5b), and Neu1 and GDP-FucT1 transcript levels were similar in both cell types.  
Surprisingly, C2GnT1 transcripts were detected at higher levels in B-cells than in monocytes.  




cells have high levels of ST3GalI transcripts whereas monocytes have very low levels.  Thus, 
altogether, the "transcript signature" of B-cells reflects an enzyme expression pattern that 
would impede sLeX display.  
 
Figure 5.  Analysis of glycosyltransferase gene expression on human monocytes and B-cells.  (a) Synthesis 
of O-linked and N-linked glycans carrying the sLeX determinants.  O-glycan synthesis is initiated by an N-
acetylgalactosaminyltransferase that transfers an N-acetylgalactosamine residue (GalNac) to a serine or 
threonine, forming the Tn antigen. Tn antigen can be sialylated by the activity of the α(2,6)-sialyltransferase 
ST6GalNac-II, yielding the sialyl-Tn antigen (sTn),  which ceases further sugar modification.  Alternatively, the 
transfer of galactose (Gal) to Tn antigen leads to formation of T antigen (core 1) by core 1 β(1,3)-
galactosyltransferase (Core 1GalT).  T antigen sialylation can be catalyzed by α(2,3)-sialyltransferase ST3GalI 
or α(2,6)-sialyltransferase ST6GalNac-II, forming sialyl-T (sT) or sialyl-6T (s6T) antigens, respectively.  In 
absence of sialylation, core 1 can be modified by addition of N-acetylglucosamine (GlcNAc) by β(1,6)-N-
acetylglucosaminyltransferase (C2GnT1), forming the “core-2” structure.  Repetitive sequential, alternating 
additions of galactose and N-acetylglucosamine, respectively, create the lactosaminyl glycan chain that serves as 
an acceptor for terminal sialofucosylations to create sLeX.  On the substrate N-glycan Man5GlcNAc2 structure, 
biosynthesis of hybrid and complex glycans is initiated by the action of N-acetylglucosaminyltransferase-1 
(GlcNAcT1/MGAT-1), which adds a GlcNac residue to the mannose present on the α(1-3)-arm of the core 
mannose.  The resulting structure can either lose two mannose units off the α(1-6)-arm of the core mannose (by 
action of mannosidase II), leading to the formation of complex N-glycans, or not lose these mannoses, 
generating hybrid N-glycans.  The sialyltransferases (ST3GalIII, IV and VI) terminate the elongation of both O- 
and N-Glycans by creating sialylated lactosamine chains that can be then fucosylated by the action of the 
fucosyltransferases FTIII, V, VI and VII, creating sLeX.  Neuraminidases 1 and 3 (Neu1, Neu3) and Fucosidase 
1 (Fuc1) may then remove sialic acids or fucose moieties, respectively, down-regulating the expression of sLeX 
epitopes.  (b) Real-time PCR analysis of glycosyltransferases involved in sLeX biosynthesis in monocytes (black 




B-cells exhibit a “transcript signature" of glycosyltransferases that favors a lower expression of sLeX synthesis 
compared to monocytes.  Experiments were performed with a minimum of six healthy donors. 
 
FTVII exofucosylation enhances the expression of functional E-selectin ligands 
Cell surface α(1,3)-exofucosylation can yield increased expression of E-selectin ligands,5,32 
but only if target cells display (unfucosylated) sialylated lactosaminyl glycans that can be 
converted to sLeX determinants.  To assess the extent to which α(1,3)-exofucosylation would 
enforce E-selectin ligand expression among the different PBMC subsets and the identity of 
relevant glycoprotein E-selectin ligands thus created, we treated cells with the enzyme 
fucosyltransferase VII (FTVII) in the presence of donor GDP-fucose.  FTVII-treated 
monocytes showed dramatically increased expression of many HECA-452-reactive 
glycoproteins, including bands corresponding to CLA/CD43E, HCELL and the ~70kDa 
molecule (Figure 6a).  To assess which of the protein scaffolds are preferentially targeted by 
exofucosylation, E-Ig-immunoprecipitates from lysates of buffer-treated and FTVII-treated 
monocytes were resolved by SDS-PAGE, and blotted with anti-PSGL-1, anti-CD44, and anti-
CD43 antibodies.  CD43E expression was dramatically increased following FTVII treatment, 
whereas the expression of CLA and HCELL increased to a lesser extent (Figure 6a).  
Interestingly, despite exhaustive immunoprecipitation of CD44 (Figure 6b), we observed 
persistent E-Ig-reactivity in the cleared lysates, indicating the presence of another sLeX-
decorated scaffold protein within the CD44 MW range.  
For each lymphocyte subset, PSGL-1, CD43 and CD44 were sequentially 
immunoprecipitated from buffer-treated and FTVII-treated cells.  For CD4+T-cells, there was 
a minor increase in expression of CLA and CD43E after exofucosylation with a more marked 
increase in HCELL (Figure 6c).  In contrast, in CD8+T-cells, CLA and CD43E expression 
increased following FTVII treatment with only a minor increase in HCELL expression.  
However, in B-cells, exofucosylation engendered only CD43E, indicating that CD44 on B 
cells are not decorated with relevant acceptor sialyllactosaminyl glycans (Figure 6c). 
To analyze the impact of exofucosylation on E-selectin binding of PBMC subsets, we 
compared the ability of buffer-treated and FTVII-treated cells to engage with E-selectin under 
physiological shear stress conditions.  FTVII treatment resulted in significant increases in the 
number of tethering/rolling cells among all PBMC subsets (Figure 6d), yielding a 1.5- to 3-




fold increase in rolling of CD8+T-cells, and a relatively modest but significant increase in 
rolling of B-cells.  To assess E-selectin-dependent rolling/tethering specificity, PBMC subsets 
were sialidase-treated or HUVECs were pre-incubated with a function-blocking antibody 
against E-selectin; in each case, dramatic reductions in tethering/rolling was observed 










Figure 6.  E-selectin ligand expression on monocytes and lymphocytes is increased by cell surface α(1,3)-
fucosylation.  (a) FTVII-mediated exofucosylation of monocytes creates E-selectin ligands on multiple cell 
surface glycoproteins.  Human monocytes were treated with fucosyltransferase VII (FTVII) or buffer alone 
(BT).  Cell lysate was immunoprecipitated with E selectin-Ig (E-Ig IP), resolved by SDS-PAGE, and blotted 
with HECA-452, anti-PSGL-1, anti-CD43 or anti-CD44 antibodies.  A marked increase in E-Ig reactivity on the 
CD43 scaffold was observed, with smaller increases of E-Ig reactivity on PSGL-1 and CD44.  (b) FTVII-
mediated exofucosylation of monocytes creates a novel ~90-kDa E-selectin ligand. CD44 immunoprecipitation 
was performed on cell lysate from FTVII-treated monocytes.  Total cell lysate (Total), CD44 immunoprecipitate 
(IP), and cleared lysate (Supn) were resolved by SDS-PAGE and blotted with anti-CD44 mAb (left) or E-Ig 
(right).  Following complete clearance of CD44, E-Ig-reactivity persists at ~90 kDa, indicating enforced 
expression of a presently unknown E-selectin ligand.  (c) FTVII-mediated exofucosylation of CD4+T-cells, 
CD8+T-cells, and B-cells variably converts PSGL-1, CD43 and/or CD44 to E-selectin ligands.  Human CD4+T-
cells, CD8+T-cells, and B-cells were treated with fucosyltransferase VII (FTVII) or buffer alone (BT), and 
lysates were immunoprecipitated with PSGL-1, CD43, or CD44 mAbs.  Immunoprecipitated products were 
resolved by SDS-PAGE and blotted with E-Ig.  As shown in blot, exofucosylation of CD4+T-cells increases E-
selectin binding primarily on CD44, whereas exofucosylation increases E-selectin binding on all three scaffold 
proteins of CD8+T-cells, and exclusively on CD43 of B-cells.  (d) FTVII treatment creates functional E-selectin 
ligands on monocytes and lymphocytes.  Human monocytes, CD4+ and CD8+T-cells and B-cells were treated 
with fucosyltransferase VII (FTVII) or buffer alone (BT), and were subsequently perfused into a parallel-plate 
flow chamber seeded with TNF-α-stimulated HUVEC at shear stresses of 0.5, 1, 2, 4, and 8 dynes/cm2.  All 
PBMC subsets exhibited significantly increased tethering/rolling after FTVII treatment.  To control for E-
selectin-dependent rolling specificity, PBMCs were pre-treated with sialidase, or HUVECs were preincubated 




In areas of tissue inflammation, those circulating leukocytes which express relevant 
molecular effectors of extravasation will accumulate at the affected site.  In humans, the 
migration of circulating leukocytes into inflamed tissues is principally initiated by binding to 
E-selectin, which is induced by inflammatory cytokines within endothelial beds at all sites of 
inflammation.33-35  To date, studies of the function and structure of leukocyte E-selectin 
ligands have focused largely on neutrophils.  Our knowledge of the E-selectin ligands 
expressed among circulating mononuclear cells is grossly incomplete, and prior studies of 
mononuclear leukocyte E-selection ligands have concentrated principally on mouse cells.4 
Though sLeX is an E-selectin binding determinant in both humans and mice, there are 
significant differences between human and murine leukocyte biology, and, more broadly, 
immunobiology.36 Accordingly, an appropriate understanding of human leukocyte trafficking 
requires study of human cells, ideally, primary human cells.  Here, we investigated the 
function and structural biology of the E-selectin ligands expressed on the major subsets of 
native human peripheral blood mononuclear cells (PBMCs): monocytes, B-cells, and CD4+ 




Our findings reveal a previously unsuspected functional and structural diversity of E-selectin 
ligand expression among PBMC subsets. Using the parallel-plate flow chamber, we observed 
that among PBMCs, monocytes exhibit the most robust E-selectin binding activity under 
shear stress conditions, followed by CD4+T-cells, but CD8+T and B-cells exhibit little to no 
activity.  These findings were consistent with flow cytometry results showing that monocytes 
exhibit the greatest reactivity to E-selectin-Ig (E-Ig) and to HECA-452, followed, in 
decreasing order, by CD4+T-cells, CD8+T-cells, and B-cells.  The strong correlation between 
HECA-452 staining and both E-Ig-reactivity and E-selectin binding under shear stress is 
reflective of the fact that sLeX is the predominant E-selectin binding determinant expressed 
on PBMCs.  Moreover, the major carriers of this determinant are glycoproteins rather than 
glycolipids, as shown by the significant abrogation of HECA-452 reactivity upon cell surface 
protein digestion with bromelain.   
To identify the specific E-selectin ligands expressed by PBMCs, Western blotting was 
conducted using E-Ig as a probe.  In monocyte lysates, we observed three distinct E-Ig-
reactive bands under reduced SDS-PAGE conditions: the upper band (~120-130 kDa) is 
comprised of CD43E and the monomer form of CLA, the middle band (~80-90 kDa) is 
HCELL, and the lower band (~70 kDa) is a currently-unidentified E-selectin ligand unrelated 
to the structure known as MPO-EL.16  Our dataset is the first to describe expression of 
CD43E on monocytes.  CD43 has previously been described to function as an E-selectin 
ligand on both human and murine T-cells14,37,38 and  HSPCs,5 and on murine neutrophils.39   
In western blots of CD4+T-cell lysates, we observed two distinct E-Ig-reactive bands at ~120-
130 kDa and ~80-90 kDa, while CD8+T-cells express only one E-Ig-reactive band at ~120-
130 kDa and B cells do not express any E-selectin-reactive glycoproteins.  As with 
monocytes, the ~120-130kDa band consists of CD43E and the monomer form of CLA, both 
of which are natively expressed by CD4+ and CD8+T-cells.  In addition, we identified HCELL 
as the ~80-90 kDa E-selectin ligand expressed by CD4+T-cells.   
Our data show, for the first time, that HCELL, a human E-selectin ligand previously 
recognized on native HSPCs5,15, can be expressed on mature human leukocytes.  However, 
HCELL of human HSPCs and of CD4+T-cells expresses its E-selectin-reactive 
sialofucosylated determinants on N-glycans, whereas the HCELL glycoform of monocytes 
displays these determinants on O-glycans.  By western blot, the E-Ig-reactivity of HCELL is 




blot rolling assays indicate that HCELL is a functional E-selectin ligand in both monocytes 
and CD4+T-cells.  HCELL is the most potent E-selectin ligand expressed on human cells1,5, 
and HCELL expression on human monocytes and CD4+T-cells is consistent with the higher 
capacity of these cells to undertake tethering/rolling adhesive interactions on TNF-α-
stimulated endothelium under shear stress (Figure 1a).  Importantly, we found that human 
PBMCs do not express the glycoprotein known as E-selectin ligand-1 (ESL-1) that functions 
as the most potent E-selectin ligand on mouse leukocytes.40 Collectively, this discrepancy and 
the observed differences in HCELL expression among PBMCs underscore the key fact that 
there is considerable species-specific and cell-specific variability in the structural biology of 
E-selectin ligands.	   
To gain mechanistic insight into cell type-specific differences in E-selectin ligand expression, 
we performed quantitative PCR studies of relevant glycosyltransferases directing sLeX 
synthesis on B-cells and monocytes, and performed α(1,3)-exofucosylation of the different 
PBMC subsets to probe the breadth and relative level of expression of sialyllactosaminyl 
glycan acceptors.  Human B-cells have low expression of fucosyltransferase genes, but 
broadly express transcripts encoding the α(2,3)-sialyltransferases necessary for the 
production of sialyllactosaminyl glycans.  Moreover, compared to monocytes, B-cells 
expressed higher and lower levels of ST3GalI and MGAT-1, respectively.  A higher 
expression of ST3GalI is associated with the formation of the sialyl-T (sT) antigen, blocking 
core-2 formation and thereby down-regulating sLeX displayed on O-glycans.41  The lower 
expression of MGAT-1 results in fewer lactosaminyl glycans on N-glycans.42  Collectively, 
this pattern of glycosyltransferase gene expression, in addition to the relatively low 
expression of scaffold proteins for sLeX decorations, accounts for the paucity of E-selectin 
ligand expression in B-cells.  However, among all the different PBMC subsets, α(1,3)-
exofucosylation markedly increased E-selectin binding activity, indicating that each subset 
displays acceptor terminal sialylated type-2 lactosamine units that can be extrinsically 
fucosylated to create the sLeX determinant.  Notably, the protein scaffolds preferentially 
targeted by exofucosylation in the various PBMC subsets were strikingly different.  The fact 
that monocytes, CD4+ and CD8+T-cells express equivalently high levels of PSGL-1, CD44, 
and CD43 - and yet these proteins are differentially modified with sialofucosylated lattice - 
indicates that there is cell-specific sorting/segregation of protein scaffolds that serve as 
acceptors for glycan modification within the Golgi-apparatus.  Paradoxically, although B-




CD43E, indicating that CD43 is the predominant carrier of sialyllactosaminyl glycans on B-
cell surface (Figure 6c).  Commensurately, although exofucosylation upregulated E-selectin 
binding activity on all PBMC subsets (Figure 6d), B-cells had the lowest capacity to engage 
E-selectin under hemodynamic shear conditions. 
The orchestration of immunity critically depends on the efficient migration of relevant 
immune effector cells.  The ability of circulating leukocytes to adhere to vascular 
endothelium is fundamental to initiating and propagating any immune response, and, as such, 
the distinct repertoires of adhesion molecules expressed on the surface of PBMCs are tightly 
linked to the roles of such cells in immunity.  This study is the first comprehensive analysis of 
the structures that serve as E-selectin ligands on relevant subsets of primary human PBMCs.  
The observed distinct differences in E-selectin ligand expression among circulating human 
lymphocytes and monocytes provide key insights into their native ability for migration in 
steady-state into skin or marrow (where E-selectin is constitutively expressed), and in 
response to inflammation and/or tissue injury (where E-selectin expression is upregulated).43  
Notably, our results provide first evidence that human monocytes exhibit remarkably high E-
selectin ligand activity which is conferred by expression of multiple E-selectin ligands 
including HCELL, a highly potent E-selectin ligand. The high E-selectin binding activity of 
monocytes offers mechanistic insight on the conspicuous propensity of these cells to adhere 
to inflamed vascular endothelium, a process that underlies several vascular inflammatory 
diseases, including atherosclerosis.44  Moreover, the prominent E-selectin ligand activity 
mediates monocyte tropism to inflamed endothelial beds thereby licensing 
immunosurveillance appropriate to the role(s) of these cells as key sentinels of host defense 
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Protein  Forward Primer (5’–3’)  Reverse Primer (5’–3’)  Reference 
FTIII 
 GCCGACCGCAAGGTGTAC TGACTTAGGGTTGGACATGATATCC 45 
FTIV  
 GGGTTTGGATGAACTTCGAGTCG GGTAGCCATAAGGCACAAAGACG OriGene 
FTV  
 ACCTGAGCTACTTTCACTGGCG TCAGGTGAACCAAGCCGCTATG OriGene 
FTVI  
AATGGGTCCCGCTTCCCAGACAG GCGTCCGTACACGTCCACCTTG 46 
FTVII  
TCCGCGTGCGACTGTTC GTGTGGGTAGCGGTCACAGA 45 
FTIX 
TCCCATGCAGTTCTGATCCAT GAAGGGTGGCCTAGCTTGCT 45 
GlcNacT-1/MGAT-1 
CCTATGACCGAGATTTCCTCGC TGAAGCTGTCCCTGCCCGTATA OriGene 
C2GnT1  
AACCCCTTAGTAAAGAAGAGGCG  AGCAGCCTGTCAAGCATTTCA  PrimerBank  
GDP-Fucose Transporter 1  
CTGCCTCAAGTACGTCGGTG CCGATGATGATACCGCAGGTG 47  
ST3GalI  
AAGAGGACCCTGAAAGTGCTC  CTCCAGGACCATCTGCTTGG  PrimerBank  
ST3GalIII  
GCCTGCTGAATTAGCCACCAA GCCCACTTGCGAAAGGAGT  PrimerBank  
ST3GalIV  
CTTCCTGCGGCTTGAGGATTA  CTCACTCCCCTTGGTCCCATA  PrimerBank  
ST3GalVI  
ACTGCATTGCATATTATGGGGAA  TGGCTTTGATAAACAAGGCTGG  OriGene  
ST6GalNAcII  
ACTTCCGTGGCCTGTTCAATC  GGCGATGACTTGGTGAGAGAG  PrimerBank  
Neu1  
GGAGGCTGTAGGGTTTGGG  CACCAGACCGAAGTCGTTCT  PrimerBank  
Neu3  
AAGTGACAACATGCTCCTTCAA  TCTCCTCGTAGAACGCTTCTC  PrimerBank  
Fucosidase1 
AGTCACCCTGTTGCCTATGG TTTGGCGCTTTTAGATTGCT 48  
Supplemental Table S1 









Supplemental Fig. S1 
E-selectin-reactive 70kDa unidentified glycoprotein in monocytes is a cell surface protein.  Monocyte 
surface was labeled with biotin derivate products and lysed.  Biotinylated proteins were collected on 
streptavidin beads, SDS/PAGE resolved, blotted, and stained with E-Ig.  Three E-Ig reactive bands were 
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KEY POINTS 
(1) HCELL, a CD44 glycoform that potently binds E-selectin, is expressed on human 
CD14-selected monocyte-derived DCs (CD14-S mo-DCs).   
(2) CD44 engagement on CD14-S mo-DCs triggers VLA-4-dependent adhesiveness, 






The ability of circulating dendritic cells (DCs) to extravasate at inflammatory sites is critical 
to immunoregulation.  Here, we examined the adhesion molecules mediating transendothelial 
migration (TEM) of culture-expanded human monocyte derived-DCs (mo-DCs) on TNFα-
stimulated HUVEC monolayers.  We observed that in absence of applied chemokine 
gradients, mo-DCs undertake TEM and that mo-DCs generated by monocyte enrichment via 
CD14-selection (CD14-S) display 2-fold greater TEM than those generated following plastic 
adherence-selection (PA-S).  Binding assays using function-blocking mAb and substrate 
adhesion molecules showed that the augmented TEM of CD14-S mo-DC is E-selectin- and 
VLA-4-dependent, and that engagement of E-selectin ligands induces VLA-4 activation on 
CD14-S mo-DCs but not on PA-S mo-DCs.  Biochemical studies showed that E-selectin 
binding glycoforms of PSGL-1 (i.e., CLA) and CD44 (i.e., HCELL) were both expressed on 
CD14-S mo-DCs, but only CLA was found on PA-S mo-DCs.  Exoglycosylation of CD14-S 
mo-DCs using α-(1,3)-fucosyltransferase significantly increased expression of CLA and 
HCELL, and these glycoengineered cells exhibited increased TEM.  To evaluate how 
engagement of CD44 and PSGL-1 each influence TEM of mo-DCs, cells were treated with 
their ligands hyaluronic acid or P-selectin, respectively, prior to incubation with stimulated 
HUVECs.  Ligation of CD44 on CD14-S mo-DCs, but not CD44 on PA-S mo-DCs, triggered 
VLA-4 activation and TEM, whereas PSGL-1 ligation had no effect on VLA-4 function.  
These findings highlight structural and functional pleiotropism of CD44 in priming TEM of 
culture-expanded mo-DCs, and suggest that strategies to enforce HCELL expression could 
boost CD14-S mo-DC recruitment at inflammatory sites by augmenting E-selectin-driven, 









Dendritic cells (DCs) are leukocytes specialized to capture and present antigens. DCs are 
located within tissues throughout the body, where they serve as sentinels of host defense, 
orchestrating immune responses by activating naïve and memory T cells.1  Though DCs can 
prime T cell immunoreactivity within tissues in situ,2,3 they typically exit tissues via afferent 
lymphatics, thereafter accumulating in lymph nodes wherein they induce proliferation of 
antigen-responsive T cells.  As such, the extravasation of DC at inflammatory sites enables 
antigen presentation and T cell activation.4  Previous studies have indicated that in vitro 
conditions for generating DCs can negatively affect tissue migration in vivo, thus markedly 
lessening their efficacy in adoptive DC-based immunotherapeutics.5,6   
Extravasation of blood-borne cells involves a multistep cascade of events initiated by 
hemodynamic shear-resistant adhesion of cells to target endothelium.  This important 
function is mediated most efficiently by engagement of selectins with sialofucosylated 
glycans, prototypically sialyl Lewis X (sLex; NeuAc-α(2,3)-Gal-β(1,4)-[Fuc-α(1,3)]GlcNAc-
R), displayed on cell surface protein or lipid scaffolds.7  The vascular selectins are comprised 
of E- and P-selectin, which are inducible by inflammatory cytokines.8,9  Sialofucosylated 
ligands for vascular selectins serve as tissue “homing receptors” on circulating cells, and 
mediate tethering and rolling of the cells on the endothelium (Step 1).  The cells then undergo 
“Step 2” activation of integrin adhesiveness, typically via chemokine receptor signaling, 
leading to firm adhesion on the endothelium (Step 3), and then transendothelial migration 
(TEM) (Step 4).7  Importantly, the principal inflammatory cytokines, tumor necrosis factor−α 
(TNFα) and interleukin (IL)-1β, upregulate both E- and P-selectin expression in murine 
endothelial cells, but the promoter elements responsive to TNFα and IL-1β in the human P-
selectin gene are absent.10  Thus, in humans, E-selectin receptor/ligand interactions play a 
predominant role in recruitment of cells to inflammatory sites, prompting development of 
strategies to enforce E-selectin ligand expression on relevant human cells to optimize their 
utility in adoptive immunotherapeutics. 
The molecular effectors mediating DC adherence to endothelium and consequent TEM have 
not been fully elucidated.  To date, P-selectin glycoprotein ligand-1 (PSGL-1) is the only sLex 
scaffold reported to be expressed on human DCs, and PSGL-1 is the principal P-selectin 
counterreceptor in human mo-DCs.11-13  Though a heavily sialofucosylated glycoform of 




described on DCs,11 our knowledge of the breadth and function of human mo-DC 
glycoconjugate counterreceptors for E-selectin is incomplete.  In humans, hematopoietic stem 
cells express a CD44 glycoform known as Hematopoietic Cell E-selectin/ L-selectin Ligand 
(HCELL),14,15 which serves as a potent E-selectin ligand.  CD44 expression is characteristic 
of human DCs and is known to be critical for DC lodgment within T cell zones of lymph 
nodes and formation of immunological synapses,16,17 but its role in mediating recruitment of 
blood-borne DC into tissues has not been evaluated. 
In this study, we examined TEM of human blood monocyte-derived DCs (mo-DCs) on 
primary cultures of human umbilical vein endothelial cells (HUVECs) treated with TNFα to 
mimic inflammation-related endothelial expression of E-selectin and vascular cell adhesion 
molecule-1 ((VCAM-1), a ligand for integrin VLA-4).  We observed that mo-DCs generated 
from monocytes enriched using CD14-bead selection (CD14-S mo-DCs) or plastic adherence 
selection (PA-S mo-DCs) can each execute TEM in absence of applied chemokine gradients, 
but CD14-S mo-DCs display much greater TEM than do PA-S cells.  TEM is dependent on 
engagement of mo-DC E-selectin ligands, and, notably, both HCELL and CLA are expressed 
by CD14-S mo-DCs whereas only CLA is expressed on PA-S mo-DCs.  Engagement of 
CD44 on CD14-S mo-DCs, but not CD44 on PA-S mo-DCs, directly activates VLA-4 
thereby programming TEM on TNFα stimulated HUVECs, and enforced HCELL expression 
by α-(1,3)-exofucosylation of CD14-S mo-DC significantly increases TEM.  Collectively, 
these findings unveil a previously unrecognized structural and functional versatility of CD44 
on culture-expanded human DCs, and suggest that glycosylation of CD44 to engender 
HCELL expression may be exploited to promote DC migration to sites of inflammation. 
 
 
Material and Methods 
Cell isolation and culture  
Human peripheral blood mononuclear cells (PBMCs) were isolated from blood of healthy 
donors obtained by venipuncture, under protocols approved by the Institutional Review Board 
of Brigham & Women’s Hospital, with Informed Consent provided as per the Declaration of 




(Miltenyi Biotech) (CD14-S) or by plastic adherence (PA-S), and cultured as described.18,19  
After 5 days, mo-DCs were matured with TNFα (25 ng/mL, R&D Systems) for 2 or 3 days 
(as specified), or left untreated (immature DCs).  For activation, mo-DCs were treated with 
200 ng/ml of phorbol 12-myristate 13-acetate (PMA, Sigma) in RPMI media for 30 min at 
37ºC.  HUVECs were obtained from the BWH Pathology Core facility and cultured as 
described.13,20   
 
Antibody reagents and flow cytometry 
Cell surface staining of mo-DCs for flow cytometry was performed as described 
previously13,18 using commercially-available mouse E-selectin-human Fc Ig chimera (E-Ig) 
and antibody reagents directed to sLex, CD14, CD44, PSGL-1, MHC-II,  CD86, and to 
resting and activation-dependent epitopes of VLA-4 and LFA-1 (for full description, see 
Supplemental Methods).  	  
 
Blot Rolling Assay 
Blot rolling assays to detect E-selectin ligands on PVDF membrane blots of cell lysate 
proteins resolved by SDS-PAGE were performed as previously described,21 (see 
Supplemental Methods for details).  
 
Isolation of RNA and Real-Time PCR  
Total RNA was extracted and reverse transcribed as described.18  Real-Time PCR (RT-PCR) 
was performed using SYBR Green PCR Master Mix (Applied Biosystems).  Primers were 
selected from PrimerBank22 (supplemental Table S1) and gene expression was normalized to 
GAPDH (endogenous reference) expression.  The normalized mRNA expression was 
computed as a permillage fraction (‰), which means the proportion of target mRNA per 
thousand of the reference GAPDH mRNA expression, calculated by using the 2-ΔCT×1000 





Transendothelial migration (TEM) assays  
For TEM analysis under non-shear conditions, mo-DCs (4×105 cells/ well) were labeled with 
carboxyfluorescein succinimidyl ester (CFSE, Molecular Probes) and placed in a transwell 
chamber containing HUVEC monolayers  (cultured on 8 µm pore membrane, Millipore); to 
induce HUVEC E-selectin and VCAM-1 expression, monolayers were exposed to TNFα (40 
ng/mL) for 6 h (“stimulated” HUVECs).  All assays were performed under serum- and 
chemokine-free conditions at 37°C for 12 h, and cell migration to the underside of transwell 
membrane was quantified by fluorescence microscopy.  Controls consisted of evaluation of 
TEM on unstimulated HUVEC monolayers, and on stimulated HUVECs treated with function 
blocking anti-human E-selectin or isotype control mAb (20 µg/mL, 30 min).  In some 
experiments, mo-DCs were treated with function blocking anti-VLA-4 mAb HP2/1 
(Millipore) or anti-LFA-1 mAb 2425 (20 µg/mL, 30 min) or pertussis toxin (PTX, Sigma) 
(250 ng/mL, 2 h).   
For TEM analysis under hemodynamic fluid shear conditions, HUVECs were cultured on the 
underside of a transwell insert, stimulated with TNFα (as above), and placed into a flow 
chamber mounted on an inverted microscope, as previously described.20  Mo-DCs (4×106 
cells/mL) were perfused at 37°C over HUVECs at an initial shear rate of 0.5 dynes/cm2 with 
subsequently increasing shear stress stepwise every 30 seconds until 7.5 dynes/ cm2.  The 
number of tethering and rolling mo-DCs, per cm2 HUVEC area was quantified during each 30 
second segment and the number of cells that became firmly adherent was recorded.20  The 
average rolling velocity, a measure of selectin binding strength, was evaluated at 2.0 dyn/cm2, 
as the displacement of the centroid of the cell over 1 sec intervals.  All experiments were 
performed and video-recorded for analysis. 
 
CS-1 fragment binding assay following E-selectin and hyaluronic acid engagement   
Mo-DCs were placed in culture plates seeded with CHO-E or with mock transfectants (CHO-
mock), or coated with E-Ig or high molecular weight hyaluronic acid (HA), as detailed in the 
Supplemental Methods.  Binding of mo-DCs to segment-1 peptide (CS1) was then assessed 





Western blotting and immunoprecipitation 
Immunoprecipitation of CD44, PSGL-1, and E-selectin ligands (collected using E-Ig as 
probe) was conducted as described in the Supplemental Methods.  Cell lysate proteins or 
immunoprecipitated proteins were resolved on reducing SDS-PAGE gels and 
electrotransferred to PVDF membranes.  E-Ig staining was done using a 3-step protocol (E-Ig 
immunostaining, followed by rat anti-mouse CD62E mAb (R&D Systems), then followed by 
horseradish peroxidise (HRP)-conjugated anti-rat IgG).  Specificity for E-Ig binding was 
confirmed by loss of E-Ig reactivity in presence of EDTA and following sialidase treatment 
(to remove sialic acid from sLex). 
 
Fucosyltransferase VI treatment 
Cells were treated as previously described26 with 60 mU/mL FTVI27, and effectiveness of 
α(,3)-exofucosylation was assessed by flow cytometry and western blot analysis of sLex 
expression and E-Ig reactivity (for details, see Supplemental Methods).  
 
Statistical analysis 
Data are expressed as the mean ± standard deviation (SD).  Statistical significance was 
determined using the GraphPad PRISM software version 6.00 (San Diego, CA).  Differences 
between means were determined by one-way analysis of variance.  Multiple comparisons 






CD14-S mo-DCs display markedly higher TEM than PA-S mo-DCs on stimulated 
HUVEC monolayers 
To assess whether monocyte enrichment methods affect endothelial adhesive interactions of 
differentiated mo-DCs, we compared the ability of CD14-S and PA-S mo-DCs to execute 
TEM on unstimulated HUVECs and HUVECs stimulated with TNFα to up-regulate E-
selectin and VCAM-1 expression.28  While both types of mo-DCs have higher TEM on 
stimulated compared to unstimulated HUVECs, CD14-S mo-DCs undertake markedly more 
TEM on stimulated HUVECs compared to PA-S mo-DCs (Figure 1A); this augmented TEM 
was abrogated by function blocking antibodies against E-selectin and by sialidase treatment 
of mo-DCs, highlighting a key role for E-selectin receptor/ligand interactions in the 
extravasation process (Figure 1A).  Moreover, the heightened TEM of CD14-S mo-DCs was 
blocked by function-blocking mAb to the VCAM-1 ligand, VLA-4 (i.e., α4β1 or 
CD49d/CD29) but not to the ICAM-1 ligand LFA-1 (αLβ2, CD11a/CD18) (Figure 1A), 
indicating that the observed TEM on stimulated HUVEC requires engagement of both E-
selectin/E-selectin ligands and VLA-4/VCAM-1.  Furthermore, pretreatment with pertussis 
toxin (PTX), a specific inhibitor of Gαi-dependent signaling, inhibited TEM of both types of 
mo-DC (Figure 1A), indicating that G-protein-mediated signaling is requisite for mo-DC 
transmigration.  
In human mesenchymal stem cells and lymphoid cells,26,27,29 it has been reported that 
engagement of E-selectin ligands directly up-regulates VLA-4 integrin-mediated binding in 
the absence of chemokine input.  We thus sought to examine whether β1 integrin activation 
occurs following engagement of E-selectin ligands on CD14-S and PA-S mo-DCs.  To assess 
VLA-4 function, we tested mo-DC adhesiveness to CS-1 fibronectin fragment, binding to 
which depends on activation of VLA-4.  Engagement of CD14-S mo-DCs on immobilized E-
selectin significantly increased adhesiveness of these cells to CS-1 fibronectin fragment 
(Figure 1B). CS-1 adhesiveness was significantly reduced by function-blocking mAb against 
E-selectin, confirming the contribution of E-selectin engagement in priming VLA-4 binding 
to CS-1 (Figure 1B).  However, engagement of PA-S mo-DCs on E-selectin did not induce 
significant mo-DC adherence to CS-1 fibronectin (Figure 1B), which was consistent with 
their reduced TEM ability on stimulated HUVECs.  Staining with mAb directed to activation 




immobilized E-selectin and was not observed on PA-S cells, consistent with lack of 
fibronectin binding by these cells (Figure 1C).  Activation of the β2-integrin LFA-1 
(CD11/CD18) after engagement on immobilized E-selectin was not observed on CD14-S mo-
DCs (Supplemental Figure S1).  Collectively, these data show that engagement of E-selectin 
ligands on human CD14-S mo-DCs, but not PA-S mo-DCs, leads directly to activation of 
VLA-4 and subsequent transmigration.  
 
Figure 1.  Transendothelial migration of mo-DCs is dependent on engagement of E-selectin ligands and 
VLA-4.  (A) Transendothelial migration (TEM) assay of CD14-S and PA-S mo-DCs on HUVEC monolayers.  




DCs transmigrated on non-stimulated HUVECs. TEM was assessed using mo-DCs (untreated), mo-DCs 
preincubated with isotype control or with function blocking anti-LFA-1 mAb or with function blocking anti-
VLA-4 mAb, HUVECs preincubated with function blocking anti-E-selectin mAb, and mo-DCs treated with 
sialidase or pertussis toxin (PTX).  (B) Adhesiveness to CS-1 fibronectin fragment of CD14-S or PA-S mo-DCs.  
Cells were first incubated on uncoated or E-selectin-coated plates and then tested for binding to CS-1 peptide 
coated plates.  Mo-DCs were stained with crystal violet and adherence was quantified by measuring light 
absorbance at 595 nm. Function blocking anti-E-selectin mAb was used as negative control and PMA treatment 
used as a positive control.  (C) Flow cytometry analysis of activated β1-integrin expression by CD14-S and PA-
S mo-DCs.  Mo-DCs were incubated on uncoated plates or on E-selectin-coated plates, or cells were stimulated 
with PMA, and then stained with mAb HUTS-21 that identifies an activation-dependent epitope of β1-integrin 
(CD29*).  Graph values represent the mean fluorescence intensity of HUTS-21 staining (n= 3, mean ± SD) 
subtracted from the values obtained using isotype control.   
 
HCELL is expressed by CD14-S mo-DCs 
To identify the molecular effectors of mo-DC TEM, we compared expression of E-selectin 
ligands and of VLA-4 in both CD14-S and PA-S mo-DCs.  By flow cytometry, expression of 
VLA-4, PSGL-1, and CD44 was equivalent between CD14-S and PA-S mo-DCs (Figure 2A), 
and, though HECA-452 reactivity (i.e., sLex expression) was similar on both types of mo-
DCs, E-Ig reactivity was slightly higher in CD14-S mo-DC (Figure 2A).  However, western 
blot analysis of reduced SDS-PAGE gels revealed pronounced differences in E-Ig-reactive 
bands between CD14-S and PA-S mo-DCs (Figure 2B).  For both types of mo-DCs, E-Ig 
stained a ~120-130 kDa band, characteristic of the PSGL-1 glycovariant, CLA (Figure 2B).  
E-selectin-reactive proteins (i.e., E-Ig immunoprecipitants) of CD14-S and PA-S mo-DCs, 
showed equivalent reactivity with PSGL-1 (Figure 2C) thus confirming the expression of 
CLA by both types of mo-DCs.  Importantly, only CD14-S mo-DCs showed an additional E-
Ig reactive ~80-90 kDa band (Figure 2B), a migration pattern consistent with that of the 
CD44 glycoform HCELL.  Consistently, CD44 immunoprecipitated from CD14-S mo-DCs, 
but not from PA-S mo-DCs, showed reactivity with E-Ig, confirming that the E-Ig reactive 
~80-90 kDa protein on CD14-S mo-DCs is HCELL (Figure 2D).  Moreover, in blot rolling 
assays, CD44 immunoprecipitated from CD14-S mo-DC lysates supported CHO-E rolling 





Figure 2: Analysis of VLA-4 and E-selectin ligand expression on mo-DCs. (A) Representative flow 
cytometry analysis of mo-DCs staining using mAbs to CD49d (VLA-4), PSGL-1 and CD44, and HECA-452 mAb 
and E-Ig.  Grey lines represent isotype control (or, for E-Ig, staining in the absence of Ca2+), dotted black line 
represents PA-S mo-DCs and solid black lines are CD14-S mo-DCs.  (B-D) Analysis of glycoprotein E-selectin 
ligands expressed by mo-DCs:  (B) Equivalent amounts of cell lysates of CD14-S and PA-S mo-DCs were 
resolved by SDS-PAGE electrophoresis, and immunoblotted with E-Ig chimera.  Two E-selectin-reactive bands 
were visible in lysates of CD14-S mo-DCs (~130 kD and ~80 kD), whereas only one band (~130 kD) was 
reactive on PA-S mo-DCs;   (C)  Equivalent amounts of cell lysates of  CD14-S and PA-S mo-DCs were 
immunoprecipitated with E-Ig, and immunoprecipitates  were then electrophoresed and immunoblotted  with 
anti-PSGL-1 mAb;  (D) CD44 immunoprecipitates (CD44 IP) from equivalent amounts of cell lysates of CD14-
S and PA-S mo-DCs were immunoblotted with E-Ig chimera or anti-CD44 mAb.  (E) Blot rolling assay of 
CD44 immunoprecipated from CD14-S mo-DCs.  CD44 immunoprecipitates were resolved by SDS-PAGE, 




were perfused over blots at 1.4 dyn/cm2 and then shear stress was increased to 4.2 dynes/cm2. E-selectin-
dependent tethering and rolling was observed at the CD44 band (arrow).  Assays were performed in the presence 
or absence of 5 mM EDTA, or following preincubation of CHO-E with isotype control mAb or function 
blocking anti-human E-selectin mAb (clone 68-5H11).  
 
Ligation of CD44 triggers β1-integrin activation in CD14-S mo-DCs  
To assess the relative contribution(s) of HCELL to the augmented E-selectin-mediated TEM 
of CD14-S mo-DCs, we compared the effects of engagement of CD44/HCELL and PSGL-
1/CLA on VLA-4 function.  We examined whether the ligation of each of the pertinent 
scaffold proteins, CD44 and PSGL-1, to their canonical ligands, hyaluronic acid (HA) and P-
selectin, respectively, alter VLA-4 binding activity.  Notably, exposure of CD14-S mo-DCs 
to HA (Supplemental Figure S2) consistently resulted in β1-integrin activation (Figure 3A), 
but exposure of PA-S mo-DCs to HA did not yield β1-integrin activation, nor did engagement 
of either CD14-S or PA-S mo-DCs with P-selectin (Figure 3A).  Moreover, in CD14-S mo-
DCs, but not PA-S mo-DCs, CD44 engagement with HA increased mo-DC adhesiveness to 
CS-1 fibronectin in a VLA-4-dependent manner (Figure 3B).  These data highlight the 
predominant role of CD44 ligation in VLA-4 activation, thereby indicating that observed 
effects of E-selectin engagement on VLA-4 activation of CD14-S mo-DCs are mediated 
through HCELL. 
 
Figure 3.  VLA-4 binding activity is triggered by engagement of CD44 on CD14-S mo-DCs.  (A) Flow 
cytometry analysis of activated β1-integrin expression.  Expression of the activation-dependent epitope of CD29 
(HUTS-21) was assessed on CD14-S mo-DCs (white bars) and PA-S mo-DCs (black bars) incubated on plates 
coated with either E-selectin, P-selectin, or HA, or stimulated with PMA.  Graph values represent the mean 




CD14-S and PA-S mo-DCs to CS-1 fibronectin fragment.  Mo-DCs were incubated on uncoated plates or plates 
coated with HA, and then collected for analysis of binding to CS-1 peptide coated on plates.  Integrin activation 
by treatment with PMA was used as positive control; the numbers of CS-1-adherent cells were quantified by 
light absorbance (595 nm) following crystal violet staining.  As shown in the Figure, binding to HA by CD14-S 
mo-DCs, but not by PA-S mo-DCs, induced VLA-4 adhesion to CS-1 peptide, which was abrogated by 
treatment  with anti-VLA-4 blocking mAb (HP2/1).  Values are means ± SD (n= 3).  Statistically significant 
differences (P ≤ 0.05) related to HA engagement are indicated by brackets and asterisks.  
 
TNFα-treatment boosts TEM of CD14-S mo-DCs  
The inflammatory cytokine TNFα induces DC maturation30 and is routinely used in clinical 
applications.31  We thus assessed whether TNFα treatment could affect mo-DC TEM ability.  
When treated with TNFα, both CD14-S and PA-S mo-DCs showed characteristic increased 
expression of MHC Class II antigens and the co-stimulatory moleculeCD86,32 however, only 
CD14-S  mo-DCs displayed  increased transmigration on stimulated HUVEC (Figure 4A).  
TEM of CD14-S mo-DCs was abrogated by function-blocking anti-E-selectin mAb, by 
sialidase treatment of mo-DCs, by function-blocking anti-VLA-4 mAb and by PTX treatment 
of mo-DCs, confirming a role for both E-selectin receptor/ligand interactions and G-protein-
signaling in driving VLA-4-dependent adhesive interactions (Figure 4A).  
To determine whether the enhanced CD14-S mo-DC TEM following TNFα treatment could 
be secondary to changes in integrin levels, we measured the cell surface expression of the 
heterodimer chains of VLA-4 and LFA-1.  While no increase was observed on the cell 
surface expression of the CD29, CD18 or CD11a integrin subunits, surface expression of 
CD49d was considerably augmented after TNFα treatment (Figure 4B).  TNFα-treated mo-
DCs also showed a significantly increased expression of the activation epitope of β1-integrin 
upon engagement on CHO-E cells and, commensurately, displayed increased VLA-4 binding 
to the CS-1 fibronectin fragment (Figure 4C).  Altogether, these data indicate that TNFα 
induces VLA-4 expression on CD14-S mo-DCs, and confirms a role for E-selectin 






Figure 4.  TNFα-treatment of mo-DCs affects TEM and VLA-4 activity.  (A) Transendothelial migration 
(TEM) assay of untreated (Unt) and TNFα-treated CD14-S and PA-S mo-DCs.  The relative TEM value was 
calculated as the ratio of transmigrated cells on TNFα-stimulated HUVECs compared with cells transmigrated 
on non-stimulated HUVECs.  TEM values were analyzed for HUVECs preincubated with function blocking 
anti-E-selectin mAb clone 68-5H11, for mo-DCs preincubated with function blocking anti-VLA-4 mAb HP2/1 
or isotype mAb, and for mo-DCs treated with sialidase or PTX.  (B) Flow cytometry analysis of cell surface 
expression of integrins VLA-4 and LFA-1 on CD14-S mo-DCs.  Histograms show the staining in untreated 
(dotted black line) and TNFα-treated (solid black line) mo-DCs.  Grey lines represent isotype control.  (C) 
Analysis of CD14-S mo-DCs binding to CS-1 fibronectin fragment. Adhesion of untreated (Unt) or TNFα-treated 
CD14-S mo-DCs (TNFα) to CS-1 peptide was assessed following incubation of mo-DCs on plates containing 
monolayers of E-selectin-transfected CHO cells (CHO-E), mock transfected CHO (CHO-mock), or plates 
containing no CHO cells (uncoated).  After incubation, cells were collected for binding to CS-1 peptide coated 
on plates.  The number of CS-1-adherent cells was quantified by light absorbance (595 nm) following crystal 
violet staining.  Cells activated with PMA (positive control) bound avidly to CS-1, and pre-incubation of cells 
on CHO-E markedly augmented binding to CS-1.  Incubation with anti-VLA-4 blocking antibody (HP2/1) for 




± SD (minimum of n=4).  Statistically significant differences (P ≤ 0.05) related to CHO-E engagement are 
indicated by brackets and asterisks.  
 
TNFα treatment of CD14-S mo-DCs sustains E-selectin ligand expression during culture 
To assess whether the differences in TEM and integrin activation in CD14-S mo-DCs 
cultured in presence or absence of TNFα reflected differences in expression of E-selectin 
ligands, we performed flow cytometry, parallel plate based assays, and western blot analysis 
to assess E-selectin binding of these cells.  Following differentiation of monocytes into mo-
DCs, there was no difference in flow cytometry profile of E-Ig staining between day 0 CD14-
S cells (Figure 2A) and those cells cultured for three days in absence (“untreated”) or 
presence of TNFα (“matured mo-DCs”) (Figures 5A).  However, compared to untreated 
CD14-S mo-DCs, TNFα-treated CD14-S mo-DCs showed markedly lower rolling velocity on 
stimulated HUVECs under hemodynamic fluid shear conditions (indicative of increased E-
selectin avidity) (Figure 5B), and western blot analysis showed significantly greater E-Ig 
staining of lysates (Figure 5C).  Specifically, compared with cells at start of culture (Day 0 
cells), Day 3-cultured untreated mo-DCs showed significantly reduced levels of CLA and 
HCELL (i.e., E-Ig reactive bands at~120-130 kDa and ~80-90 kDa, respectively), whereas 
TNFα-treated mo-DCs showed sustained E-Ig reactivity, with blot profile similar to that 
observed on Day 0 (Figure 5C).  In contrast to CD14-S mo-DCs, the blot profile of E-Ig 
reactivity of PA-S mo-DCs was unchanged by TNFα treatment (Supplemental Figure S3).  
Notably, though E-Ig staining patterns by western blot were markedly different, CD44 levels 
were only slighter higher on CD14-S mo-DCs between Day 0 and Day 3 of culture (Figure 
5D), indicating that observed markedly increased HCELL expression (i.e., higher E-Ig 
reactivity) reflects increased content of sLex on the CD44 scaffold and not changes in 





Figure 5.  E-selectin ligand expression on cultured human CD14-S mo-DCs is preserved by TNFα 
treatment.  (A) Flow cytometry analysis of E-Ig reactivity on CD14-S mo-DCs.  Representative histograms of 
E-Ig staining of untreated mo-DCs (dotted black line) and mo-DCs treated with TNFα (solid black line) 
collected after 3 days of culture.  Grey line represents E-Ig staining in absence of Ca2+.  (B) Rolling adhesive 
interactions on TNFα-stimulated HUVECs of cultured CD14-S mo-DCs untreated (Unt) or treated with TNFα 
(TNFα) for 3 days. Rolling velocities were measured at shear stress of 2.0dyn/cm2.  The velocity was calculated 
by measuring the  displacement of the centroid of the cell over 1 sec.; lower rolling velocity of TNFα moDCs 
indicates higher avidity to E-selectin. (C) Western blot analysis of E-Ig reactivity of whole cell lysates of CD14-
S mo-DCs.  Cells were treated (+) or not (-) (at day 0) with TNFα and collected at day 3 after treatment. TNFα-
treated mo-DCs show higher E-Ig reactivity at bands at ~130 kD and ~80 kD.  (D) Western blot analysis of 
CD44 expression of CD14-S mo-DCs.  Cells were collected at day 0 and day 3 with (+) or without (-) TNFα 
treatment.  As shown in the figure, TNFα treatment sustains the expression of HCELL in vitro.  (E) Schematic 
of sLeX biosynthesis on N- and O-glycans.  Enzymes that were analyzed in this study are indicated in grey next 
to the arrows: core 2-synthase (C2GnT1), sialyltransferases (ST3GalI, III, IV and VI, ST6GalNAcII), 
fucosyltransferases (FTIV, VI and VII), and sialidases (Neu1, Neu3).  (F) Real-time PCR analysis showing 
relative expression of selected genes.  The relative mRNA level was computed as the permillage fraction (‰, 
i.e., the proportion of target mRNA per thousand of the reference GAPDH mRNA expression) of mo-DCs 
treated for 3 days with TNFα (grey bars) or left untreated (white bars).  Values are means ± SD (n= 3).  





The E-selectin binding determinant sLex is displayed on O-glycans in CLA33 and on N-
glycans in HCELL.34  To assess whether TNFα induces expression of enzymes critical to the 
biosynthesis of sLex11,13,35 (Figure 5E), we performed RT-PCR to analyze expression of the α-
(1,3)-fucosyltransferases FTIII, FTIV, FTVI and FTVII, and the α-(2,3)-sialyltransferases 
ST3GalIII, ST3GalIV, and ST3GalVI, which add fucose and sialic acid, respectively, to 
lactosaminyl glycan precursors of sLex.36  Moreover, we evaluated the expression of the core 
2-synthase, C2GnT1, which forms the scaffold glycan for polylactosamine extension on O-
glycans, and the enzymes ST3GalI and ST6GalNAcII, each which act on core 1 O-glycans 
and antagonize core 2 extensions (Figure 5E), thereby down-regulating O-glycan expression 
of sLex.11,37  We also analyzed the expression of Neu1 and Neu3 sialidases in mo-DCs,38 
which are known to remove sialic acid moieties from sLex.35  As shown in Figure 5F, TNFα-
treated mo-DCs showed significantly more expression of FTVI, FTVII and ST3GalVI  and 
less expression of ST3GalI and ST6GalNAcII, compared to that of untreated cells, with no 
differences in RNA transcripts encoding sialidases Neu1 and Neu3.  Altogether, these 
changes in glycosyltranserase gene expression would serve  to augment display of cell 
surface sLex on both O- and N-glycans. 
 
FTVI treatment increases the expression of functional E-selectin ligands and increases 
E-selectin ligand/VLA-4-dependent transendothelial migration of CD14-S mo-DCs.  
HCELL is prominently expressed by human hematopoietic stem/progenitor cells, including 
the human hematopoietic progenitor cell line KG1a.39  Compared with KG1a cells, the levels 
of E-selectin ligands and of HCELL expressed by CD14-S mo-DCs are relatively modest 
(Figure 6A).  We thus sought to determine whether stereoselective α-(1,3)-exofucosylation 
with FTVI27 could boost surface expression of E-selectin ligands.  Following FTVI treatment 
of mo-DCs, we consistently observed a considerable increase in E-Ig reactivity in both CLA 
and HCELL (Figure 6B), and exofucosylated CD14-S mo-DCs displayed increased 
transmigration (~2-fold more) compared to buffer-treated mo-DCs (Figure 6C).  Notably, 
exofucosylation of PA-S mo-DCs also increased E-Ig binding, with increased reactivity at 
~130 kDa (consistent with CLA) and de novo expression of a faint E-Ig-reactive ~80-90 kDa 
band (consistent with HCELL; Supplemental Figure S4).  However, PA-S mo-DCs treated 
with FTVI displayed no significant change in transmigration compared to buffer treated mo-




To further analyze the effect of FTVI treatment on CD14-S mo-DCs, we assessed CD14-S 
mo-DC binding to unstimulated and TNFα-stimulated HUVECs under physiological shear 
stress conditions.  On stimulated HUVECs, the mo-DCs exhibited a modest capacity to tether 
and roll, with cells transitioning to firm adherence under flow (Figure 6D).  Notably, FTVI 
treatment of CD14-S mo-DCs led to a significant increase in the number of tethering/rolling 
and firmly adherent cells and markedly decreased rolling velocity compared to that of buffer 
treated (BT) cells (Figures 6D and 6E), indicating increased adhesion to E-selectin.  FTVI 
treatment did not alter the expression levels of CD44 or PSGL-1 or of other proteins involved 
in cell trafficking such as β1- and β2-integrins (Supplemental Figure S6), suggesting that the 
decreased rolling velocity of α-(1,3)-exofucosylated mo-DCs was primarily due to increased 





Figure 6.  Enforced fucosylation of human CD14-S mo-DCs yields higher E-selectin binding.  (A) Western 
blot analysis comparing E-selectin binding (E-Ig reactivity) of KG1a and CD14-S mo-DCs.  Input lysates on 
each blot were normalized to equivalent cell numbers.  (B) Effects of exofucosylation on E-selectin ligand 
expression of mo-DCs.  CD14-S mo-DCs were buffer treated (BT) or FTVI-treated, and lysates (of equivalent 
cell numbers) were analyzed by Western blot for reactivity with E-Ig.  (C) Transendothelial migration (TEM) 
assay of buffer treated (BT) and FTVI-treated mo-DCs.  The relative TEM value is the ratio of mo-DCs 
transmigrated on TNFα-stimulated HUVECs compared with mo-DCs transmigrated on non-stimulated 
HUVECs. TEM was assessed using mo-DCs (untreated), HUVECs preincubated with function blocking anti-E-
selectin mAb clone 68-5H11, mo-DCs preincubated with function blocking anti-VLA-4 mAb HP2/1 or isotype 
mAb, and mo-DCs treated with sialidase or PTX.  (D) Analysis of mo-DCs tethering/rolling interactions and 
firm adherence on TNFα-stimulated HUVEC monolayers under flow conditions.  Left: Shear stress was 
increased stepwise every 30 seconds, and the number of tethering/rolling cells per cm2 of HUVEC was counted, 
during each 30 second segment. Right: At the end of each time segment, the number of cells that became firmly 
adhering per cm2 area was measured.  (E) Average rolling velocity of BT- and FTVI-treated mo-DCs perfused 
over TNFα-stimulated HUVECs.  The velocity was estimated at 2.0 dyn/cm2 flow, as the displacement of the 
centroid of the cell over 1 sec.  Values are means ± SD (n= 3).  Statistically significant differences are indicated 





There is great hope that DC-based immunotherapy approaches will yield improved outcomes 
for a variety of conditions including cancer, infectious diseases and autoimmune diseases.  A 
proximate hurdle in achieving this promise is to deliver the cells to relevant tissue(s) where 
they can then encounter cognate antigen(s) for presentation to immunologic effectors.  
Human DCs can be generated in vitro from human monocyte precursors (mo-DCs)30 in 
sufficient numbers for clinical applications following CD14 immunomagnetic separation 
(CD14-S) and plastic adherence separation (PA-S) of blood monocytes.40  It has been 
reported that these different monocyte isolation methods may affect phenotypic proprieties of 
the generated DCs5,41, yet it is unknown whether different monocyte enrichment techniques 
could have subsequent effects on DC-endothelial interactions critical to extravasation at 
target tissues.  Accordingly, in this study, we examined DCs derived from both PA and 
CD14-S monocyte selection for their capability to undergo transendothelial migration (TEM), 
and the adhesion molecules mediating TEM for each of these mo-DC populations.   
To compare E-selectin ligand expression in each mo-DC population, we performed flow 
cytometry and western blot analysis using E-Ig as a probe.  By flow cytometry, E-Ig 
reactivity was slightly higher in CD14-S mo-DCs compared to PA-S mo-DC, but Western 
blot revealed a striking difference in the profile of E-selectin ligands: while both mo-DC 
types showed robust staining at a ~120-130 kDa band representing the monomer form of 
CLA (the glycovariant of PSGL-1 that binds E-selectin), only CD14-S mo-DCs showed an E-
Ig-reactive glycoprotein at a ~80-90 kDa band.  Biochemical studies indicated that this 
second band represents HCELL, the specialized glycovariant of CD44 that binds E-selectin.  
Notably, the finding that HCELL is expressed on CD14-S mo-DCs is novel, as HCELL 
display was previously thought to be restricted only to primitive human hematopoietic 
progenitor cells and certain adenocarcinoma cells.15,34,42 
Our studies reveal that engagement of CD14-S mo-DCs with E-selectin leads to a remarkable 
increase in VLA-4-mediated adhesiveness to TNFα-stimulated HUVEC monolayers.  To 
examine the relative roles of HCELL and CLA in endothelial adhesive interactions, mo-DCs 
were exposed to hyaluronic acid and to P-selectin, ligands specific to the protein scaffolds 
CD44 and PSGL-1, respectively.  Importantly, we observed that ligation of CD44, but not 
PSGL-1, induced VLA-4 activation, indicating that E-selectin ligation of HCELL, and not 




In contrast to the canonical multistep model of cell migration, whereby engagement of 
chemokine receptor(s) (step 2) is obligatory to achieve integrin activation (step 3), we 
observed that HCELL ligation by E-selectin alone triggers PTX-inhibitable endothelial 
transmigration, consistent with a G-protein-dependent inside-out stimulation of VLA-4 
activity.  This capacity of E-selectin to initiate mo-DC transmigration is due to the fact that 
sLex binding determinants are expressed on the CD44 scaffold, thereby engendering CD44 
ligation.  Though this CD44-dependent “step 2-chemokine bypass pathway” has been 
described in human mesenchymal stem cells following enforced HCELL expression by cell 
surface glycan engineering,26,27 these results are the first to indicate that natively-expressed 
HCELL and VLA-4 can function in a bimolecular axis to drive transmigration of a human 
leukocyte. 
TNFα is widely used to promote the maturation of DCs in immunotherapy.31  This pro-
inflammatory cytokine characteristically increases the expression of E-selectin and VCAM-1 
on endothelial cells,10,43 but the effect of this cytokine on E-selectin ligands expression or on 
VLA-4 expression on mo-DCs was previously unknown.  Our data show that TNFα preserves 
the expression of HCELL on culture-expanded CD14-S mo-DCs, which otherwise undergoes 
time-dependent decay following differentiation of DC from monocytes.  TNFα also increases 
expression of VLA-4, and, therefore, the combined effect on HCELL and VLA-4 expression 
would license augmented β1-integrin activation and consequent TEM on endothelial beds 
expressing both E-selectin and VCAM-1.  
 In agreement with previous reports,13,44 our data indicate that TNFα induces significant 
changes on glycosyltransferase gene expression in CD14-S mo-DCs.  As compared to 
untreated CD14-S mo-DCs, TNFα-treated DCs express lower levels of transcripts encoding 
ST3GalI and ST6GalNAcII, and higher levels of that of C2GnT1.  This pattern would 
promote the expression of core 2 glycan structures that are requisite for elaboration of the 
CLA glycoform of PSGL-1.  In addition, TNFα treatment upregulates expression of the 
fucosyltransferases FTVI and FTVII and of the sialyltransferase ST3GalVI, which, 
collectively, heighten requisite α-(1,3)-fucosylation and α-(2,3)-sialylation of lactosamine 
chains to create sLex.45  This pattern of glycosyltransferase gene expression would serve to 
sustain HCELL expression, as observed in TNFα–treated CD14-S mo-DCs.  
Apart from cytokine effects on expression of Golgi glycosyltransferases, cell surface sLex 




explored whether α-(1,3)-exofucosylation with FTVI would program increased expression of 
mo-DC E-selectin ligands.  FTVI places fucose in α-(1,3)-linkage to an acceptor N-
acetylglucosamine located specifically within a terminal α-(2,3)-sialylated type 2 lactosamine 
unit (NeuAcα2-3Galβ1-4GlcNAcβ1-R, Figure 5E).  We found that FTVI treatment of CD14-
S mo-DCs increased both HCELL and CLA expression and markedly enhanced TEM ability.  
However, in contrast, FTVI treatment of PA-S mo-DCs did not augment HCELL expression, 
and, despite increased CLA expression, TEM was unchanged after FTVI treatment of PA-S 
mo-DCs.  These findings indicate that glycoengineering to increase HCELL expression 
augments TEM of mo-DCs, whereas enforced CLA expression does not, therefore 
highlighting a key role for HCELL in licensing mo-DC TEM.  
The results of our studies open new insights into the role of CD44 in DC biology.  Our 
findings that human DCs express HCELL have important implications for elucidating the 
molecular basis of DC migration and for optimizing DC migration in adoptive cell 
therapeutics.  The observation that HCELL is expressed by CD14-S mo-DCs but not by PA-S 
mo-DCs indicates that in vitro monocyte isolation/DC generation methods impact expression 
of E-selectin ligands and mo-DC transmigration.  While TNFα is well-known to upregulate 
expression of E-selectin and VCAM-1 on endothelial cells, the data here indicate that TNFα 
also preserves the expression of E-selectin ligands on culture-expanded mo-DCs, thereby 
priming E-selectin- and VLA-4-dependent transmigration of mo-DCs (see model represented 
in Figure S6).  Our findings thus offer a unifying perspective on the role of TNFα in 
recruitment of DCs to sites of inflammation.  Altogether, the results of this study yield novel 
insights into functional diversity of CD44 in the biology of DC TEM, and also raise the 
possibility that expressly modifying HCELL expression in mo-DCs could improve the 
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Supplemental Methods  
Antibody reagents and flow cytometry 
Cell surface staining for flow cytometry was performed using commercially-available mouse 
E-selectin-human Fc Ig chimera (E-Ig) and antibody reagents.  Monocyte purity was 
evaluated by flow cytometry for expression of CD14, and differentiation and maturation of 
mo-DCs were evaluated by staining for expression of MHC-II, and CD86 (mAbs from BD 
Biosciences).  Anti-CD44 mAb 2C5 and recombinant mouse E-selectin-human Fc Ig chimera 
(E-Ig) were from R&D Systems.  HECA-452, anti-CD29 and anti-CD49d mAbs were from 
BD Biosciences.  Activation-dependent epitopes of VLA-4 and LFA-1 were evaluated using 
mAb HUTS-21 (specific for β1 chain (CD29) (BD Biosciences)) and mAb 24 (specific for 
integrin β2 (CD18) chain of CD11/CD18 heterodimers (Hycult Biotech)), respectively.   
 
Blot Rolling Assay 
Western blots of PVDF membrane preparations stained with anti-CD44 were rendered 
transparent with Hanks balanced salt solution (HBSS) containing 2 mM Ca2+ and 10% 
glycerol and were placed in the parallel plate flow chamber.  Chinese hamster ovary (CHO) 
cells transfected with full-length human E-selectin cDNA (CHO-E) were suspended (106 
cells/mL) in HBSS containing 2 mM Ca2+ and perfused over blots at 1.4 dyn/cm2 and 
incremented up to 4.2 dyn/cm2.  The number of cells rolling within and outside relevant 
immunostained bands of the blot was recorded and quantified within each field of view by 
video microscopy.  Controls for non-specific binding consisted of CHO-E cells in media 
containing 5 mM EDTA (chelating Ca2+ to prevent E-selectin adhesion), and incubation of 
CHO-E cells in presence of function-blocking anti-E-selectin mAb.  Mock transfectants 
(CHO-mock) were used as control to analyze background levels of CHO adhesive 







CS-1 fragment binding assay following E-selectin and hyaluronic acid engagement   
Mo-DCs were placed in culture plates seeded with CHO-E or with mock transfectants (CHO-
mock), or coated with E-Ig (10 µg/mL) or high molecular weight hyaluronic acid (HA, 
Sigma) (5 µg/µL).  Mo-DCs, suspended in HBSS containing 2 mM Ca2+, were placed onto 
the various plates for 30 min on a rocker platform (5-10 rpm).  The cells were collected by 
vigorous pipetting, washed in HBSS without Ca/Mg, and then placed onto tissue culture 
plates previously coated with connecting segment-1 peptide (CS1) (Fibronectin-40 
(Millipore, 10 µg/mL)).  Mo-DCs were allowed to bind for 45 min at 37ºC in RPMI-1640/10 
mM HEPES/0.2% BSA.  Plates were then washed and adherent cells were identified by either 
crystal violet staining (absorbance 595 nm) or CFSE labeling (fluorescence signal).  
 
Immunoprecipitation 
Cell lysates were precleared with protein G-agarose (Invitrogen) and then incubated with 
anti-CD44 mAb (2C5) or anti-PSGL-1 mAb (KPL-1). For immunoprecipitation using E-Ig 
chimera, lysis buffer contained 2mM Ca2+.  Antibody or E-Ig immunoprecipitates were 
collected using protein G-agarose beads, which were washed with lysis buffer, pelleted and 
then resuspended in reducing sample buffer.  The bead suspension was boiled, and 
supernatant (released protein) was subjected to SDS-PAGE, transferred to PVDF membrane, 
and blots were immunostained. 
 
Fucosyltransferase VI treatment 
Cells were treated with 60 mU/mL FTVI (Sigma), in HBSS containing 20 mM HEPES, 0.1% 
human serum albumin (HSA, Sigma) and 1 mM GDP-fucose (CarboSynth) for 45 min at 
37ºC.  Control consisted of cells treated with buffer containing all components except FTVI 
enzyme.  The efficacy of the FTVI treatment was confirmed by evaluating for increased 
expression of E-selectin ligands as assessed by both flow cytometry and western blot analysis 





Supplemental Figures  
Table S1. Pairs of primers used in Real Time PCR assays. 
 
 
Supplemental Fig. S1 
E-selectin ligand engagement on CD14-S mo-DCs does not lead to direct LFA-1 activation.  Mo-DCs were 
incubated on uncoated or on E-selectin coated plates, or stimulated with PMA, and then stained with mAb 24 
that recognizes an activation-dependent epitope of CD11/CD18 β2-integrin (CD11/CD18*).  Graph values 
represent the mean fluorescence intensity of mAb 24 staining (n= 3, mean ± SD), subtracted from the values 





                                   
Supplemental Fig. S2  
CD14-S and PA-S mo-DCs adhere to hyaluronic acid.  CD14-S or PA-S mo-DCs were incubated on plates 
coated with hyaluronic acid (HA).  The number of HA-adherent cells was quantified by light absorbance at 595 
nm following crystal violet staining.  Negative controls consisted on uncoated or BSA coated plates.  Values are 
mean ± SD (n= 3).  
 
                           
Supplemental Fig. S3  
TNFα treatment on human PA-S mo-DCs does not preserve E-selectin ligand expression.  PA-S mo-DCs 
were treated (+) or not (-) with TNFα and collected at day 3 after treatment.  Lysates of equivalent cell numbers 












Supplemental Fig. S4  
Enforced fucosylation of human PA-S mo-DCs increases E-Ig reactivity but does not affect 
transmigration.  (A) Western blot analysis of E-selectin binding (E-Ig) of buffer treated (BT) and FTVI-treated 
PA-S mo-DCs.  PA-S mo-DCs were buffer treated (BT) or FTVI-treated, and lysates (of equivalent cell 
numbers) were analyzed by Western blot for reactivity with E-Ig.  (B) Transendothelial migration (TEM) assay 
of buffer treated (BT, white bars) and FTVI-treated mo-DCs (grey bars).  The relative TEM value is the ratio of 
PA-S mo-DCs transmigrated on TNFα-stimulated HUVECs compared with PA-S mo-DCs transmigrated on 
non-stimulated HUVECs.  TEM was assessed using mo-DCs (untreated), HUVECs preincubated with function 
blocking anti-E-selectin mAb clone 68-5H11, mo-DCs preincubated with function blocking anti-VLA-4 mAb 
HP2/1 and mo-DCs treated with sialidase or PTX. Values are mean ± SD (n= 3). 
 
 
Supplemental Fig. S5  
FTVI treatment does not affect cell surface protein expression.  Flow cytometry analysis of E-Ig reactivity, 
MHC-II, CD44, PSGL-1, CD29, CD49d, CD18 and CD11a staining on buffer treated (BT, white bars) and 





Supplemental Fig. S6  
Schematic representation of molecular events that occur in the human dendritic cell (DC) extravasation 
process. In inflamed tissues, post-capillary endothelial cells express E-selectin and VCAM-1, which are induced 
by pro-inflammatory cytokines such as TNFα.  TNFα can also augment expression of E-selectin ligands, 
including HCELL, and VLA-4 on DCs.  Engagement of HCELL on DCs with endothelial E-selectin leads to G-
protein-mediated signaling and activates VLA-4 integrin, resulting in firm adhesion of DCs to endothelial cells 
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KEY POINTS 
(1) CD43E, HCELL and CLA, the E-selectin reactive glycoform of CD43, CD44 and 
PSGL-1, respectively, are expressed on human blood monocyte-derived DCs 
(2) Murine bone marrow derived-DCs do not express any glycoprotein with E-selectin 





Dendritic cells (DCs) are the most effective and versatile antigen-presenting cells, and 
therefore, they have been used as anti-cancer vaccines. However, the success of this therapy 
is limited by the fact that most of the adoptive transferred DCs do not reach the target tissue 
from the vasculature. Therefore, strategies to control the binding of DCs to endothelium are 
essential to improve their recruitment and to induce a more rapid and accurate antitumor 
immune responses. Thus, we analyzed the cognate E-selectin ligand(s) on human monocyte-
derived DCs and murine DCs, obtained from different cellular sources. Westernblot analysis 
using E-selectin-Ig chimera (E-Ig) as a probe show that human mo-DCs generated from adult 
peripheral blood (APB) monocytes display great E-selectin binding. To define the relevant 
glycoproteins with E-selectin binding activity, lysates from human APB mo-DCs were 
immunoprecipitated using E-Ig and resolved by western blot. In addition to the already 
reported glycoforms of PSGL-1 “CLA” and of CD44 “HCELL”, APB mo-DCs also express 
the functional E-selectin reactive glycoform of CD43 “CD43E”. By contrast, umbilical cord 
blood (UCB) mo-DCs are devoid of E-selectin reactive glycoproteins, although they express 
lipid scaffolds that display E-selectin reactive determinants. Notably, enforced 
exofocusylation of both types of mo-DCs profoundly increased E-selectin adherence under 
hemodynamic shear stress conditions. Finally, murine DCs generated from bone marrow 
precursors (BM-DCs) or obtained from spleen (sDCs) show a completely different E-selectin 
ligand profile between them. Murine sDCs, but not BM-DCs, express CLA, whereas BM-
DCs only display E-selectin reactive glycolipids. Our work describe the major glycoprotein 
E-selectin ligands of human and mouse DCs, disclosing critical species and cellular sources 









Dendritic cells (DCs) are unique in their ability to prime both naïve and memory T cell 
immune responses.1 DCs arise from a common bone marrow myeloid hematopoietic 
progenitor, and after development, DC precursors egress the bone marrow and migrate via 
bloodstream to peripheral tissues, where they survey for signs of danger.2  In the periphery, 
DCs capture antigens and following phenotypic changes migrate to secondary lymphoid 
organs, where they interact and activate T cells.3 In addition, DCs are also able to activate 
naïve and memory B cells, NK cells and NKT cells and are one of the few cells capable of 
cross-presenting exogenous antigens to CD8+T cells via Major Histocompatibility complex 
Class-I (MHC-I), a crucial mechanism for the generation of anti-tumor cytotoxic T cell 
responses.3-5  Given these pivotal immune boost features, vaccination with autologous DCs 
pulsed with patient’s tumor-antigens has been explored either in combination with classical 
chemotherapy or/and radiotherapy or after treatment, in order to prevent cancer relapses.6-8 
However, one of the immediate obstacles to anti-cancer DC-based vaccines success is the 
delivery of ex vivo generated DCs into target sites.3 The tumor tissue is rich in infiltrating 
effector memory T cells.9 Direct migration of ex vivo generated DCs to these sites would 
enhance local antigen-presentation to infiltrating T cells, and therefore, induce faster and 
stronger antitumor-specific cytotoxic T cell responses than priming directly naïve T cells in 
lymph nodes.10,11 However, a recent study demonstrated that, in clinical trials involving these 
DC-based vaccines, a large number of injected DCs do not move from vascular to 
extravascular compartments and remained at the injection site.12 Therefore, a greater 
understanding of the effectors mediating physiologic trafficking and tissue transmigration of 
vascularly-administered DCs is critical to accomplish the great benefit of DC-based anti-
cancer vaccines, which rely on efficient delivery of these cells to target sites of disease in the 
patient.  
To get into inflamed/tumor sites, ex vivo generated DCs have to engage through several 
adhesion contacts with endothelial cells via a cascade of molecular of events.13 This process 
deeply depends on the initial adhesive interactions responsible by the slowing down of 
leukocyte rolling velocity along endothelium surface, to velocities well below the local blood 
flow rate. Vascular E-selectin and its counter ligands are the main mediators of leukocyte 
deceleration on target endothelium.13 E-selectin is an inducible endothelial molecule 




microvasculature displays an elevated concentration of E-selectin.14,15  This molecule exhibits 
binding-affinity to glycoproteins and glycolipids decorated with sialyl Lewis X (sLeX) – a 
terminal tetrassacharide modified with an α(2,3)- linked sialic acid substitution on galactose 
and an α(1,3) linked fucose modification on N-acetylglucosamine.16 
Several glycoproteins have been identified and characterized as E-selectin ligands expressed 
on mature hematopoietic cells. These are the heavily sLeX-decorated glycoforms of: PSGL-1 
(known as Cutaneous Lymphocyte Antigen (CLA))17, CD44 (known as Hematopoietic Cell 
E-/L-selectin ligand (HCELL)), CD43 (known as CD43E)18, MGF-160 (known as E-selectin 
ligand-1 (ESL-1))19, β2 integrins (CD18/CD11)20 and L-selectin21. So far, only CLA22 and 
HCELL (Videira et al., unpublished data) have been characterized as E-selectin ligands 
expressed on human DCs, whereas murine DCs transiently express CLA.23 While CD43E is 
expressed by human and murine T cells24,25 and by human monocytes (Silva et al., 
unpublished data), it is unknown whether it also plays a role as E-selectin ligand on DCs.  
Accordingly, in the present study, we sought to perform a detailed analysis of the E-selectin 
glycoprotein ligands expressed in human and mouse DCs. For that, we used human monocyte 
derived-DCs (mo-DCs), obtained from two different blood sources (adult peripheral blood 
(APB) and umbilical cord blood (UCB)), and murine DCs, either derived from bone marrow 
(BM-DCs) or spleen (sDCs). Collectively, our findings reveal previously unsuspected 
differences in E-selectin ligand expression between different cellular sources of DCs, as well 
species-specific differences. Particularly notable is the demonstration of CD43E expression in 
human APB mo-DCs, in addition to HCELL and CLA, whereas UCB mo-DCs are generally 
devoid of E-selectin reactive glycoproteins.  Our results also highlight the feasibility of 
exofucosylation as a platform technology for optimizing the trafficking properties of human 






Materials and Methods 
Mice 
Six to eight week old C57BL/6 mice were housed and bred at the animal facility of Instituto 
Gulbenkian Ciência (IGC, Oeiras, Portugal). Mice were sacrificed by carbon dioxide 
inhalation followed by cervical dislocation. The Institutional Animal Care and Use 
Committee (IACUC) approved all procedures, which were in agreement with the Federation 
of European Laboratory Animal Science Associations (FELASA) directives, approval ID 
number AO10/2010. 
 
Generation of human mo-DCs 
Human DCs were differentiated from monocytes, which were isolated from either adult 
peripheral blood (APB) or umbilical cord blood (UCB) from healthy donors, under protocols 
approved by the Institutional Review Board of Brigham & Women’s Hospital (BWH), with 
informed consent provided as per the Declaration of Helsinki. 
Briefly, after peripheral blood mononuclear cells (PBMCs) isolation by Ficoll-Paque density 
gradient centrifugation (Sigma-Aldrich, St Louis, MO), monocytes were enriched using anti-
CD14 coated magnetic beads (Miltenyi Biotech, Auburn, CA). Monocytes were then cultured 
for 5 days at a concentration of 1 × 106 cells/mL in complete RPMI medium (RPMI medium 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100µg/mL 
penicillin/streptomycin and 1% pyruvate (all from Gibco, Grand Island, NY, USA)). For 
monocyte differentiation into DCs, 750 U/mL of interleukin-4 (IL-4, R&D, Minneapolis, 
MN, USA) and 1000 U/mL of recombinant human (rh) granulocyte-macrophage colony-
stimulating factor (GM-CSF, R&D) were added to the culture every two days, as previously 
described.26 
 
Generation of murine Bone marrow DCs 
Tibias and femurs from C57BL/6J mice were removed and bone-marrow (BM) flushed out 
with RPMI medium. For lysis of erythrocytes, BM cells were ressuspended in a 0.17M Tris-




ressuspended in RPMI complete medium supplemented with 10 ng/mL of recombinant 
mouse GM-CSF (Immunotools, Friesoythe, Germany) and cultured at 1×106 cells/mL on six-
well plates for 5 or 8 days.27  
 
Isolation of CD11c+ DCs from mouse spleen  
Female C57BL/6J mice (6–8 weeks old) were subcutaneously injected with 2×106 of B16 
melanoma cells secreting murine FMS-like tyrosine kinase 3 ligand (B16-Flt3-L), in order to 
induce a large production of splenic immature DCs (sDCs). After 15 days of tumor injection, 
mice were sacrificed, spleen collected and splenocytes obtained by mechanical disruption.  
Further CD11c+ cells isolation was performed by positive immunomagnetic selection, using 
anti-CD11c magnetic Microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany).  
 
Flow cytometry 
Monoclonal antibodies (mAbs) used include anti-CLA clone HECA-452, anti-human CD43 
clone 1G10, anti-human PSGL-1/CD162 clone KPL-1, anti-human CD44 clone 515, anti-
mouse PSGL-1 clone 4RA10, anti-mouse CD44 clone IM7, anti-mouse CD43 clone S7 (all 
from BD Biosciences), anti-human CD44 clone 2C5 (R&D Systems) and anti-human CD18 
clone 7E4 (beckaman Coulter). 
All antibody solutions were prepared at 10 µg/mL in PBS. Cells were incubated with primary 
antibody or isotype control for 30 min at 4ºC, washed twice and incubated with secondary 
antibody for 30 min at 4ºC. For E-Ig (R&D Systems, 10 µg/mL) staining, DPBS with Ca2+ 
and Mg2+ was used for all incubations, dilutions, and washing. The secondary antibody used 
was a biotinylated antihuman IgG (1:200) followed by streptavidin-PE (5 µg/mL) staining. 
Flow cytometry using Attune® Acoustic Focusing Cytometer (Life Techonologies, Grand 







Whole cell lysates preparation 
Cell membrane proteins were isolated by sonication followed by incubation in lysis buffer 
containing 2% NP-40. In brief, cells were washed twice in PBS and resuspended in ice-cold 
lysis buffer containing 150mM NaCl, 50mM Tris-HCI (pH 7.4), 0.02% NaN3, 20 µg/mL 
PMSF and protease inhibitor cocktail tablet (Roche). Cell suspension was subject to three 
rounds of sonication and to solubilize the membranes, NP-40 was added to a final 
concentration of 2% and the ruptured cells were left rotating overnight at 4ºC. After, lysates 
were centrifuged, and supernatants containing the proteins were collected. Amount of lysate 
in each lane was normalized to cell number for each western blots performed. 
 
Western blot analysis 
Protein samples were diluted 1:3 into 4X SDS/β-mercaptoethanol loading buffer (Boston 
products, Boston, USA), boiled and then resolved on 7.5% SDS-PAGE electrophoresis gels 
(Bio-rad Laboratories, Hercules, Ca). Subsequently, resolved proteins were transferred to 
polyvinylidene difluoride membranes (PVDF membranes, Bio-Rad) and blocked with 10% 
skimmed milk in TBS/0.1% Tween 20 for at least one hour.  Western blots were probed with 
primary antibodies followed by incubation with appropriate HRP-conjugate antibodies and 
chemiluminescence detection using Lumi-Light Western blotting substrate  (Roche).  
 
Immunoprecipitation studies 
To immunoprecipitate E-selectin binding proteins, cell lysate were prepared in an altered 
lysis buffer containing 2mM CaCl2, otherwise cell lysates were prepared as mentioned above. 
Cell lysates were incubated with antibodies or E-Ig (each at 3µg of antibody per 6 million of 
cells) for 2 hours at 4ºC and then incubated with protein G-agarose for 4 hours at 4ºC under 
constant rotation.  Antigen-antibody- bound protein G beads were washed then diluted in 1.5 
X SDS/β-mercaptoethanol loading buffer and boiled to release antigens. The 







The expression of E-selection ligands was also analyzed by fluorescence microscopy. 
Monocytes from APB were allowed to adhere to poly-lisine coated cover glasses, and 
cultured for 6 days in the presence of GM-CSF and IL-4, as mentioned above. After blocking 
with 5% bovine serum albumin (BSA, Sigma) for 30 minutes, cells were stained with E-Ig for 
one hour, washed and incubated with appropriated fluorescent-conjugated secondary 
antibody. For F-actin staining, cells were permeabilized with triton and then incubated with 
phalloidin for 20 minutes. As a negative control, E-Ig binding was also tested in the presence 
of 20mM of EDTA.  The cells were mounted on glass slides in 90% of glycerol solution. 
Images were acquired with a Leica TCS SP2 AOBS confocal microscope (Leica Microsystem 
GmbH, Mannheim, Germany) and assembled with Leica Confocal Software LCS Lite 2.6 
(Leica Microsystem) 
 
Blot rolling assay 
The blot rolling assay was performed as described previously.28 Western blots of CD43 
immunoprecipitated products from DC total cell lysates were stained with HECA-452 mAb 
and rendered translucent by immersion in Hank’s balanced salt solution (HBSS) with 10% 
glycerol, 10mM HEPES (pH 7.4) and 5mM CaCl2.  The blots were placed under a parallel-
plate flow chamber, and Chinese hamster ovary (CHO) cells transfected with full-length 
human E-selectin cDNA (CHO-E) were perfused over blots at a shear stress of 0.17 
dynes/cm2.  The number of interacting cells within and outside each stained region of the blot 
was videotaped for subsequent analysis.  Mock-transfected CHO cells (CHO-M) were used to 
assess the specificity of the adhesive interactions on each stained region. 
 
Enforced fucosylation of DCs by FTVII-treatment  
Cells were treated with 0.07 mg/mL of fucosyltransferase VII (FTVII) (R&D systems) in 
HBSS containing 10 mM HEPES, 0.1% human serum albumin and 1mM GDP-fucose 
(Sigma-Aldrich), for 60 minutes at 37ºC.  As negative control, cells were treated in the same 
buffer but without FTVII (buffer-treated).  Cell viability was assessed routinely by trypan 




Microfluidic adhesion assay 
To assess cell rolling, human umbilical vein endothelial cells (HUVECs) were grown to 
confluence in Bioflux microfluidic channels coated with 250µg/mL of human plasma 
fibronectin (Sigma-Aldrich).  To stimulate the expression of E-selectin, HUVECs were 
incubated with 40 ng/mL of recombinant human tumor necrosis factor (TNF)-α (R&D), for 4 
hours at 37ºC prior to use in the adhesion studies.  DCs left untreated (buffer treated-BT) or 
FTVII-treated were suspended at a concentration of 10 × 106 cells/mL and perfused through 
the channels, at an initial shear rate of 0.5 dynes/cm2; subsequently adjusted to shear stress 
ranging from 0.5 to 16 dynes/ cm2.  Controls for non-specific binding consisted of sialidase-
treated DCs. All experiments were video-recorded for analysis and the number of rolling and 







Glycoform of CD43, CD43E, is a functional E-selectin ligand on human APB mo-DCs 
We have previously reported that CLA and HCELL are E-selectin ligands on human adult 
peripheral blood (APB) mo-DCs (Videira et al, unpublished data). In this study, we 
performed several biochemical studies and observed that, apart from CLA and HCELL, the 
glycoform of CD43 is also a functional E-selectin ligand expressed on the cell surface of mo-
DCs obtained from APB. 
Lysates of human APB mo-DCs resolved by SDS-PAGE and exposed by westernblot using 
E-selectin-Ig chimera (E-Ig) stained an E-Ig reactive ~120-130 kDa band, characteristic of 
CLA, and a ~80-90 kDa band, characteristic of HCELL (Figure 1a). Consistently, PSGL-1 
immunoprecipitates from human mo-DC total cell lysates stained with E-Ig showed a ~120-
140 kDa band, corresponding to CLA. However, after an exhaustive PSGL-1 
immunoprecipitation (IP), confirmed by the absence of a PSGL-1-reactive band in the 
supernatant (Supn), an E-Ig reactive band continued to appear on the supernatant with the 
same molecular weight of PSGL-1 (Figure 1b). This suggests the presence of another sLeX-
scaffold protein in the cell lysates of human APB mo-DCs that co-migrates with PSGL-1 in 
reducing condition electrophoresis. Based on the electrophoretic mobility and since that the 
sLeX-decorated glycoform of CD43 has been described to also migrate at ~120-130 kDa,24 we 
checked for the presence of CD43 on mo-DCs by both flow cytometry and Western blot 
techniques. After confirming the presence of CD43 on mo-DC cell surface (Figure 1c), we 
performed a CD43 IP from human mo-DC total cell lysate and observed the presence of an E-
Ig-reactive band on the CD43 immunoprecipitate product (Figure 1d). 
To assess the E-selectin ligand activity of the sLeX-glycoform of CD43 under physiologic 
flow conditions, we performed blot-rolling assays, on blots containing the CD43 
immunoprecipitate product from APB mo-DC lysates.  CHO-E rolling interactions were 
consistently observed on the CD43 band (Figure 1e).  Specificity for E-selectin was 
demonstrated by the elimination of CHO-E cell rolling outside of band or by the lack of 





Figure 1. CD43 is functional E-selectin ligand on human mo-DCs from APB. a) Western blot analysis of 
whole cell lysate of human ABP mo-DCs stained with E-Ig. E-Ig staining of APB DC lysates resolved under 
reduced SDS-PAGE conditions revealed two principal bands at ~120-130 kDa and ~80-90 kDa. b) Western 
blot analysis of PSGL-1 immunoprecipitation from human APB mo-DCs. PSGL-1 was immunoprecipitated 
(IP) from human APB mo-DCs total cell lysate, resolved by SDS-PAGE, blotted, and stained with E-
selectin-Ig chimera (E-Ig). “Supn” corresponds to the cleared lysate, i.e., following PSGL-1 
immunoprecipitation.  As shown, there is an E-Ig reactive band in the Supn lane, indicating the presence of 
another HECA-452-decorated glycoprotein that co-migrates with CLA. c) Representative flow cytometry 
histogram of CD43 expression on human APB mo-DCs.  Grey line represents incubation with isotype control 
and black line represents incubation with specific antibody.  d) Western blot analysis of E-Ig-reactivity of 
CD43. CD43 proteins were immunoprecipitated from cell lysates of human ABP mo-DCs, resolved by SDS-
PAGE, blotted, and stained with E-Ig or anti-CD43 antibody.  In addition, E-selectin ligands were 
immunoprecipitated (E-Ig IP), resolved by SDS-PAGE, blotted, and stained with anti-CD43.  Human APB 
mo-DCs express CD43 that display E-selectin reactive epitopes.  e) Blot rolling assay performed on 
immunoprecipitates of CD43 from mo-DCs.  CD43 immunoprecipitate was resolved by SDS-PAGE, blotted 







Exofucosylation creates the E-selectin reactive glycoform of CD18 and new E-selectin-
reactive glycoforms of CD44 on human APB mo-DCs 
As previously demonstrated, α(1,3)-exofucosylation of cell surface glycans increases the 
expression of E-selectin ligands and thereby improves tethering and rolling properties of 
treated cells. (Videira et al., unpublished data; Silva et al., unpublished data) In particular, 
identification of cell surface glycoproteins capable of E-selectin binding following α(1,3)-
exofucosylation allows for assessment of scaffold proteins that display sialylated 
lactosaminyl glycans, yet are not E-selectin ligands only because they lack relevant 
fucosylation.13 We thus sought to determine whether exofocusylation would enforce the 
expression of new E-selectin ligands among human APB mo-DCs and which of the protein 
scaffolds are preferentially targeted by this enzymatic modification.  
To this end, we treated human APB mo-DCs with the α(1,3)-fucosyltransferase FTVII  and 
then performed an E-Ig immunoprecipitation (IP) from both FTVII treated and BT-treated 
human mo-DCs cell lysates; IP products were SDS-PAGE resolved and blotted with anti-
HECA-452, anti-PSGL-1, anti-CD44 and anti-CD43. Western blot analysis of the E-Ig IP 
products from human mo-DC lysates showed a profound increase in HECA-452 reactivity 
following FTVII treatment (Figure 2a). This increased HECA-452 reactivity correlated 
specifically with the formation of E-reactive glycoforms of both CD43 and CD44 (Figure 
2a). Interestingly, while FTVII exofucosylation created the standard isoform of HCELL  
(~80-90kDa), additional higher molecular weight variant isoforms of CD44 were created, as 
was observed by the formation of multiple high molecular CD44 reactive bands the in E-Ig 
product (Figure 2a). The glycoform of PSGL-1, CLA, was also increased after enforced 
FTVII exofocusylation, though only in a small amount relative to that of CD43E and HCELL. 
Surprisingly, another E-selectin reactive glycoprotein was created after enforced 
exofocusylation. As shown in Figure 2b, a CD18 reactive band appears in the E-Ig IP 
product from FTVII-treated moDC lysate lane with a molecular weight of ~80-90 kDa. This 
observation suggests the presence of sialylated lactosamine chains on CD18 scaffold that are 






Figure 2. E-selectin reactive glycoform of CD18 is created after enforced exofucosylation. a) FTVII-
mediated exofucosylation of APB mo-DCs increases mainly HCELL and CD43E expression. Human APB mo-
DCs were FTVII-treated (FTVII) or Buffer treated (BT) and then lysated. Cell lysates were submitted to an E-Ig 
IP followed by SDS-PAGE and blotted with anti-HECA-452, anti-CD44, anti-CD43 and anti-PSGL-1 
antibodies. A marked increase in E-Ig reactivity of the CD43 and CD44 scaffolds was observed, with a smaller 
increase in the E-Ig reactivity of PSGL-1.  (b) FTVII-mediated exofucosylation of APB mo-DCs creates a novel 
E-selectin binding glycoform of CD18.  E-Ig immunoprecipitation was performed on cell lysates from FTVII-
treated and BT mo-DCs.  Total cell lysate (Total), immunoprecipitate (IP), and cleared lysate (Supn) were 
resolved by SDS-PAGE and blotted with anti-CD18 mAb. CD18-reactivity on E-Ig IP lane was observed, 
indicating enforced expression of an E-selectin ligand glycoform of CD18. c) Functional E-selectin ligands can 
be formed after FTVII reaction. Parallel plate flow chamber analysis of tethering and rolling interactions of 
buffer treated (BT) and FTVII-treated mo-DCs (FTVII) on TNF-α-activated HUVECs. FTVII treatment of APB 
mo-DCs significantly augmented their ability to tether and roll under shear stress conditions. 
 
To further analyse the effect of FTVII treatment, we assessed the ability of human APB mo-
DCs to bind to TNF-α-stimulated HUVEC monolayers under physiological shear stress 
conditions. BT-mo-DCs exhibited a modest capacity to tether and roll, whereas, FTVII 
treatment led to a significant increase in the number of tethering/rolling mo-DCs, and of 
firmly adherent cells (Figure 2c). These data suggest that the E-selectin-binding glycoforms 
of CD43 and CD44, as well the new-formed E-selectin reactive CD18 glycoform, may play 





Localization of E-selectin ligands at cell surface of human APB mo-DCs  
We next determinated the localization pattern of E-selectin ligands on the cell surface of 
human mo-DCs.  Human monocytes were cultured on poly-lysine coated plates in the 
presence of GM-CSF and IL-4 for 7 days. After differentiation into mo-DCs, these cells were 
co-stained with FITC-conjugated E-Ig and rhodamine-conjugated phalloidin. As shown in 
Figure 3, E-selectin ligand distribution (green) is predominantly coincident with F-actin 
localization (red), particularly with dendritic cell protrusions.  The co-distribution of E-
selectin ligands and F-actin in human mo-DCs suggests that E-selectin reactive determinants 
are mainly localized to the migration front of these cells.  
 
 
Figure 3. Immunostaining of human mo-DCs shows co-localization of E-selectin ligand reactivity and F-
actin staining. Human mo-DCs were double labeled with E-Ig, for E-selectin ligands (green), and rhodamine-
conjugated phalloidin (red) for F-actin. Images of slices were obtained in a Leica TCS SP2 AOBS confocal 
microscope and assembled with Leica Confocal Software. 
	  
Umbilical cord blood monocytes derived-DCs do not express any glycoprotein with E-
selectin binding activity 
The characterization of E-selectin ligand expression on DCs derived from human APB 
monocytes opened new insights into the understanding of DCs migratory functionality. 
However, little is known regarding E-selectin ligands expressed by DCs procured from other 
human cellular sources. There is emerging interest in the development of new methods 




Monocytes obtained from umbilical cord are currently being studied to investigate their 
potential as an alternative DC source.  Thus, we sought to analyze the E-selectin binding 
pattern of mo-DCs derived from umbilical cord blood (UCB). For this purpose, we examined 
their E-selectin binding reactivity by Western blot and flow cytometry analysis, using E-Ig as 
a probe, as it binds to sialofucosylated E-selectin binding determinants. Unexpectedly, and in 
contrast to APB mo-DCs, Western blot analysis revealed that these cells do not express 
glycoproteins with E-selectin binding activity, as shown by the absence of E-Ig reactivity 
(Figure 4a). Interestingly, by flow cytometry the level of E-Ig reactivity was positive (Figure 
4b), suggesting that human UCB mo-DCs express E-selectin binding determinants mainly 
displayed on cell surface via glycolipid scaffolds. The distinct E-selectin ligand expression 
pattern between UCB and APB mo-DCs prompted us to analyze the E-Ig reactivity of 
monocytes, the mo-DC precursors. Intriguingly, monocytes from umbilical cord blood 
showed strong E-Ig reactivity by westernblot analysis, staining two E-selectin reactive bands 
at ~120-130 kDa band and ~80-90 kDa. Yet, E-Ig reactivity was slightly lower compared to 
APB monocytes (Figure 4c). This data suggests that the E-selectin ligand glycoprotein 
expression on UCB mo-DCs is lost during the DC differentiation and is not intrinsic to UCB 
monocytes.  
We next assessed whether enforced α(1,3)-fucosylation would increase surface expression of 
E-selectin ligand glycoproteins on UCB mo-DCs. After FTVII reaction, westernblot analysis 
showed that mo-DCs from UCB exhibit a marked increase in expression of glycoproteins 
with E-selectin binding activity. Distint bands were revealed with molecular weights 
corresponding to CLA/CD43E (~120-140 kDa) and HCELL (~80-90 kDa) (Figure 4d).  The 
expression of glycoproteins E-selectin binding reactivity after exofocusylation shows that 
UCB mo-DCs natively express unfocusylated sialyllactosamine units on protein scaffolds. 
Therefore, the lack of E-selectin ligand determinants on protein scaffolds is potentially due to 
an insufficient activity of α(1,3)-fucosylatransferases and/or higher activity of 
α(1,3)fucosidases. 
To fully assess the impact of enforced exofocusylation, BT-treated or FTVII-treated UCB 
mo-DCs were perfused over TNF-α stimulated HUVEC under physiologic shear stress. As 
shown in Figure 4e, FTVII-treated UCB mo-DCs maintained high levels of rolling and 




treated UCB mo-DCs displayed a dramatically decreased ability to tether and roll at shear 
stress levels higher than 1 dynes/cm2. 
	  
Figure 4. Mo-DCs obtained from UCB do not express glycoproteins with E-selectin binding reactivity. a) 
Western blot analysis of E-Ig-reactive proteins of human APB and UCB mo-DCs. Whole cell lysates from APB 
and UCB mo-DCs were resolved by SDS-PAGE and blotted with E-Ig chimera. ABP mo-DCs show high E-Ig 
reactivy, whereas UCB mo-DCs lack E-Ig staining. CD44 staining (molecular weight ~80-90kDa) was used as 
protein loading control. b) Representative flow cytometry histogram of E-Ig staining of UCB mo-DCs.  Grey line 
represents E-selectin binding in the absence of Ca2+ (EDTA) and black line represents incubation with E-Ig. As 
shown, human UCB mo-DCs show E-Ig reactivity by flow cytometry c) Western blot analysis of whole cell 
lysate of human APB and UCB monocytes stained with E-Ig. E-Ig staining of both APB and UCB monocyte 
lysates resolved under reduced SDS-PAGE conditions revealed strong E-Ig reactivity. CD44 staining (molecular 
weight ~80-90kDa) was used as protein loading control. d) Western blot analysis of E-Ig reactivity of UCB mo-
DCs that were buffer treated (BT) or FTVII-treated (FTVII). FTVII-mediated exofucosylation of UCB mo-DCs 
creates E-selectin ligands on multiple cell surface glycoproteins. CD44 staining (molecular weight ~80-90kDa) 
was used as protein loading control. e) FTVII treatment creates functional E-selectin ligands on UCB mo-DCs.  
Human UCB mo-DCs treated with FTVII (FTVII) or buffer alone (BT) were perfused into a parallel-plate flow 
chamber seeded with TNF-α-stimulated HUVECs.  FTVII-treated cells exhibited a significantly increase of 





Murine DCs do not express the E-selectin binding glycoform of CD44  
To determine the E-selectin ligand expression pattern on murine DCs, we analysed by 
western blot and flow cytometry two types of DCs: bone-marrow derived DCs (BM-DCs) 
and splenic DCs (sDCs). Interestingly, these two types of murine DCs showed different E-
selectin ligand reactivity patterns between each other. 
Murine BM cells were isolated from bone marrow and grown for either 5 or 8 days in the 
presence of GM-CSF, allowing differentiation of BM precursors into DCs. After 
differentiation, DCs typically express a combination of cell surface markers, such as CD11c, 
major histocompatibility complex class II (MHC-II) and CD11b (myeloid marker). In 
cultures growing for 5 days, we typically observed a differentiation of BM precursors into 
DCs of about 55% and these cells were characterized by a high expression of CD11b and low 
expression of MHC-II, suggesting an immature phenotype, whereas in cultures growing for 8 
days, around 70% of the cells were CD11c+, CD11bhigh and MHC-IIhigh, suggesting a mature 
phenotype. 
Although, murine BM-DCs showed a strong E-Ig and HECA-452 reactivity by flow 
cytometric analysis (Figure 5a), our western blot results suggest that these cells don’t express 
any glycoproteins with E-selectin binding activity, as evidenced by the absence of E-Ig 
reactivity at both culture time periods assessed (Figure 5b); even though these cells express a 
signifivant amount of protein scaffolds, such as CD44 and PSGL-1 (data not shown). These 
data indicate that the E-selectin ligand epitopes expressed on murine BM-DCs are 
prominently displayed in glycolipids. Interestingly, when we analyzed by flow cytometry the 
expression of E-selectin ligands at day 5 and 8, we observed that E-selectin ligand expression 
tend to decrease over time, i.e BM-DCs grown for 5 days exhibited a higher expression of E-







Figure 5. Murine BM-DCs do not express glycoproteins with E-selectin ligand activity. a) Flow cytometry 
analysis of E-selectin ligand expression on murine BM-DCs assessed by E-Ig and HECA reactivity. Black lines 
represent E-Ig or HECA reactivity of BM-DCs cultured for 5, whereas, darker grey lines represent E-Ig or 
HECA reactivity of BM-DCs cultured for 8 days. Lighter grey lines represent isotype control (or E-selectin 
binding in the absence of Ca2+). BM-DCs show considerable E-Ig and HECA reactivity that declines with 
increased culture time period. b) Western blot analysis of HECA-452 reactivity of whole cell lysates from murine 
BM-DCs. BM-DCs lack HECA-reactive glycoproteins. 
 
By contrast, sDCs showed a strong HECA-452 reactivity by both flow cytometry (Figure 6a) 
and western blot (Figure 6b) analysis. Westernblots of total sDCs cell lysate blotted for 
HECA-452 showed a reactive ~120-130kDa band. Due to the molecular size of this HECA-
reactive band, we immunprecipitated PSGL-1 from murine sDCs total lysate and stained with 
HECA-452. Westernblots of E-Ig immunoprecipitated products followed by PSGL-1 staining 
were also performed (Figure 6b). In both cases, we confirmed that the HECA-452 reactive-




Figure 6. CLA is expressed by murine splenic DCs. a) Flow cytometry analysis of E-Ig, HECA-452 and 
PSGL-1 expression on murine sDCs. Grey lines represent isotype control (or E-selectin binding in the absence 






of E-Ig, HECA and PSGL-1. b) Identification of glycoprotein E-selectin ligands expressed by murine sDCs. 
Left: Western blot analysis of whole cell lysate from murine spleen DCs. Total cell lysates were resolved by 
SDS-PAGE and blotted with anti-HECA-452 or anti-PSGL-1 antibodies. Right: E-selectin ligands and PSGL-1 
from murine sDCs were immunoprecipitated and then resolved by SDS-PAGE and blotted with PSGL-1 and E-




Dendritic cells (DCs) are highly efficient antigen-presenting cells that play a key role in the 
induction of immunity.29 Due to their ability to elicit both innate and adaptive immune 
responses, DCs have been exploit as a powerful toll in anti-cancer vaccines during the last 
two decades.30  Although DC-based vaccines are able to induce tumor-specific immune 
responses in mice models, limited progress has been shown in clinical trials, since they are 
ineffective at inhibiting tumor growth in treated cancer patients.31 Thus, new strategies are 
urgently needed to overcome the poor objective clinical response observed. It is well 
established that tumor microenvironment is rich in tumor infiltrating effector memory T cells, 
therefore, directing DCs to these tissues would enhance local antigen presentation and induce 
a stronger and quicker cellular-mediated anti-cancer immune response.9 Since tumor 
microvasculature highly expresses E-selectin and the recruitment of circulating leukocytes to 
these sites is mainly mediated by binding to vascular E-selectin,13 we sought to perform a 
detailed characterization of the E-selectin ligands that are expressed by human and mouse 
DCs, obtained from different cellular sources, and develop methodologies that could up-
regulate the expression of these molecules. Our results opened new insights into species-
specific and cellular sources-specific differences in the expression of E-selectin ligands by 
DCs, providing a novel understanding on DCs migration to sites of inflammation/ tumor in 
mice and humans. 
Human DCs can be generated from different cellular sources, however the most common 
approach used, in immunotherapy, is the differentiation of DCs from monocytes.32 These are 
normally obtained from peripheral blood, but recently there has been an increasing interest in 
monocytes obtained from umbilical cord blood sources.33 In this study, we first analyzed the 
E-selectin reactive determinants displayed in the protein scaffolds of both adult peripheral 
blood (ABP) and umbilical cord blood (UCB) monocyte-derived DCs (mo-DCs). Our data 
show that human APB mo-DCs display a large set of glycoprotein E-selectin ligands, in 




decorated form of PSGL-1, CLA, and the E-selectin reactive glycoform of CD44, HCELL. 
(Videira et al., unpublished data) Here, our data is the first to show that the glycoform of 
CD43, CD43E, is also an E-selectin ligand expressed by APB mo-DCs. Moreover, in blot 
rolling assays of CD43 immunoprecipitates from APB mo-DC lysates, CD43 strongly 
supported E-selectin-specific interactions, suggesting that CD43E is a functional E-selectin 
ligand on APB mo-DCs. CD43 is a surface sialomucin expressed exclusively on 
hematopoietic cells34 and has previously been described to function as an E-selectin ligand on 
both human24 and murine25,35 T cells, on human CD34+ and mouse LSK cells,36 on murine 
neutrophils37 and on human monocytes (Silva et al., unpublished data). Notably, 
immunofluorescence studies show that the E-selectin binding epitopes are distributed 
prominently to the migrating front of APB mo-DCs, with particular relevance for the veil 
like-cell actin-rich protrusive structures. In amoeboid cells, like DCs, migration is highly 
dependent on cortical actin cytoskeletal tension, therefore co-localization of E-selectin 
ligands with F-actin filaments may facilitate interaction of E-selectin ligands with E-selectin 
on endothelial surfaces.38,39  
On the other hand, we observed that UCB mo-DCs do not natively express any glycoprotein 
with E-selectin ligand activity. Nevertheless, UCB mo-DCs show E-selectin binding activity 
by flow cytometry, which suggests that these cells have E-selectin binding determinants 
displayed in glycolipid scaffolds. While E-selectin binding determinants can be displayed via 
protein or lipid scaffolds, glycoproteins play a major role in the initial contact to E-selectin 
under hemodynamic shear stress. Glycolipids are significantly smaller than glycoproteins, 
and therefore not accessible to E-selectin as glycoproteins.40,41 Thus, our data may suggest a 
malfunctioning ability of UCB mo-DCs to migrate to inflamed tissues since they lack E-
selectin reactive glycoproteins. Indeed, our finding is in agreement with previously studies 
reporting that UCB cells display a poor ability to migrate to bone marrow, where E-selectin is 
expressed constitutively.42,43  
To assess whether we could augment the DC cell surface expression of E-selectin ligands, 
and thereby, increase their ability to migrate to inflamed tissues, we performed α(1,3)-
exofucosylation of both APB and UCB mo-DCs and analyzed their E-Ig reactivity and ability 
to bind to E-selectin under hemodynamic flow conditions. Enforced exofucosylation 
markedly induces E-selectin binding activity in both types of mo-DCs, as assessed by western 




under shear stress conditions is also dramatically enhanced. Notably, enforced fucosylation of 
APB mo-DCs, not only induces increased expression of functional CLA, HCELL and 
CD43E, but also the newly formed E-selectin reactive glycoform of CD18 and high 
molecular weight glycoforms of HCELL. So far, the E-selectin glycoform of CD18 had only 
been described on neutrophils,44 while the high molecular weight E-selectin reactive 
glycoforms of CD44 had only been described in certain types of tumor cells.45 The enhanced 
ability of FTVII-treated APB mo-DCs to tether and roll under hemodynamic flow conditions 
compared to untreated cells (BT) highlight the role of the newly formed glycoforms of CD18 
and CD44 as potent E-selectin ligands. Concerning the exofucosylation of UCB cells, the 
creation of sLeX determinants indicates that these cells natively express sialylated lactosamine 
units, which can be extrinsically fucosylated. Therefore, the lack of E-selectin reactive 
glycoproteins on UCB mo-DCs is due to the lack of fucose residues within the sialylated 
lactosamine units, which can be overcome by an exofucosylation reaction step.  
Striking differences related to the E-selectin binding profile were also observed between 
murine bone marrow derived DCs (BM-DCs) and murine splenic DCs (sDCs). Similar to 
human UCB mo-DCs, murine BM-DCs are devoid of E-selectin reactive glycoproteins, but 
not of E-selectin binding glycolipids, while sDCs strongly express CLA. Interestingly, BM-
DCs that were grown for 5 days exhibited a higher expression of E-selectin ligands 
determinants, as assessed by flow cytometry, than those grown for 8 days. BM-DCs cultured 
for 5 days were not fully differentiated and exhibit a more immature phenotype. Thus, these 
observations suggest that a higher expression of E-selectin ligand epitopes are associated with 
an immature and incomplete differentiation phenotype of murine BM-DCs.  Also, it is 
striking that any of these murine DCs express the E-selectin reactive glycoform of CD44, 
HCELL, which is the most potent E-selectin ligand described so far.36 Indeed, HCELL has 
only been described in human cells, while the others E-selectin reactive glycoproteins 
reported (CLA and CD43E) have been described to function as E-selectin ligands in both 
human and murine cells.13  
Collectively, our findings disclose critical and undiscovered cellular sources-specific and 
species-specific diversity in the expression of E-selectin ligand glycoproteins among DCs. 
Our data suggest that monocytes isolated form adult peripheral blood may be a better source 
for ex vivo generated anti-cancer DC-based vaccines since APB mo-DCs natively display 
high amounts of E-selectin ligands, which are required for DC migration to inflamed/tumoral 




autoimmune disease contexts. Finally and similar to previous studies,36,41 we demonstrate that 
exofucosylation is a powerful platform technology for enforcing E-selectin ligand expression, 
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Dendritic cells (DCs) hold promise for anti-cancer immunotherapy, as they initiate strong and 
long-lived specific T cell responses. However, at the clinical setting, their efficiency is 
limited and the identification of strategies to improve DC responses is critically needed. Sialic 
acids have a potential immunomodulatory role due to their exposed location at the termini of 
cell surface glycans. Human DCs have a high content of sialic acids, which influences their 
maturation and co-stimulation capacity. Here, we aimed to understand whether exogenous 
desialylation, obtained by sialidase treatment, improves DC-mediated anti-tumor immune 
responses. Compared to fully sialylated DCs, the desialylated human DCs, loaded with whole 
tumor cell antigens showed enhanced ability to induce autologous T cells to proliferate, to 
secret Th1 cytokines, and to specifically kill tumor cells. Desialylated human DCs showed an 
increased expression of MHC class I and II and co-stimulatory molecules and secretion of IL-
12. Desialylated HLA-A*02:01 DCs pulsed with synthetic long or short peptides from the 
tumor antigen gp100 displayed enhanced antigen cross-presentation or peptide binding to 
MHC-I, as evaluated based on the activation of gp100280–288 specific CD8+ cytotoxic T cells. 
To evaluate whether the effect was restricted to human DCs, we also evaluated murine DCs. 
Concordantly, desialylated murine DCs displayed higher MHC class I and II and co-
stimulatory molecules and antigen cross-presentation on MHC-I. These DCs showed higher 
ability to activate antigen-specific CD4+ and CD8+ T cells, to specifically kill antigen-
expressing melanoma cells. Taken together, our data demonstrates that desialylation improves 
the capacity of DCs to elicit T cell-mediated anti-tumor activity. This improvement is related 
with enhanced antigen presentation through MHC-I due to increased MHC-I expression and 
binding of antigen to MHC-I. 
This study offers key insights to optimize the capacity of DCs to boost anti-tumor immunity, 
and indicates that treatment with an exogenous sialidase is a potential technology to improve 







Dendritic cells (DC) are the most potent antigen-presenting cells of the immune system and 
thus critical to initiate anti-tumor immune responses. Several studies have shown the potential 
of these cells as therapeutic vaccination against cancer.1-4 However, only a few vaccines have 
been approved for clinical use.5 One of the challenges has been the establishment of efficient 
approaches that enhance the maturation profile of DCs and in particular the presentation of 
antigens to cytotoxic T cells.6 In fact, efficient induction of anti-tumor responses, requires 
that DCs undergo proper maturation, characterized by: increased expression of major 
histocompatibility complex (MHC) molecules, needed to present antigens to T cells; 
increased expression of co-stimulatory molecules, such as CD80 and CD86, to promote DCs 
interaction with T cells;7 and secretion of pro-inflammatory cytokines, such as the Th1-
inducing cytokine interleukin (IL)-12, required for anti-tumor activity.8 Importantly, 
endogenous antigens are presented through MHC-I molecules to CD8+ cytotoxic T cells, after 
proteasomal degradation, while exogenous antigens are classically presented via MHC-II to 
CD4+ helper T cells, after processing via the endolysosomal route.2 DCs are also endowed 
with unique antigen processing pathways that enable exogenous antigens to escape 
endolysosomes and then enter proteasomal degradation to be presented in the context of 
MHC-I molecules, in a process called cross-presentation.9,10 Furthermore, exogenously 
supplied high affinity peptides can bind directly to MHC-I, without previous endocytosis and 
processing.11 Since most tumor-associated antigens used for DC vaccination are of exogenous 
origin, strategies that foment antigen presentation through MHC-I are crucial for the 
generation of CD8+ cytotoxic T cells response, and thereby for the generation of an anti-
tumor immune response.10,12,13 
Glycans that decorate cell membrane proteins play a key role in the modulation of cell-cell 
and receptor-ligand interactions in several immunological processes.14-16 The terminal 
positions of these glycans may be occupied by a negatively charged and non-reducing 
monosaccharide, named sialic acid.17 Due to this exposed location, sialic acids are involved in 
many immunological functions. This includes the regulation of the immune cell activation 
through sialic acid recognition by Siglecs, a family of inhibitory sialic acid–dependent 
receptors18 and sialic acid recognition by certain microbes upon infection.19,20 Sialic acid may 
also alter the biophysical properties of cellular interactions by providing negative charge 
repulsion between cells, and therefore mask or prevent recognition by other receptors such as 




types and varying markedly with regard to cell differentiation and stimuli.23,24  
In previous studies, we demonstrated that the surface of human monocyte-derived DCs 
(MoDCs) is highly sialylated mainly due to the enzymatic activity of the sialyltransferases 
ST3Gal-I and ST6Gal-I, which contribute to the α(2,3)- and α(2,6)-sialic acid transfer to cell 
surface glycoconjugates, respectively. The removal of sialic acids by sialidase treatment 
induces DC maturation.24 Consistently, desialylated MoDCs loaded with toxoid antigen have 
increased ability to activate autologous T cells.25 Our observations suggest that the sialic 
acids present at cell surface of DCs contribute to dampen DC maturation and further ability of 
DCs to activate T cells. Yet, the role of cell surface sialic acids in DC immunogenicity 
against tumor cells is still unknown.   
Here, we first sought to investigate whether DCs generated by well-established methods 
employed in clinical trials (e.g., NCT01042366, NCT00683241, and NCT00442754) had 
improved anti-tumor immune responses when treated with sialidase. Our data show that 
sialidase treatment of human MoDCs, loaded with whole tumor cell antigens, improves their 
ability to specifically activate autologous T cells and consequently, enhances T cells’ ability 
to kill tumor cells. We further assessed the cellular effects of sialidase treatment and observed 
these MoDCs showed increased antigen-presenting and co-stimulatory abilities, resulting in 
higher polarization of T cells towards a Th1 phenotype. Murine splenic DCs (sDCs) also 
showed a similar improved capacity to induce anti-tumor immune responses when treated 
with sialidase. Notably, both MoDCs and sDCs showed increased cross-presentation of 
antigens through MHC-I to CD8+ T cells. These results indicate that desialylation of DCs 
represents an efficient and powerful tool to elicit tumor-specific immune response, with 
potential impact in DC-based anti-tumor immunotherapy. 
 
 
Materials and Methods 
Reagents  
Culture media, RPMI-1640, DMEM and IMDM, fetal bovine serum (FBS), non-essential 
amino acids, sodium pyruvate, trypsin-EDTA, L-glutamine and glutamax were purchased 




stimulating factor (GM-CSF), IL-2 and tumor necrosis factor (TNF)-α, and the cell isolation 
immunomagnetic beads were obtained from Miltenyi Biotec (Bergisch Gladbach, Germany). 
Recombinant human IL-4 was purchase from R&D Systems (Minneapolis, MN, USA). The 
CellTrace™ CFSE Cell Proliferation Kit was purchased from Molecular Probes, and annexin 
V from Immunotools (Friesoythe, Germany).  
The following anti-human antibodies (mAbs) were used: fluorescein isothiocyanate (FITC)-
conjugated anti-CD1a from BD Biosciences (San Jose, CA, USA); phycoerythrin (PE)-
conjugated anti-CD1c from BioLegend (San Diego, CA, USA); allophycocyanin (APC)-
conjugated anti-HLA-DR from Immunostep (Salamanca, Spain); and APC conjugated anti-
CD3, anti-CD4; peridinin chlorophyll protein (PercP)-conjugated anti-CD8; PE–conjugated 
anti-CD14, anti-CD40, anti-CD69 and anti-CD80; and FITC-conjugated anti-CD45 and anti-
CD86 mAbs from Immunotools. 
The following anti-mouse mAbs were used: FITC-conjugated anti-CD11c, APC-conjugated 
anti-B220, anti-CD11b, PercP-conjugated anti-CD8α, PE-conjugated anti-IAb and anti-CD86 
mAbs from BD Biosciences; PercP-conjugated anti-CD4, FITC-conjugated anti-H-2Kb, 
biotin-conjugated CD80 and PE-conjugated anti-SIINFELK/H-2Kb mAbs from eBioscience 
(San Diego, USA); PE-conjugated streptavidin (Biolegend) was used in combination with 
biotin-conjugated anti-CD80 mAb. Unless otherwise stated, remaining reagents and media 
were purchased from Sigma Chemical Co. (Sigma, St Louis, MO, USA). 
 
Flow cytometry  
Cell surface staining was assessed by using fluorescence-conjugated or unlabeled mAb 
followed by fluorescently-conjugated secondary mAb, according to manufacturer 
instructions. For characterization of murine splenic DCs (sDC), blockade of nonspecific 
binding was performed by pre-incubation with 1% of anti-mouse CD16/32 (eBioscience) for 
30 min at 4ºC. Data was acquired using either an Attune Acoustic Focusing Cytometer 
(Applied Biosystems, USA) or a FACSCalibur Cytometer (Becton-Dickinson, FranklinLakes, 
NJ, USA) and data analysed using either the Attune Cytometric Software v2.1 or the FlowJo 





Human tumor cell line culture and preparation of whole cell lysates 
The HLA-A*02:01 positive breast cancer cell line MCF-7 was originally isolated from a 
pleural effusion of a 69-year-old caucasian woman with a diagnosis of invasive breast ductal 
carcinoma.26 The MCF-7-GFP is a MCF-7 variant that constitutively expresses the green 
fluorescent protein (GFP). Both cell lines were obtained from American Type Culture 
Collection and routinely cultured in complete DMEM media: DMEM medium with 10% 
FBS, 2 mM L-glutamine, and 100 µg/mL penicillin/streptomycin.  
To obtain cell lysates as source of antigens, cells were grown until 80% confluence, collected, 
washed and resuspended in RPMI medium at a concentration of 5×106 cells/mL. Cells were 
lysed through four freeze (-80 ºC) and thaw (37 ºC) cycles and the cell debris removed by 
centrifugation. Complete cell lysis was confirmed microscopically by trypan blue and by 
culture test. The protein concentration of the tumor cell lysates was determined using Pierce 
BCA Protein Assay kit (Thermo Scientific; Germany) 
 
Generation of human MoDCs  
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of human 
peripheral blood from healthy volunteers provided by the Portuguese Blood and 
Transplantation Institute, after informed consent and approval by institutional ethical 
committee. Monocytes were enriched using anti-CD14 mAb-coated immunomagnetic beads. 
The CD14+ cells were cultured at a concentration of 1 × 106 cells/mL in RPMI 1640 medium, 
10% FBS, 2 mM L-glutamine, 100µg/mL penicillin/streptomycin, 1% pyruvate and 50 µM 2-
mercaptoethanol (complete RPMI medium) supplemented with 750 U/mL of IL-4 and 1000 
U/mL of GM-CSF, as described previously.27 After 5-7 days in culture, the generation of 
MoDC, was confirmed by flow cytometry analysis.   
 
Mice  
Six to eight weeks old C57BL/6 (B6) mice, and the B6 transgenic mice OT-I (producing 
OVA-specific MHC-I restricted CD8+ T cells) and OT-II (producing OVA-specific MHC-II 
restricted CD4+ T cells) were housed and bred at the animal facility of Instituto Gulbenkian 




followed by cervical dislocation. All procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC), in agreement with the Federation of European 
Laboratory Animal Science Associations (FELASA) directives, approval ID number 
AO10/2010. 
 
Murine cell culture 
The mouse melanoma cell line B16, transfected with the FMS-like tyrosine kinase 3 ligand 
gene (B16-Flt3-L) was gently provided by Dr. J. Lafaille (Skirball Institute of Biomolecular 
Medicine, NYU, USA) and cultured in complete RPMI medium. The B16 cell line 
transfected with the ovalbumin gene (B16-OVA) was gently provided by Dr. L. F. Moita 
(IMM, Lisboa, Portugal) and was grown in complete DMEM medium. Cells were split 
approximately every three days, after cell detachment using trypsin/EDTA. 
 
Generation of murine DCs 
To generate large numbers of splenic DCs (sDCs), female C57BL/6 mice were injected 
subcutaneously in the flank with 2 × 105 B16-Flt3-L cells, as described.28 After 10 to 15 days, 
mice were sacrificed and splenocytes isolated by mechanical disruption of spleens and 
filtered. After red blood cell lysis (150 mM NH4Cl, 10mM KHCO3, 0.1mM Na2EDTA), the 
sDCs were further sorted by positive immunomagnetic selection using anti-CD11c mAb-
coated immunomagnetic beads following manufacturer´s instructions. The isolated cell 
fraction was typically ~ 97% CD11c+ cells. Further characterization of DC subsets was 
performed (Supplementary Figure S1).  
 
T cell isolation and culture  
The human T cells used in this work comprised the CD14- cell fraction of PBMCs (> 70% 
CD3+ cells), obtained after immunomagnetic isolation of monocytes (CD14+), described 
above. For cytotoxicity experiments, T cells were further enriched using anti-CD3 mAb-
coated immunomagnetic beads (> 97% CD3+ cells). The CD8+ T cells  transduced with a 




described.29 Murine T cells were obtained from splenocytes from B6.OT-I and B6.OT-II TCR 
transgenic mice, obtained by spleen mechanical disruption, followed by red blood cell lysis, 
as described above. 
 
Antigen loading and stimulation of DCs 
For loading MoDCs with tumor antigen, MoDCs were incubated with protein lysate (1mg per 
5×106 MoDCs, per mL), in complete RPMI medium, for 4h at 37 ºC. When needed, MoDCs 
were stimulated for 24h with TNF-α (1000 IU/mL). 
For loading sDCs with OVA, sDCs were incubated with OVA (0.1mg per 0.5×106 sDCs, per 
mL), in complete RPMI medium, for 4-6h at 37ºC. 
 
Sialidase treatment 
Cells were treated with sialidase from Clostridium perfringens (Roche Diagnostics, Basel, 
Switzerland) at a concentration of 0.1 U/mL per 50×106 cells in 50 mM sodium phosphate 
buffer (pH 6.0) or RPMI medium for 60 min at 37ºC. Treatment was stopped by diluting 10 
times the reaction volume with complete RPMI medium. The efficacy of sialidase treatment 
was confirmed by lectin staining with FITC-labeled Sambucus nigra lectin (SNA), -Maackia 
amurensis lectin II (MAA) and -Peanut agglutinin lectin (PNA) (Vector Laboratories, 
Peterborough, UK) (Supplementary Figure S2). Control experiments consisted of cells 
incubated in the same conditions but without sialidase enzyme or incubated with heat-
inactivated sialidase (sialidase boiled for 20 min at 100ºC). After treatment, cell viability was 
evaluated by staining with 7-Aminoactinomycin D (7AAD, BD Biosciences) and annexin V 
and analyzed by flow cytometry (Supplementary Figure S3).  
 
Proliferation Assays 
T cell proliferation was accessed based on the carboxyfluorescein succinimidyl ester (CFSE) 
dilution assay. Briefly, T cells were labeled with CFSE, according to manufacturer 




human cells, the MoDC: T cell ratio was 1:5 (0.4×105 DC: 2×105 T cells/well) and, 18h later, 
10 IU/mL of IL-2 was added.   
For experiments with murine cells, the sDC: OT-I or OT-II splenocytes ratio was 1: 2 
(2.5×105 sDC: 5×105 T cells/well). The percentage of proliferated cells was calculated, by 
flow cytometric analysis, based on the percentage of population that showed reduced CFSE 
signal. 
 
Antigen presentation assay    
To evaluate antigen presentation in HLA-A*02:01 MoDCs, the cells were loaded with gp100 
antigen peptides: gp100280-288 short peptide (YLEPGPVTA) and gp100280-304 long peptide 
(YLEPGPVTANRQLYPEWTEAQRLDC); that contain an amino acid sequence (underlined) 
that binds to the HLA-A*02:01 allele. MoDCs were incubated with several concentrations of 
gp100 peptides in RPMI medium, for 3 to 4 hours, at 37ºC. After three washing steps, 
MoDCs were co-cultured with gp100-specific CD8+ T cells,29 in IMDM medium, in a 
MoDC: T cell ratio of 3: 10. Following overnight incubation, the secretion of IFN-γ cytokine 
into supernatant was measured by Enzyme-linked immunosorbent assay (ELISA).  
To assess the presentation of the OVA derived peptide SIINFEKL bound to H-2Kb (murine 
MHC-I), sDCs loaded with OVA were stained with the anti-SIINFELK/H-2Kb (25-D1.16 
clone) mAb and analysed by flow cytometry. 
 
Cytotoxicity Assays  
HLA-A*02:01+ MoDCs loaded with tumor cell lysates were used to prime autologous CD3+ 
T cells, as described above. Co-cultures were maintained for 2-3 weeks, and T cells were 
pulsed every week with HLA-A*02:01+ antigen-loaded MoDCs. IL-7 (5 ng/mL) was added at 
day 1 of culture and at the days of MoDC reload; and IL-2 (10UI/mL) was added at day two. 
Primed T cells were then cultured against target tumor cells MCF-7-GFP, in a ratio of 5 T 
cells per 1 tumor cell, for 5h at 37ºC. The apoptosis of MCF-7-GFP was determined based on 
the acidification of cell cytoplasm, which leads to decreased or complete loss of GFP 
fluorescence intensity. Thus, the percentages of tumor cells that do not undergo GFP 




cell survival. 30 The T cell cytolytic capacity, i.e., T cell degranulation, was evaluated by 
detecting at cell surface the lysosomal-associated membrane protein 1 (CD107a, LAMP-1), 
expressed in the membrane of cytotoxic granules.31 Briefly, anti-CD107a mAb was added to 
the T cell: tumor cell co-cultures and after 1h, brefeldin A was added to block protein 
secretion. Following incubation for 4 h at 37ºC, the expression of the CD107a molecules was 
evaluated in CD3+ cells, by flow cytometry. 
For experiments with murine cells, splenocytes from OT-I and OT-II mice were primed by 
incubation with OVA-loaded sDCs, for 72h, as described above. The mouse melanoma cell 
line B16-OVA was labeled with CFSE, following the manufacturer instructions, and used as 
target tumor cell. The primed splenocytes were added to the B16-OVA cells at a ratio of 5 
splenocytes per 1 tumor cell and co-cultured for 24h at 37°C. Tumor cell killing was 




The cytokine production was measured using ELISA technique, according to the 
manufacturer’s instructions. Human IL-4, IL-6, IL-10, IL-12, TNF-α and IFN-γ ELISA 
development kits were purchased from Immunotools. Mouse IL-6, TNF-α and IFN-γ ELISA 
development kits were purchased from Prepotech (Hamburg, Germany). Cytokine 
concentration was calculated as pg/mL using the specific standard curves. 
 
Statistical analysis 
Data were analyzed using GraphPad Prism 6 (GraphPad Software, Inc). The significance of 
differences between series of results with three or more groups was assessed using the one-
way ANOVA. Data with two groups were analyzed by Student-t-test. Tests were considered 





Desialylated MoDCs loaded with whole tumor antigens have a higher ability to induce 
anti-tumor T cell responses 
We first sought to assess the effect of sialic acid removal from the cell surface on the ability 
of DCs generated by methods employed in clinical trials to induce specific anti-tumor T cell 
responses. Therefore, we primed T cells with autologous desialylated MoDCs loaded with 
MCF-7-tumor cell lysates. Based on the CFSE dilution method, T cells primed with 
desialylated MoDCs showed a robustly higher proliferation, when compared to those primed 
with fully sialylated MoDCs (Figure 1A). To further characterize the profile of T cells 
generated by desialylated MoDCs exposure, the secretion of the Th1 cytokines - TNF-α and 
IFN-γ - and the Th2 cytokine - IL-4 - was analyzed. As shown in Figure 1B, when compared 
with T cells primed by fully sialylated MoDCs, T cells primed by desialylated MoDCs 
secreted slightly higher levels of IFN-γ and TNF-α. The expression of IL-4 by T cells was not 
altered when primed either by fully sialylated or desialylated MoDCs (Figure 1B). 
Thus, desialylated MoDCs have improved capacity to prime autologous T cells, as shown by 
their ability to induce T cell proliferation and production of Th1 cytokines, which are crucial 
for the induction of anti-tumor immune responses.  
 
Figure 1. Desialylation of human MoDCs loaded with whole tumor cell antigens induces T cell activation. 




loading with MCF-7 lysates (TL), as source of whole tumor cell antigens. MoDCs were then used in co-cultures 
with autologous T cells for 4-8 days in the presence of 10 IU/mL of IL-2. (A) Induction of T cell proliferation by 
MoDCs. T cells were previously labeled with CFSE and the progeny, i.e., the percentage of T cells that 
proliferated, was estimated by flow cytometry, based on the CFSE dilution. The histograms show representative 
experiments where T cells were co-cultured with: unloaded MoDCs (panel a), MoDCs loaded with MCF-7 
lysates (panel b) and sialidase treated MoDCs loaded with MCF-7 lysates (panel c). Unstimulated T cells (panel 
d) served as negative control and phytohaemagglutinin (PHA)-stimulated T cells (panel e) as positive control. 
Tabled values represent the mean percentage of proliferative cells ± SEM of 2 independent assays. (B) Th1 
cytokines secreted in DC: T cell co-culture. The cytokines secreted into the co-culture supernatants, following T 
cell stimulation with MoDC were measured by ELISA (n=6). Graph values represent the mean concentration 
(pg/mL) ± SEM.    
 
The cytotoxicity of primed HLA-A*02:01+ T cells was then tested against MCF-7 breast 
cancer cells stably expressing GFP (MCF-7-GFP). The viability of the tumor cells was 
measured based on evaluation of loss of fluorescence due to cytoplasm acidification in the 
MCF-7-GFP cells. The degranulation of cytotoxic granules from T cells was also evaluated 
by the appearance of CD107a (LAMP-1) at T cells’ surface. As shown in Figure 2A, tumor 
cell viability was significantly decreased when incubated with T cells that had been 
previously primed with desialylated MoDCs loaded with tumor-antigens, compared to those 
incubated with T cells primed with fully sialylated MoDCs. In agreement, the highest 
degranulation of T cells was observed when the cells were primed with desialylated MoDCs, 
as shown by the higher number of T cells expressing cell surface CD107a (Figure 2B).  
 
 
Figure 2. Desialylation of human MoDCs loaded with whole tumor cell antigens improves T cell 
cytotoxicity against tumor cells. MoDCs obtained from HLA-A*02:01 donors were treated with sialidase 
(Sia), for 1 hour at 37ºC or left untreated, followed by loading with lysates of the breast cancer cell line MCF-7 
(TL). Autologous CD3+ T cells (T) were co-cultured with MoDCs loaded with MCF-7 lysates (MoDCTL), or 
MoDCs that were sialidase treated and loaded with MCF-7 lysates (MoDCsia+TL). After 3 weeks, CD3+ T cells 




cultured with MCF-7 as control. (A) T cells primed with desialylated human MoDCs loaded with MCF-7 lysates 
induce higher tumor cell death. Tumor cell apoptosis was evaluated by assessing the intensity of GFP reporter in 
MCF-7 tumor cells. Graph values represent the percentage ± SEM of viable tumor cells (GFP+) of four 
independent assays. Statistically significant differences were calculated using t-test (*P < 0.05) (B) T cells 
primed with desialylated MoDCs show higher degranulation. The degranulation of cytotoxic T cells against 
tumor cells was determined by the percentage of T cells expressing CD107a at cell surface. Graph values 
represent the percentage ± SEM of CD107a+ T cells of at least four independent assays.  
 
Desialylated human MoDCs loaded with tumor antigens show higher levels of 
maturation and co-stimulatory markers and IL-12 secretion 
To shed light on the mechanism behind the observed higher anti-tumor T cell responses 
induced by desialylation of MoDCs, we analyzed the maturation profile of desialylated 
MoDCs, loaded or not with tumor-antigens. For that, the expression of maturation markers, 
namely the MHC-I and MHC-II antigen-presenting molecules, and the expression of co-
stimulatory molecules, such as CD80 and CD86, were assessed after sialidase treatment. 
Sialidase treatment of unloaded MoDCs significantly increased the expression of all 
maturation markers compared to untreated MoDCs (Figure 3A, left panels). Similarly, a 
significantly improved maturation phenotype was observed after sialidase treatment of 
MoDCs loaded with MCF-7 lysates (Figure 3A, right panels); yet, sialidase effect was 
restricted to MHC-I and MHC-II molecules, and did not extent to the co-stimulatory 
molecules CD80 and CD86 (Figure 3A, right panel). The combination of sialidase treatment 
with tumor-antigen upload did not alter the expression of other co-stimulatory molecules, 
such as CD40, and of the chemokine receptor CCR7, when compared with fully sialylated 
MoDCs (results not shown). Given the Th1 profile of T cells primed by desialylated MoDCs, 
we further evaluated the effect of sialic acid removal from DC surface on their ability to 
secrete Th1-inducing cytokines, IL-12, TNF-α and IL-6, and the immune-inhibitory Th2-
inducing cytokine IL-10. A significant increase in the expression of IL-12 was observed in 
desialylated MoDCs loaded with tumor antigens compared with those that were not treated 






Figure 3. Desialylated MoDCs show higher levels of maturation and expression of pro-inflammatory 
cytokines (A). Desialylated MoDCs show a higher maturation phenotype than fully sialylated MoDCs. The 
expression of several maturation markers was evaluated by flow cytometry. MoDCs were first treated with 
sialidase (Sia) for 1h at 37ºC and then loaded (A, right panel) or not (A, left panel) with MCF-7 lysates (TL), for 
3h at 37ºC, as described in Materials and methods. Graph values represent the mean fluorescence intensity 
(MFI) (average±SEM) of at least three independent assays. Statistically significant differences were calculated 
using t-test (*P < 0.05, **P < 0.01 and ***P < 0.0001) and refers to the difference between untreated and 
sialidase treated conditions.  (B) Sialidase treatment of MoDCs elicits IL-12 secretion. The cytokines secreted 
by MoDCs following sialidase treatment were measured by ELISA. Data represent the cytokine concentration 
(pg/mL average±SEM) of 6 independent experiments. Statistically significant differences were calculated using 
t-test (*P < 0.05 and **P < 0.01) and refers to the difference between untreated and sialidase treated conditions.  
 
Our data show that desialylation of MoDCs boosts DC maturation, in particular the 




Desialylated murine splenic DCs show higher levels of maturation and co-stimulatory 
markers  
To investigate whether the sialidase effect was restricted to human DCs, we analysed the 
maturation profile of desialylated murine sDCs. Therefore, we analysed the expression of 
MHC and co-stimulatory molecules by sDCs after sialidase treatment. sDCs that were treated 
with sialidase showed a significantly higher expression of H-2kb (MHC-I), IAb (MHC-II), 
CD80 and CD86, molecules (Figure 4). Thus, desialylation of murine sDCs leads to a 
stronger induction of maturation, similar to human MoDCs. 
                    
Figure 4. Sialidase treatment of murine sDCs induces their maturation. Evaluation of maturation markers 
after sialidase treatment. Murine sDCs were treated with sialidase or left untreated and the maturation markers 
evaluated by flow cytometry. Statistical significance (*P < 0.05 or **P < 0.001) refers to the difference between 
fully sialylated and desialylated sDCs, calculated using t-test. Values represent the means of the MFI of at least 
six independent assays.  
 
Desialylation of murine splenic DCs induces antigen-specific CD4+ and CD8+ T cell 
proliferation and activation 
Since desialylated sDCs showed an increased maturation phenotype, we next examined 
whether desialylation would result in a better ability of sDCs to prime antigen specific T 
cells. To assess this, sDCs were loaded with the model antigen OVA, desialylated and then 
co-cultured with either OVA-specific CD4+ or CD8+ T cells, from transgenic OT-II or OT-I 




secretion by T cells, were assessed. Compared with fully sialylated OVA-pulsed sDCs, 
desialylated OVA-pulsed sDC induced significantly higher OVA-specific CD4+ T cell 
proliferation (Figure 5A), as determined by CFSE dilution method. Accordingly, the 
activation of CD4+ T cells was significantly improved when these cells were primed with 
desialylated OVA-pulsed sDCs, as demonstrated by the evaluation of the percentage of 
CD69+CD44high T cells. To assess whether priming with desialylated sDCs would induce a 
Th1 profile on CD4+ T cells, we analyzed the levels of IL-6, TNF-α and IFN-γ secretion by 
primed CD4+ T cells. As shown in Figure 5A, the secretion of all three Th1-cytokines was 
significantly up-regulated when CD4+T cells were primed with desialylated OVA-pulsed 
sDCs compared to T cells primed with fully sialylated OVA-pulsed sDCs. Taken together, 
these results show that sialidase treatment of sDCs significantly improves their ability to 
induce the proliferation and activation of CD4+ T cells with improved Th1 profile. 
Regarding CD8+ T cells, desialylated sDCs showed a modest tendency to induce 
proliferation, but a considerable ability to activate them, based on the percentage of 
CD69+CD44high T cells (Figure 5B). The secretion of IL-6, TNF-α and IFN-γ cytokines were 




             
Figure 5. Sialidase treatment of murine sDCs induces OVA-specific CD4+ and CD8+T proliferation and 
activation. Murine sDCs were pulsed with OVA for 4h and treated or not with sialidase for 1h. A) Desialyated 
sDCs strongly induce proliferation, activation and differentiation of CD4+T into a Th1 effector phenotype. 
Splenocytes from OT-II were isolated and co-cultured with the sDCs for 72h in a ration of 1:2 (DCs: 
splenocytes). After 72 h, the percentage of proliferating and activated CD4+T cells was determined using a 
CFSE dilution and evaluating of surface expression CD69 and CD44, respectively (gating on CD4+ T cells). 
Flow cytometry analysis show an increase in proliferation of CD4+T cells primed with fully sialylated OVA-
pulsed DC. We assessed for IFN- 𝛾, IL-6, and TNF-α secretion in the supernatants of co-cultures by ELISA; a 
significant increase in all cytokines tested was observed after CD4+ T cells were co-cultured with desialylayed 
OVA-pulsed sDCs compared with fully sialylated ones. Statistical significance (*P < 0.05 or **P < 0.001), 
calculated using t-test, refers to the difference between fully sialylated and desialylated sDCs. B) Desialyated 
sDCs induce activation of CD8+T. Splenocytes from OT-I were isolated and co-cultured with sDCs for 72h in a 
ration of 1:2 (DCs: splenocytes) The proliferation and activation of CD8+T cells was determined by CFSE 
dilution and cell surface expression of CD69 and CD44 markers (gating on CD8+ T cell). CD8+ T cells that were 
treated with sialidase-treated DCs showed a significant expression of CD69 and CD44 markers compared to 
fully sialylated OVA-pulsed sDCs  (*P < 0.05). The levels of IFN- 𝛾, IL-6, and TNF-α production in the 





Desialylation of murine splenic DCs leads to improved T cell-mediated tumor cell death  
To investigate whether OVA-specific CD4+ and CD8+ T cells primed with desialylated sDCs 
would have a higher ability to induce tumor cell cytotoxicity, we co-cultured the primed T 
cells with the OVA-expressing melanoma cell line, B16-OVA. Interestingly, B16-OVA 
tumor cells that were incubated with either CD4+ (Figure 6A) or CD8+ T cells (Figure 6B), 
previously primed with desialylated OVA-pulsed sDCs, showed significantly less viability 
than those incubated with T cells primed with fully sialylated OVA-pulsed sDCs (Figure 6). 
Thus, desialylation of sDCs improves their ability to prime antigen-specific T cell-mediated 
immune response against tumor cells.  
                 
Figure 6. Sialidase treatment of murine sDCs loaded with OVA improves T cell cytotoxicity against tumor 
cells. Induction of cytolysis of tumor targets was tested by co-culturing untreated (light grey bars) or sialidase 
treated (black bars) OVA-pulsed DCs and splenocytes from either OT-II (A) or OT-I (B) mice for 72h. After, 
primed T cells and OVA-expressing B16 mouse melanoma cells (B16-OVA) were co-cultured for 24h. B16-
OVA tumor cell death was assessed by staining with 7-AAD and annexin-V and analyzed by flow cytometry. 
Sialidase treatment of OVA-pulsed sDCs induced a higher tumor cell cytotoxicity compared to fully sialylated 
ones. Statistical significance (*P < 0.05 or **P < 0.001) refers to the difference between fully sialylated and 
desialylated sDCs (n=2). C) Desialylated sDCs show improved presentation of endocytosed ovalbumin-derived 
peptide SIINFEKL, bound to MHC class I. Murine splenic DCs were first incubated with OVA and treated 
(black bars) or not (grey bars) with sialidase. After these treatments, the presentation of the ovalbumin-derived 
peptide SIINFEKL bound to H-2Kb (murine MHC class I) epitopes was analysed by flow cytometry, using the 




(**P < 0.001) refers to the difference between fully sialylated and desialylated sDC and it was determined using 
t-test. 
 
Desialylated murine sDCs showed improved presentation of OVA-derived peptide  
The presentation of antigens through MHC-I, by DCs to cytotoxic T cells, includes the cross-
presentation of antigens, an essential mechanism to present endocytosed exogenous antigens 
via MHC-I.9  
Since the activation of CD8+ T cells by OVA-pulsed sDCs implies cross-presentation of 
peptides derived from the endocytosed OVA, via MHC-I, we then assessed the ability of 
sDCs to cross-present OVA-derived peptides through MHC-I. For this purpose, after 
incubation with OVA, and treatment with sialidase, sDCs were stained with the 25-D1.16 
mAb that specifically recognizes the processed OVA peptide- SIINFEKL bound to H2-Kb. 
This assay readily detected cross-presenting murine sDCs and showed that, sialidase treated 
sDCs had a significant higher cross-presentation of the SIINFEKL peptide through MHC-I 
(Figure 6C). Thus, the data indicates that desialylation of murine sDCs improves the cross-
presentation of antigens, via MHC-I. 
 
Sialidase treatment improves antigen presentation via MHC-I by human MoDCs 
We next determined whether improved antigen cross-presentation was also extensible to 
human desialylated DCs. Additionally, we also analyzed whether DC desialylation would 
affect the presentation of exogenously supplied high affinity peptides that bind directly to 
MHC-I molecules, without previous cell internalization.  
To address this, we loaded HLA-A*02:01+ MoDCs with short and long peptides derived from 
the gp100 tumor antigen. The peptides share the gp100280–288 sequence (YLEPGPVTA) that 
binds to HLA-A*02:01. The short peptide binds directly to MHC-I, whereas the long peptide 
needs to be internalized, conducted into phagosomes and processed to be incorporated into 
MHC-I, before it is cross-presented. The MoDCs were then loaded with both peptides and 
their ability to prime gp100280–288 specific CD8+ T cell clones was evaluated, based on their 
IFN-γ secretion ability. As shown in Figure 7, desialylated MoDCs loaded either with 




CD8+ T cells. The data suggests that desialylation of MoDCs improves antigen presentation 
through MHC-I. This is due to an increase in antigen cross-presentation and to the fact that 
exogenously supplied peptides bind to desialylated MHC-I with higher affinity.  
 
 
Figure 7. Sialidase treatment of human MoDCs improves antigen cross-presentation via MHC-I to CD8+ 
T cells. Gp100-specific CD8+ T cells were co-cultured overnight with gp100-loaded MoDCs, that have been 
previously treated or not with sialidase (MoDCsia+gp100 and MoDCgp100, respectively). Short gp100 peptides (A) 
and different concentrations of the long gp100 peptide (B) were used. To evaluate the activation of CD8+ T 
cells, the secretion of IFN-γcytokine was measured by ELISA (mean± SEM) (n= 3). Statistical significance (*P 




The use of DC-based vaccines for active immunotherapy of cancer patients has gained 
increasing interest among scientific community.32 However, the successful use of these cells, 
as a cancer vaccine, has been limited and only a small percentage of objective clinical 
responses has been observed in clinical trials.4,33 The immediate hurdle for the success of 
DCs immunotherapy is to improve their ability to prime T cells, so they can elicit an effective 
and long-lasting anti-tumor immune response.  
Terminal sialylation of cell surface glycans is involved in several immune physiological 
mechanisms, including immune recognition and regulation of immune-cell differentiation and 
maturation. We were the first to report that human MoDCs, which are commonly employed 
in clinical trials (e.g., NCT00834002, NCT00814892, and NCT01525017) display a high 




maturation of MoDCs decreases cell surface sialylation, due to a down-regulation of 
sialyltransferase activity.25,34 Also, sialic acid removal or deficiency improves the DCs’ 
maturation status.25,35 On the other hand, MoDCs with a higher α(2,6)-linked sialic acid 
content exhibit a more tolerogenic and immature phenotype,36 suggesting that sialylation of 
MoDCs may be involved in immune-dampening. Yet, it is unknown whether shortage of cell 
surface sialic acid level affects the ability of MoDCs to induce proper anti-tumor immune 
responses. Accordingly, in this study we assessed the ability of desialylated MoDCs to induce 
anti-tumor immune responses. To address this, desialylated MoDCs were generated using a 
recombinant sialidase, which rapidly leads to a transient cell surface desialylation, while 
preserving MoDC viability. Desialylation of MoDCs was observed up to 24h, after enzymatic 
treatment and then, after 48h, MoDC have already recovered their typical sialic acid content 
(data not shown), probably due to protein turnover. 
Human desialylated MoDCs, pulsed with whole tumor antigens from the breast cancer cell 
line MCF-7 induced a significant higher proliferation of T cells, compared to fully sialylated 
MoDCs. Increased T cell proliferation was accompanied by an increased secretion of IFN-γ 
and TNF-α, typical of a Th1-induced response. Concomitantly, T cells primed by desialylated 
MoDCs pulsed with tumor cell lysates exhibited the highest cytotoxic activity against MCF-7 
tumor cells. This higher capacity of desialylated antigen-loaded MoDCs to prime T cells may 
be due to the fact that desialylated MoDCs show an increased expression of antigen-
presenting and co-stimulatory molecules, which is in agreement with our previous reports.25 
Furthermore, desialylation of MoDCs loaded with tumor cell lysates resulted in a remarkable 
higher secretion of IL-12 cytokine. This cytokine triggers the differentiation of CD4+ T cells 
into IFN-γ producer’s cells, thus inducing Th1 responses. The secretion of IL-10 was not 
significantly affected but showed a slight reduction in desialylated MoDCs. This is in 
agreement with the induction of a Th1 profile, since IL-10 blocks differentiation of naïve T 
cells into Th1 effector cells37,38 and limits maturation of DCs by down-regulating co-
stimulatory molecules and IL-12 production.39,40 Overall, sialidase treatment of human 
MoDCs loaded with tumor antigens induces an IL-12high IL-10low DC phenotype, that 
promotes DCs maturation and T cell differentiation into Th1 effectors, crucial for the 
generation of anti-tumor responses. Though, increased maturation of desialylated MoDCs had 
been described previously, these results are the first to indicate that desialylated MoDCs 
loaded with tumor antigens have higher capacity to prime T cell-mediated anti-tumor immune 




We then determined whether the desialylation effect was extensible to murine DCs. By using 
murine sDCs loaded with the model antigen OVA, we assessed their capacity to prime 
antigen specific CD4+ and CD8+ T cells against OVA-expressing cancer cells. The results 
obtained with this model are the first showing that desialylation also induces maturation of 
murine sDCs, by improving the expression of the antigen presenting molecules MHC-I and -
II and the co-stimulatory molecules CD80 and CD86. Moreover, desialylated sDCs, pulsed 
with OVA antigens showed a remarkable higher ability to boost proliferation and activation 
of OVA-specific CD4+  T cells, and secretion of IFN-γ, IL-6 and TNF-α. Notably, both CD4+ 
and CD8+ OVA-specific T cells primed by desialylated OVA-pulsed DCs, exhibited higher 
cytotoxic activity towards OVA-expressing tumor cells, when compared to those primed with 
fully sialylated OVA-pulsed sDCs.  
Importantly, our data shows that sialidase treatment of DCs improves antigen cross-
presentation in both murine and human DCs. Sialidase treatment of murine sDCs improved 
presentation of endocytosed ovalbumin-derived peptide SIINFEKL, bound to MHC-I, as 
assessed by increased reactivity with the 25-D1.16 mAb. Treatment of human HLA-A*02:01 
MoDCs pulsed with synthetic long or short peptides from the tumor antigen gp100, displayed 
enhanced antigen presentation through MHC-I, as evaluated based on the increase of IFN-γ 
production by gp100280–288 specific CD8+ cytotoxic T cells. Since the long peptide needs to be 
internalized by MoDC, exported from lysossome to cytosol and then conducted into the 
cross-presentation process, our data is suggestive that desialylation improves antigen cross-
presentation, which is in agreement with data obtained with murine sDCs. It is possible that 
desialylation affects critical cell surface receptors, that favor antigen export from lysosomes 
to cytosol, such as the mannose receptor10, thus improving the mechanism of export of 
endocytosed antigens to the cytosol. Yet, data obtained with the short gp100 peptide that 
binds exogenously and directly to MHC-I, suggests that desialylation also improves binding 
of exogenous peptides to cell surface MHC-I. Noteworthy, our data also suggests that 
increased expression of MHC-I (either due to recycling, or newly synthesis) is a possible 
mechanism behind improved antigen presentation through MHC-I. Thus, future studies are 
envisaged to better understand how sialidase treatment of DCs induces superior antigen 
presentation to cytotoxic T cells. 
Collectively, our data show that sialidase treatment of DCs is able to induce all the 
phenotypical and functional features of maturation, including increased antigen presentation, 




report showing that an enzymatic treatment through extrinsic desialylation of in vitro 
generated DCs elicits better presentation of tumor antigens through MHC-I, which can in turn 
activates anti-tumor immune responses. Interestingly, a previous study reported that 
desialylation of CD8+ T cells is required and adequate for their effective anti-tumor response 
against glioma cancer.41 In agreement, we have shown here that removal of sialic acid from 
cell surface of an immune cell considerably boosts its anti-tumor immune response. 
Therefore, our findings suggest that sialidase treatment of DCs can be used as a powerful tool 
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Figure S1. Characterization of splenic DC subsets after CD11c positive selection. (A) Representative 
histogram of CD11c cells after positive selection. After sorting, the purity of the population was typically 
around 97%. (B) Proportion of each conventional sDC subset before and after CD11c cell sorting. In order to 
assess whether CD11c positive selection would affect the distribution of the different subsets of splenic DCs, we 
stained CD11c cells with CD4, CD8a (lymphoid DCs), B220 (plasmacytoid DCs) and CD11b (myeloid DCs) 
markers. After CD11c positive selection, the relative proportions of different sDC subsets remained roughly 













Figure S2. Lectin staining to test the efficacy of sialidase treatment. Human MoDCs (A) and murine sDCs 
(B) were treated with sialidase (grey bars) or left untreated (white bars) and stained with Sambucus nigra lectin 
(SNA; recognizing α(2,6)-sialic acids), Maackia amurensis lectin II (MAA; recognizing α(2,3)-sialic acids) and 
Peanut agglutinin lectin (PNA; recognizing T antigen- Galβ1-3GalNAcα1-Ser/Thr) and analyzed by flow 
cytometry. Values represent the means of the MFI of at least six independent assays. Statistical significance (*P 
< 0.05 or ***P < 0.0001) refers to the difference between untreated and sialidase-treated DCs. Sialidase 
treatment decreased MAA binding and increased PNA staining of both human MoDCs and murine sDCs, 
resulting from the removal of α(2,3)-linked sialic acids; removal of α(2,6)-linked sialic acids after sialidase 








                                            
Figure S3. Assessment of cell viability after sialidase treatment of DCs. Human MoDCs (A) and murine 
sDCs (B) were treated with sialidase or left untreated and dual stained with Annexin V and 7-AAD. Both human 
and murine DCs treated with sialidase exhibit no significant increase in cell death compared with untreated ones, 
suggesting that DCs can tolerate sialic acid removal relatively well and remain viable to exert their immunologic 




























7. General discussion and Final conclusions	  
Glycosylation is the most common posttranslational modification on the cell surface and is 
involved in many physiological and pathological processes. Addition of glycan structures to 
protein or lipid scaffolds can modulate their biochemical and biophysical properties and 
therefore their functionality.1 Specific carbohydrate determinants are associated with certain 
stages of cell differentiation and can modulate processes like cell-signaling and migration, 
host-pathogen interactions and tumor invasion and metastasis.2,3 Specifically, several 
immune-related processes are intrinsically linked to certain glycosylation patterns. Specific 
innate and adaptive immune mechanisms critically depend on appropriate molecular and 
cellular glycosylation.4  
One of the vital proprieties of the immune system is the ability to direct the accumulation of 
immune cellular effectors in a site-specific fashion so that a successful immune response can 
be settled.5 In the context of an inflammatory response, migration of leukocytes to sites of 
tissue injury or infection crucially dependents on transient adhesive interactions between the 
vascular E-selectin expressed on endothelial cells and its carbohydrates counter-receptors 
expressed on cell surface of leukocytes.6,7  
 
7.1 Comprehensive Analysis of Glycoprotein E-selectin Ligands Expressed on Human 
Peripheral Blood Mononuclear Cells  
The body's immune system is specialized to respond rapidly to invading pathogens, a process 
which depends on constant surveillance and swift deployment of leukocytes at relevant 
tissues. Myeloid cells constitute one of the body’s first lines of defense and are rapidly 
recruited at sites of injury.8 Subsequently, an adaptive immune response may be mounted 
where naïve lymphocytes, which continually recirculate between the bloodstream and 
secondary lymphoid tissues in search of cognate antigen, may differentiate into effector 
lymphocytes that are able to migrate into inflammatory sites in peripheral non-lymphoid 
tissues.8,9 
In chapter 3 we performed a detailed and complete description of the E-selectin ligands 
expressed by the major subsets of peripheral blood mononuclear cells (PBMCs): monocytes, 




bind to E-selectin under hemodynamic shear conditions is integrally correlated to the overall 
amount of E-selectin ligand determinants expressed by these cells. Interestingly, monocytes 
possess the highest ability to bind to E-selectin under hemodynamic shear stress and 
consistently showed the highest expression of sLeX–bearing glycoproteins among PBMC 
subsets. Our data show, for the first time, that in addition to the cutaneous lymphocyte 
antigen (CLA)10, monocytes also express non-CLA glycoproteins with E-selectin reactivity. 
Thus, we described here three new unreported monocytic E-selectin binding glycoproteins:(1) 
The glycoform of CD44 known as Hematopoietic cell E-/L selectin ligand (HCELL); (2) The 
glycoform of CD43, CD43E; and (3) An unidentified  ~70 kDa glycoprotein. After 
monocytes, CD4+T cells are the leukocytes that exhibit the highest ability to bind to E-
selectin under shear stress conditions and accordingly, express higher amounts of E-selectin 
binding determinants than CD8+T or B cells. CD4+T cells express the previously reported E-
selectin binding glycoforms of PSGL-1 (i.e., CLA) and CD43 (i.e., CD43E),11,12 and, 
remarkably, we observed that these cells also express HCELL. On the contrary, peripheral 
CD8+T and B cells express low to no levels of E-seletin ligands and therefore show little 
ability to bind to E-selectin under blood flow conditions. CD8+T cells express lower amounts 
of CLA and CD43E compared to CD4+T cells and do not express HCELL, whereas B-cells 
completely lack glycoproteins with E-selectin ligand activity.  
The differential E-selectin ligand expression profiles among PBMCs may elucidate, at least in 
part, their distinct kinetics of migration into inflamed sites during an acute inflammatory 
response. Leukocyte recruitment to sites of injury has been always assumed to result mainly 
from leukocyte chemotaxis, i.e., the ability of specific leukocyte subsets to respond to 
secreted small molecule chemical factors that would enable their accumulation to injured 
tissue.13-16 However, our data suggest that the leukocyte E-selectin binding activity may play 
the principal role in the kinetics of recruitment of the different PBMCs into sites of 
inflammation.  
Upon tissue wounding, monocytes are among the first innate immune cells to arrive to the 
injured site.9 Indeed, adherence of circulating monocytes to endothelial monolayer and 
subsequent transmigration and accumulation of these leukocytes at the injured site represent 
one of the most important events in the initiation of the inflammatory process.9,17 Then, as the 
innate immune system yields to adaptive immunity in the elaboration of immunoreactivity, 
subsequent migration of lymphocytes occurs within days. Hence, after antigen presentation 




into effector or memory T cells, which leave the lymphoid organs and migrate to inflamed 
peripheral sites, through blood circulation. Although peripheral homing properties by CD4+ 
and CD8+T cells are still in debate, several studies reported that CD4+T cells arrive and 
accumulate at the injured tissues before CD8+T cells.18-20 Indeed, in some peripheral tissues, 
such as vaginal tissue and skin, the presence of CD4+T cells seems to be critical for the 
recruitment and entry of activated CD8+T cells.18,21 Regarding B cells, their migration into 
peripheral tissue from bloodstream is poorly understood. In contrast to T cells, B cells do not 
migrate into normal peripheral tissues.19 In inflammatory milieu, various in vivo studies 
reported a poor ability of B cells to migrate into sites of acute inflammation,22,23 while others 
reported that these cells can accumulate in a very localized manner into infected tissue in 
acute or chronic inflammatory conditions, although the tempo of B cells migration into the 
inflamed tissue is much lower compared to T cells.19,24  
Notably, our results are in agreement with the kinetics of PBMC migration into inflamed 
sites, previously described in the literature. Therefore, a parallelism may be traced between 
the levels of leukocyte E-selectin ligand expression and their ability to migrate and 
accumulate into inflamed sites. Particularly, the wide repertoire of glycoprotein E-selectin 
ligands expressed by monocytes, including the highly potent HCELL25, would give them the 
advantage to accumulate to injured sites within a few hours after infection/wound challenge. 
By contrast, the poor ability of B cells to migrate into inflamed tissue23 can be due to their 
incapacity to bind to E-selectin. 
To gain further molecular understanding of the scarcity of E-selectin ligand expression in B 
cells, we performed quantitative PCR studies of relevant glycosyltransferases directing sLeX 
synthesis on B cells and monocytes. Strikingly, our results showed that peripheral blood B 
cells have low gene expression of the glycosyltransferases involved in the biosynthesis of 
sLeX, namely α(1,3)-fucosyltransferases, and high expression of competing 
glycosyltransferases for sLex-O-glycan precursor substrates, such as ST3Gal-I. In addition, B 
cells have low or no expression of the relevant E-selectin binding protein scaffolds, such as 
PSGL-1, CD43 and CD44. All together, these results may explain the absence of E-selectin 
binding activity of peripheral B cells. 
Collectively, our findings offer novel perspectives on the functional and structural 
diversity of E-selectin ligands that are expressed by different mononuclear blood subsets 




recruitment into inflamed tissues during acute or chronic inflammatory conditions. 
 
7.2 Strategies to improve the effectiveness of DC-based therapy 
Dendritic cell (DC)-based vaccines represent a promising and a novel immunotherapy for 
treatment of cancer.26 DCs are the most effective antigen presenting cells (APCs) and are 
crucial coordinators of both innate and adaptive immune systems. These cells are able to 
elicit both naïve and memory antigenic-specific immune responses, and therefore, they are 
extremely important in the induction of anti-tumor specific cytotoxic responses.27,28 However, 
DC-based vaccination have not yet been shown to translate into clinical progress.  Indeed, 
since the first DC-based vaccine clinical trial, in the mid-90s, multiple trials have been piloted 
within an extensive range of malignancies; though, only a small percentage of patients 
responded to the therapy with improved clinical outcome.29 Thus, there is an urgent need to 
develop new technologies that are able to improve the efficacy of DC-based immunotherapy. 
 
7.2.1 Elucidating the E-selectin ligands expressed by DCs: A contribution to the 
development of DC-based vaccines 
An immediate hurdle in achieving the promise of DC-based therapeutics is the safe delivery 
of these cells from vasculature to target tissue, where they can exert their immunological 
functions.26  
For clinical purpose, human DCs are most commonly obtained from differentiation of human 
blood monocyte precursors (mo-DCs),30 following CD14 immuno-magnetic selection (CD14-
S) or by plastic adherence of monocytes (PA-S).31 Therefore, in chapter 4, we investigated 
the nature and the biological functions of the chief molecular effectors involved in 
transendothelial migration of human mo-DCs obtained from both PA-S and CD14-S methods. 
Surprisingly, our results show that CD14-S mo-DCs display a significant greater 
transendothelial migration than PA-S mo-DCs; moreover, this process is dependent on E-
selectin binding and VLA-4 expression. Notably, this differential ability to transmigrate is 
due to a distinctive expression of E-selectin reactive glycoproteins. While PA-S mo-DCs only 
express the glycoform of PSGL-1 (i.e. CLA), CD14-S mo-DCs express the E-selectin binding 




by CD14-S mo-DCs and its engagement by vascular E-selectin provide them a unique ability 
to transmigrate circumventing chemokine-mediated signaling, i.e. the binding of HCELL 
(and not CLA) to E-selectin directly activates VLA-4 adhesiveness to endothelium. Although, 
this mechanism has been described in human mesenchymal stem cells following enforced 
HCELL25,32, our findings are the first to show that chemokines are not essential for human 
DC ability to transendothelial migrate.  In addition, our results show that TNFα maturation of 
CD14-S mo-DCs induces maintenance of HCELL expression, which otherwise undergoes 
time-dependent decay. This is extremely pertinent because the cytokine TNFα is one of the 
cytokines mostly used to mature DCs for immunotherapeutics.33 Lastly, we observed that 
exofucosylation of CD14-S mo-DC significantly increases expression of HCELL, and 
thereby augment their ability to undergo transendothelial migration.   
Overall, we report that the expression of HCELL by mo-DCs licenses these cells to 
transmigrate without chemokine input; HCELL expression on mo-DCs can be achieve 
by generating mo-DCs via CD14-S method and maintained by TNF-α  maturation, 
whereas exofucosylation increases its expression and therefore improves DCs 
transendothelial migration. Furthermore, the use of PA-S mo-DCs in adoptive DC-
based immunotherapy may negatively affect DC tissue migration, reducing their 
efficacy. 
In chapter 5, we performed a detailed analysis of the expression of E-selectin ligands on 
human monocyte-derived DCs and murine DCs obtained from different cellular sources.  
Although human monocytes are typically obtained from peripheral blood, there has been an 
increasing clinical interest in monocytes obtained from umbilical cord blood source (UCB).34 
Therefore, we compared the E-selectin ligand expression on human mo-DCs obtained from 
these two monocytic cellular sources. Strikingly, we observed that human mo-DCs generated 
from differentiation of UCB monocytes completely lack E-selectin reactive glycoproteins. 
Yet, our data suggest that UCB mo-DCs display E-selectin ligand determinants in lipid 
scaffolds. Contrariwise, adult peripheral blood (APB) mo-DCs display a wide repertoire of E-
selectin binding glycoproteins. As it was reported in chapter 4, these cells, which were 
generated by CD14-S method, express the E-selectin reactive glycovariants of PSGL-1 
(CLA) and of CD44 (HCELL). Moreover, in chapter 5 our data show that the glycoform of 
CD43 (i.e. CD43E) is also a functional E-selectin ligand expressed by APB CD14-S mo-DCs. 




CLA, HCELL and CD43E, but also induce the creation of the newly E-selectin reactive 
glycoform of CD18 and of high molecular weight glycoforms of HCELL. This finding is 
extremely pertinent, since CD18 is the β-chain of CD18/CD11 integrins.35   CD18/CD11 
integrins, along with β1 integrins, are the main mediators of firm adhesion of leukocyte to 
endothelium during extravasation process. Therefore, our findings may suggest a new role for 
CD18 in DC extravasation process.  
Finally, our data also show a differential expression of E-selectin binding structures among 
murine DCs obtained from different cellular sources: bone marrow derived DCs (BM-DCs) 
and murine splenic DCs (sDCs). While, murine BM-DCs are devoid of E-selectin reactive 
glycoproteins, sDCs strongly express CLA.  
Collectively, our findings disclose critical and undiscovered cellular sources-specific and 
species-specific diversity in the expression of E-selectin ligand glycoproteins among 
DCs. Importantly, our data suggest that monocytes isolated from APB may be a better 
source for ex vivo generated anti-cancer DC-based vaccines since APB mo-DCs natively 
display high contents of E-selectin ligands, which are required for DC migration to 
inflamed/tumoral tissues.  
	  
7.2.2 Immune-modulation of DC functionality via sialic acid removal 
Another reason for the limited efficacy of DC-based vaccines in inducing an effective anti-
tumor response in the treated patients is the insufficient maturation state of DCs used in the 
vaccination protocols.26 Indeed, effective DC maturation implies three signals: capacity to 
present antigens via MHC (signal 1), co-stimulation (signal 2) and expression of pro-
inflammatory cytokines (signal 3).36 Nevertheless, there is no satisfying method to induce 
simultaneously all three aspects of maturation. Thus, in chapter 6, we described a new 
methodology that can be used to induce fully maturation of DCs.  
DCs show a specific glycan profile at cell surface that can be modulated during development, 
maturation and immune regulation.1 Specifically, they exhibit high levels of surface sialic 
acids, which are known to be associated with an immature and tolerogenic phenotype.37-39 
Therefore, we sought to evaluate the effect of sialic acid removal from DC surface on their 




Using both human and murine DCs, we observed that desialylation of DCs induced a higher 
DC maturation phenotype, via the upregulation of MHC and co-stimulatory molecules and 
through the secretion of Th1 cytokines, such as IL-12.  The secretion of IL-12 by DCs is 
extremely critical for the initiation of anti-tumor immune responses, since this cytokine is the 
main inducer of Th1 immune responses, and consequently, of the generation of cytotoxic 
CD8+ T cells.40 Consistently, we observed a higher ability of desialylated DCs to induce 
proliferation, activation and differentiation of T cells into a Th1 profile; and, notably, to 
cross-present antigens, which resulted in increased priming and activation of antigen-specific 
CD8+ T cells. This fully matured phenotype of desialyated human and mouse DCs translated 
into a higher ability of these cells to induce specific and potent cytotoxic responses against 
cancer cells. We consistently observed a higher ability of T cells that were primed with 
desialylated DCs to specifically kill tumor cells. 
Collectively, our data demonstrate that desialylation of DCs is able to induce all the 
phenotypical and functional features of maturation, namely:  (1) increased antigen 
presentation, (2) increased co-stimulatory ability and (3) secretion of Th1 cytokines. 
Moreover, desialylation of in vitro generated DCs elicits cross-presentation of tumor 
antigens, which is an essential mechanism for the induction anti-tumor cytotoxic T cell 
immune responses. Thus, sialidase treatment of DC surface is a useful tool to generate 
DCs with high capacity to induce activation of potent and highly effective anti-tumor-
specific cytotoxic T cell-mediated immunity.  
 It is anticipated that the findings presented in the chapters 4, 5 and 6 will provide 
fundamental insights that will guide the development of novel therapeutic strategies using 
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During this PhD, I have also been involved in a project, which aim is to investigate the role of 
the sialylated-tumor antigens on the malignant phenotype of bladder cancer cells, on response 
to BCG therapy and immune mediated responses. 
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Background. Sialylated forms of truncated sugar chains O-linked to glycoproteins, known as 
Thomsen-Friedenreich-(TF) related antigens are aberrantly expressed in bladder cancer (BC). 
Treatment with Bacillus Calmette-Guérin (BCG) is an effective adjuvant immunotherapy of 
BC but still one third of the patients do not respond to treatment.  
Methods. To investigate the role of sialylated TF antigens on BC biology and BCG response, 
the human BC cell lines HT1376 and MCR were retrovirally transduced with 
sialyltransferases  ST3GAL1 or ST6GALNAC1 respectively, to obtain the cell lines HT1376sT 
and MCRsTn or with empty retroviruses to obtain the negative controls HT1376Nc and MCRNc. 
Cytokines secreted by transduced BC cell lines challenged with BCG and by macrophages 
stimulated with the conditioned medium of BCG-challenged BC cell lines were measured by 
multiplex immune-beads assay. Global gene expression in sialyltransferase-transduced cell 
lines was measured after BCG challenge by expression microarray. Cell cycle was studied by 
FACS analysis of propidium iodide stained cells. Student’s t test was used for statistical 
analysis. Results.  After BCG-challenge, HT1376sT secreted more IL-8 while MCRsTn 
secreted more IL-8 and IL-6 than their negative controls HT1376Nc and MCRNc. Soluble 
factors secreted by BCG-challenged BC cells strongly increased the release of cytokines IL-6, 
TNF-α,  IL-1β and IL-10 from macrophages. The stimulatory effect was higher with soluble 
factors from HT1376sT and MCRsTn cells, showing that BCG response was dependent on the 
expression of sialylated TF antigens. Microarray analysis revealed that hundreds of genes 
were modulated by either sialyltransferase, mainly toward a putatively more malignant 
phenotype. The down-regulation of several genes involved in preserving genomic stability in 
both HT1376sT and MCRsTn, resulted in signs of cell cycle alterations with accumulation of 
cells in the phases S and G2. BCG challenge resulted in a stronger modulation of the 
transcriptome in HT1376sT and MCRsTn cells than in their negative controls with a tendency, 
in MCRsTn cells, to increased expression of regulatory RNA genes.  
Conclusions. Sialylated TF antigens may turn BC biology toward a more malignant 
phenotype but, because of their ability to enhance the response to BCG treatment, their 
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Bladder cancer (BC), one of the most common cancers in Europe, is commonly treated with 
the intravesical inoculation with the Bacillus Calmette-Guérin (BCG), as an adjuvant therapy 
after surgery. In spite of its efficacy, a significant number of patients fail to respond to this 
therapy. Although the precise mechanisms involved in BCG anti-tumour activity remains 
uncertain, it is clear that BCG induces a local immune response activation [1-3]. Thus, a 
comprehensive understanding of how BCG can modulate the immune system and induce 
phenotypic changes of BC can help to further define therapeutic targets and improve patient’s 
treatment. 
Glycosylation is one of the most frequent post-translational modification of proteins, which 
undergoes profound changes in all types of cancer [4], including BC [5-8]. The biosynthesis 
of the sugar chains of glycoconjugates is mediated by glycosyltransferases, a class of 
enzymes which usually transfer a sugar from a sugar-nucleotide donor to a carbohydrate 
chain acceptor. Specifically, the sugar sialic acid is transferred by sialyltransferases, usually 
to the termini of the sugar chains. Thomsen-Friedenreich (TF)-related antigens are a group of 
small sugar chains O-glycosidically linked to serine or threonine, which includes Tn 
(GalNAc-O-Ser/Thr), T (Galβ1,3GalNAc-O-Ser/Thr) and the respective sialylated forms: 
sialyl-Tn (sTn, Siaα2,6GalNAc-O-Ser/Thr) and 3’sialyl-T (sT, Siaα2,3Galβ1,3GalNAc-O-
Ser/Thr) antigens. These antigens are aberrantly expressed in a variety of cancers, including 
BC [7-13] and play a key role in cancer progression, affecting the invasive potential and the 
immune recognition [14-16]. 
The sT antigen is present in the healthy urothelium but is overexpressed in BC, due to an 
increased expression of sialyltransferase ST3GAL1 [11]. The sTn antigen is expressed in 
75% of high grade bladder tumours but it is not observed in normal urothelium. The 
expression of sTn is correlated with an overexpression of the sialyltransferase 
ST6GALNAC1 [7, 17]. Recent data indicated that BCG immunotherapy was more efficient 
against tumours expressing sTn [8]. 
In this study, we investigated the consequences of the overexpression of sialyltransferases 
ST3GAL1 and ST6GALNAC1 and of their cognate sugar structures sT and sTn on the 
transcriptome modulation of BC cells and their ability to activate the innate immune system 





Characterization of sialyltransferase-modified cell lines. 
To understand the role of sT and sTn in BC, we first developed cell line variants 
overexpressing these antigens. The BC cell lines HT1376 and MCR were chosen for 
transfection with sialyltransferases  ST3GAL1 or ST6GALNAC1 respectively, because of their 
native low expression of  the two sialyltransferases and of  sT or sTn antigens [11]. To obtain 
cell populations with higher and more homogeneous expression of sT or sTn antigens, after 
transfection with ST3GAL1 or ST6GALNAC1, two different strategies were used: clonal 
selection for HT1376sT cells and magnetic sorting for MCRsTn. In the case of sT-expressing 
HT1376 clones, clonal selection was used due to the lack of a tool directly recognizing the sT 
antigen and the expression of sT antigen was indirectly deduced from the decreased reactivity 
with the T-specific lectin PNA. The resulting cell lines, comprised of more than 95% of cells 
either not showing PNA reactivity or expressing sTn, respectively are hereafter referred to as 
HT1376sT and MCRsTn, while their respective negative controls are HT1376Nc and MCRNc.  
The activities of ST3GAL1 and ST6GALNAC1, in HT1376 and MCR cells were measured 
by transfer of sialic acid to exogenous acceptors: benzyl-T or asialo-BSM, respectively 
(Figure. 1A). The activity of either transduced sialyltransferase was highly expressed only in 
HT1376sT and MCRsTn cells, while in HT1376Nc and MCRNc it was just above the 
background. As expected, the mRNA level of ST3GAL1 and ST6GALNAC1 was also highly 
expressed in HT1376sT and MCRsTn cells (Figure 1B), while in the respective control cells the 
two transcripts were nearly undetectable. It is worth mentioning that the level of expression 
of transduced ST6GALNAC1 was about 20 fold higher than that of transduced ST3GAL1. 
The changes in the pattern of carbohydrate structures induced by the overexpression of the 
two sialyltransferases was investigated using PNA and anti-sTn antibody staining (Figure 
1C), before and after sialidase treatment, which removes sialic acids. ST3GAL1 
overexpression in HT1376sT cells induced a dramatic decrease of PNA reactivity, compared 
to HT1376Nc, which was completely reversed by sialidase treatment, indicating that the 
masking of T antigens was mainly due to the ST3GAL1-mediated addition of α2,3-linked 
sialic acid. No sTn antigen was detectable in HT1376Nc or HT1376sT cells.   
ST6GALNAC1 overexpression in MCR cells induced the expected increase of sTn antigen, 




ST6GALNAC1 overexpression in MCR cells also led to a substantial decrease of the T 
antigen, as demonstrated by the decreased reactivity to PNA. This effect could be explained 
considering that, according to its known substrate specificity  [18], ST6GALNAC can 
mediate the α2,6-sialylation also of T antigen and of sT antigen, resulting in the biosynthesis 
of sialyl-6-T and diasialyl-T antigens (Fig. 1 D). These two antigens would not be recognized 
by PNA. Sialidase treatment induced a remarkable increase of PNA-reactivity in both MCRNc 
and MCRsTn cells. This finding demonstrated that in the former the masking of the T antigen 
was due to α2,3-sialylation of galactose (sT antigen), while in the latter the masking of the T 
antigen was probably due to both α2,3- and α2,6-sialylation.  
                     
Fig. 1. Characterization of sialyltransferase-modified BC cell lines. HT1376sT, MCRsTn cells and their 
respective negative controls HT1376Nc, MCRNc were characterized with respect to sialyltransferase activity (A), 
mRNA expression (B) and reactivity with PNA or anti sialyl-Tn (C). A: activity of ST3GAL1 and 
ST6GALNAC1 was measured by using benzyl-T and asialo-BSM as acceptors, respectively. Data are the mean 
± SD of three experiments. B: Transcript abundance was measured by real time RT PCR and expressed as 
sialyltransferase mRNA molecules/1000 b-actin molecules. Data are the mean ± SD of three experiments. C: 
PNA and anti-sTn antibody reactivity was investigated by  FACS. Black line: unlabelled cell lines when 
labelling with lectins or isotype control antibody, in case anti sTn antibody was used. Red line: cell lines without 




not only on Tn antigen but also on T and sT structures, potentially giving rise to their α2,6-sialylated 
counterparts and explaining PNA-reactivity data in MCRNc and MCRsTn. GalNAc: yellow square; Gal: yellow 
circle; Sia: purple diamond. 
 
Cytokine secretion by bladder cancer cell lines 
We next sought to assess whether the expression of ST3GAL1 or ST6GALNAC1 would have 
an effect on cytokine production by BC cells following BCG stimulation. For that, we 
evaluated the levels of several cytokines in conditioned medium of BC cells, challenged or 
not with BCG. Of the following cytokines: IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, 
IFN-γ and TNF-α, only IL-6 and IL-8 were detectable. HT1376 cells produced little or no IL-
6, which significantly increased after BCG stimulation, independently on the expression of 
ST3GAL1 (Figure 2). HT1376 natively produced high levels of IL-8, which increased further 
after BCG stimulation. Interestingly, the secretion of IL-8 was significantly higher in 
HT1376sT than HT1376Nc, after BCG challenge. 
MCR cells natively produced high levels of IL-6, which significantly increased after BCG 
stimulation, only in MCRsTn cells (Fig. 2). In contrast, secretion of IL-8 by MCR was almost 
negligible but dramatically raised after BCG stimulation. Secretion of IL-8 after BCG 
stimulation, was also significantly higher in MCRsTn cells than in negative control MCRNc  
(Fig. 2). 
                           
Fig. 2. Cytokine secretion by BCG-challenged BC cell lines. IL-6 and IL-8 were secreted by HT1376Nc, (light 




challenged with BCG for 2 hours, then they were washed and cultured in medium for 16 hours. Cytokine 
concentration was determined as described in Materials and Methods. Data are the mean ± SD of three 
experiments. ***p<0.0001; **p<0.001; *p<0.05, according to Student’s t test. 
 
Cytokine secretion by human macrophages stimulated by conditioned medium from BC 
cells 
To investigate the role played by BCG-stimulated BC cells on the first line innate immunity, 
the effect of the conditioned medium of BCG-challenged BC cells on human macrophage 
response was evaluated. The secretion of cytokines was measured in the culture medium of 
macrophages stimulated or unstimulated for 24 hours with the conditioned medium of BCG-
challenged or unchallenged BC cell lines (Figure 3). IL-8 was the only cytokine secreted at 
high levels by unstimulated macrophages, while IL-1β and IL-10, although clearly detectable, 
were produced at a very low level. Macrophages stimulated with conditioned medium from 
unchallenged HT1376 or MCR cells did not present a robust cytokine secretion. However, the 
conditioned medium from BCG-challenged BC cells induced a significant secretion of IL-6, 
IL-1β, TNF-α and IL-10 (Fig. 3). Interestingly, the induction of cytokine secretion was 
markedly stronger when BCG-challenged cells expressed either sialyltransferase (Fig. 3). The 
cytokines IL-2, IL-4, IL-12, and IL-17 were not expressed in our experiments, in any 





Fig. 3. Cytokine secretion by human macrophages treated with conditioned media of bladder cancer cell 
lines. Cytokine secretion was measured in culture media conditioned by unstimulated macrophages (gray bars) 
or stimulated with conditioned media from BCG-challenged or unchallenged BC cell lines: HT1376Nc, (light 
violet); HT1376sT (dark violet); MCRNc (light blue); MCRsTn (dark blue).  BC cells were challenged with BCG 
for 2 hours, then they were washed and allowed to condition the culture medium for 16 hours. The conditioned 
culture media of BCG-challenged or unchallenged BC cell lines was used to stimulate human monocyte-derived 
macrophages for 24 hours.  MØ: cytokines released by unstimulated macrophages; MØ + untreated: cytokines 
released by macrophages stimulated with the medium of unchallenged BC cell lines; MØ + BCG-treated: 




Macrophage stimulation by unchallenged HT1376 or MCR cells was negligible. With the exception of IL-8, the 
expression of either sialyltransferase in by BCG-challenged BC cells potentiated cytokine release by 
macrophages.  Data are the mean ± SD of 3 experiments. ***p<0.0001; **p<0.001; *p<0.05. according to 
Student's t test. 
 
Effect of sialyltransferase overexpression on the transcriptome of BC cell lines  
The overall impact of the expression of ST3GAL1 or ST6GALNAC1 sialyltransferases on the 
two BC cell lines was evaluated by analysing the transcriptome changes by expression 
microarray technology. Data summarized in Figure 4A refer to genes modulated at least by a 
log2 expression ratio ≥ 1.0 (meaning a fold change of at least 2) and show the up- or down-
regulation of genes induced by the expression of either sialyltransferase in the two cell lines. 
Both ST3GAL1 and STGALNAC1 expression induced in HT1376 or MCR significantly 
changed the expression of hundreds of genes. In particular, 448 genes (excluding the 
transduced gene) were modulated in HT1376 (187 up-regulated and 261 down-regulated) 
while 488 genes (excluding the transduced gene) were modulated in MCR cells (185 up-
regulated and 303 down-regulated) (Fig. 4A). The expression level of the transduced genes 
determined by microarray technology confirmed that expression of ST3GAL1 and of 
ST6GALNAC1 was much higher in HT1376sT, and MCRsT cells than in respective control 
(data not shown). In addition, the increase of ST6GALNAC1 expression was higher than that 
of ST3GAL1, as previously determined with real time PCR (Figure 1B). A comparison of the 
level of expression of the two transduced genes by microarray and by real time PCR indicated 
that microarray data lead to underestimate the differences in comparison with real time PCR.  
The genes modulated by the two sialyltransferases are involved in several specific cell 
functions. Owing to the well-known role of sT and sTn in cancer growth, we have focused the 
analysis on genes with a recognized role in tumour growth and progression. We have 
identified 33 modulated genes in HT1376 cells and 21 in MCR whose up- or down-regulation 
could, according to literature data, play a putative role in promoting or inhibiting cancer 
growth. Expression of ST3GAL1 in HT1376 cells induced the change towards increased 
malignancy of 19 cancer genes and toward decreased malignancy of 14 cancer genes (Fig. 
4B). The cellular functions of the cancer genes modulated toward increased malignancy by 
ST3GAL1 in HT1376 cells include the regulation of apoptosis (FRMD3), of cell growth 
(TGFB2, LOXL4), of angiogenesis (THBS1) or proteolysis (ALCAM, SERPINE2). A group of 




different DNA repair mechanisms, such as homologous recombinational repair (HR) and 
nucleotide excision repair (NER), which can be collectively referred to as “caretaker genes”, 
displayed down-regulation in HT1376sT cells (Table 1). However, if also genes with a 
modulation log2 expression ratio ≥ 0.5 were considered, the number of down-regulated 
caretaker genes in HT1376sT cells reached 28. The most remarkable changes within the group 
of 14 genes modulated toward putatively decreased malignancy in HT1376sT cells, were 
found in genes directly involved in the control of cell growth (SH3BGRL, CCND1, TPTE), 
inflammation (AIM2 and SLC39A2), proteolysis (SERPINE1, ADAM12) and angiogenesis 
(OLFML3). 
 
Fig. 4. Impact of sialyltransferase expression on gene expression in BC cell lines. The gene expression was 
evaluated in HT1376 and MCR cell lines by expression microarray technology. A: Number of genes which 
underwent up- (red) or down-regulation (green) after ST3GAL1 expression in HT1376sT and after ST6GALNAC1 
expression in MCRsTn cells, compared to their respective negative control HT1376Nc and MCRNc. The area of the 
two graphs is proportional to the number of modulated genes, which is reported below each graph. B: Number 
of genes modulated by either sialyltransferase whose changes putatively lead to increased (black) or decreased 
(white) malignancy, according to literature. The area of the two graphs is proportional to the number of 
modulated genes, which is reported below each graph. 
 
In MCRsTn cells, compared to MCRNc, the proportion between cancer genes modulated 
toward increased or decreased malignancy was 14 to 7, respectively. The cellular functions of 
the former include apoptosis (GLIPR1), cell growth (GPR87, LOX, ERBB4, LPAR6), 
angiogenesis (JAM3). The most remarkable changes of the cancer-associated genes 
modulated toward decreased malignancy in MCRsTn include PLCB1 and STC1 whose 
products stimulate cell growth, PLEK2 involved in cytoskeletal rearrangements and genes 




MCRsTn a group of 5 caretaker genes, (which became 13 when a log2 expression ratio ≥ 0.5 
was used) was down-regulated compared to MCRNc (Table 1).  
It is expected that the co-ordinate down-regulation of genes involved in DNA repair and 
mitotic fidelity leads to alterations of the cell cycle, in particular to increased percentage of 
cells in S and G2/M phases and irregular shape of the G0 + G1 peak, as observed in case of 
chromosomal instability [19].  In a typical cell cycle analysis experiment (Fig. 5) the 
percentage of cells in phases S + G2/M of the cell cycle raised from 17% in HT1376Nc to 
28% in HT1376sT and from 28% in MCRNc to 33% in MCRsTn. Moreover, the G0 + G1 cell 
population of HT1376sT was contained in a broader and less regular shaped peak than the 
corresponding peak of HT1376Nc. These alterations are consistent with the predicted effects 




                                             
Fig. 5. FACS analysis of the cell cycle of BC cell lines. Cells were stained with propidium iodide and FACS 
analyzed. Data were acquired in linear scale. Normal human lymphocytes were used as reference of a 2N resting 
cell population in G0/G1 phases of the cell cycle (region under the left bar). The region under the right bar 
contains cells with a >2N DNA content corresponding to S + G2/M phases of the cell cycle. All four BC cell 
lines gave a major peak of 2N cells and lower percentages of cells in S and G2/M phases. In both, HT1376sT and 
MCRsTn. the percentage of cells in >2N phases was remarkably increased. Representative experiment of four. 
 
Effect of BCG challenging on whole gene expression in BC cell lines  
The effect of BCG challenging on global gene expression was evaluated by classifying genes 
modulated at least by a log2 expression ratio ≥ 1.0 (fold change of at least 2) in several broad 
functional categories (Table 2). BCG challenge on HT1376Nc resulted in up-regulation of 20 




down-regulated genes was 20 and 79, respectively. Surprisingly, there were no genes 
showing parallel and consistent up- or down-regulation in the two HT1376 cell variants using 
a threshold fold change ≥ 2.0, while many genes showed parallel regulation using a threshold 
fold change ≥ 1.4 (data not shown). ST3GAL1 expression made the HT1376 cell genome 
more susceptible to BCG modulation, with a higher number of down-regulated genes. In 
particular, we observed down-regulation of a set of genes related to "aminoacid and protein 
biosynthesis" only in HT1376sT (Table 2). This functional category includes genes involved 
in the biosynthesis and transport of aminoacids, attachment of aminoacids to tRNAs and 
regulation of translation. Genes involved in cell growth and survival, genome stability, 
intracellular transport, ionic homeostasis, lipid metabolism and transport, proteolysis and 
signal transduction were also more frequently modulated in HT1376sT than in HT1376Nc. The 
majority of the genes involved in post-transcriptional regulation were RNA genes, such as 
small nuclear RNAs (snRNAs), RNU2-1, RNU4-2, SCARNA9, RNU5B-1 involved in the 
regulation of splicing, and small nucleolar RNAs (snoRNA) RNU5B-1, SNORD116-2, 
SNORA70B, which are involved in chemical modification of other RNAs. Genes falling in the 
category of inflammatory and immune response were prevalently up-regulated in HT1376Nc 
and prevalently down-regulated in HT1376sT. This category includes genes involved in 
antigen presentation (HLA-DPB1), cytokine signalling (IFNGR1, IL20RB), phagocytosis 
(CD177, NCF1), NK activity (TXNIP, ULBP1).  
In the two MCR cell variants, BCG challenging resulted in modulation of a surprisingly low 
number of genes. The only gene expression change showing parallel modulation in MCRNc 
and MCRsTn was the up-regulation of HLA-DQA2, encoding the α2 chain of major 
histocompatibility complex class II DQ, although in MCRsTn the fold change was lower than 
2. The functional category more affected by BCG challenging, but only in MCRsTn cells, was 
“post-transcriptional regulation”. Eight of the nine genes of this category were snoRNA and 
one (RNU5B-1) was a snRNA. The vast majority of BCG-modulated genes displayed a fold-
change between 2 and 3. Rarely genes were modulated at higher levels. 
 
Discussion 
Despite its effectiveness in reducing BC recurrence, treatment with BCG still comprises more 




aberrant glycan (sTn antigen) expression by cancer cells and response to BCG [8]. This 
observation opened the possibility that glycosylation could be a predictive biomarker for 
response to BCG.  
The overexpression of both ST3GAL1 [20, 21] and ST6GALNAC1 [22-25] has been widely 
studied in cellular model of breast cancer and found responsible for increased malignancy. 
However, very little is known on the role of these two enzymes in bladder cancer biology [7]. 
In this work we performed an exhaustive analysis of BC overexpressing ST3GAL1 or 
ST6GALNAC1 sialyltransferases resulting in the expression of the sT or the sTn antigens, 
respectively. We observed that in MCR cells the expression of ST6GALNAC1 led to both 
sTn expression and T-antigen inhibition, confirming that the expression of a 
glycosyltransferase induces the concomitant up-regulation of the cognate carbohydrate 
structure and the inhibition of alternative carbohydrate structures [26-29].  
The secretion of cytokines [1, 30, 31] and the modulation of the expression of MHC 
molecules [32] are well known functional consequences of BCG interaction with BC cells. 
Our study confirms that BCG induces IL-6 and IL-8 secretion by BC cells and shows for the 
first time that the BCG response is strongly stimulated by the expression of sialylated TF 
antigens.  
However, the role of inflammatory cytokines in cancer is often a double edge sword. 
In fact, both IL-6 [33-36] and IL-8 [37-40] can either promote or inhibit tumour progression 
supporting the notion that inflammation is useful to eradicate the tumour but also provides the 
necessary soil for cancer growth and progression. A key role in determining the outcome of 
the inflammatory response triggered by BCG-stimulated BC cells can be played by 
macrophages, which can be polarized to functionally different phenotypes, known as M1 and 
M2. The first, through IL-12 secretion, drives the polarization of T helper cells toward the 
inflammatory Th1 phenotype, while the second polarizes T helper lymphocytes towards the 
anti-inflammatory Th2 phenotype, which is thought to favour tumour growth [41]. However, 
M1 and M2 phenotypes are extremes in a continuum spectrum of functional conditions [41]. 
Our macrophages, which mainly secrete IL-6, IL-8 and TNF-α but little or no IL-12/IL-10 are 
probably representative of an intermediate condition. The phenotype of macrophages is of 
particular relevance in the light of the recent finding that correlated a worse response to BCG 
with the presence of M2 type macrophages [42]. Our data show that the release of 




conditioned medium of BCG-challenged BC cells expressing sialylated TF-related antigens. 
This may explain why the expression of sTn and of sialyl-6-T antigens (the biosynthesis of 
both is dependent on ST6GALNAC1) is predictive of BCG response and is associated with a 
better recurrence-free survival [8]. Thus, BCG treatment turns the expression of sTn/sialyl-6-
T from an unfavourable condition associated with increased progression to a favourable 
condition associated with a better prognosis. This conclusion is of particular interest in the 
light of our recent observation that co-culture of MCRsTn (not challenged with BCG) with 
dendritic cells has the effect of inducing a tolerogenic phenotype in dendritic cells and in T-
lymphocytes [14]. 
Previous studies have shown that the gene expression profile undergoes profound 
changes in human BC, compared with urothelium [43] and in mouse urothelium after BCG 
treatment [44]. In this study we have assessed in the two BC cell lines the effect on whole 
gene expression of the forced sialyltransferase expression and the effect of BCG. The most 
prominent feature we observed as a consequence of the constitutive expression of ST3GAL1 
in HT1376 and of ST6GALNAC1 in MCR cells was the decreased expression of several genes 
whose common feature is the preservation of genomic stability. In particular, we found down-
regulated genes involved in different mechanisms of DNA repair and in the accuracy of 
chromosomal segregation during mitosis, suggesting that the expression of either 
sialyltransferase in the two cell lines can lead to forms of genetic instability. The alterations 
of the cell cycle we observed in the two sialyltransferase-transduced cell populations included 
the accumulation of cells in the S and G2/M phases of the cell cycle and, in HT1376sT cells, 
the irregular shape of the peak containing G0 + G1 cells. These alterations are consistent with 
a slow-down of the processes of DNA synthesis and mitosis, probably because of a more 
frequent activation of checkpoint mechanisms. Consistent with the reduced number of down-
regulated “caretaker” genes, these alterations were less dramatic in MCRsTn cells than in 
HT1376sT cells.  However, none of the down-regulated “caretaker” genes was switched-off in 
either cell line, suggesting that the expected alterations would be milder that those described 
in frank chromosomal instability caused by the homozygous inactivation  of APC gene in 
colon adenoma [19]. In both HT1376sT and MCRsTn, several genes controlling cell growth 
and/or apoptosis displayed modulation. In MCRsTn the changes toward increased malignancy 
were prevalent, in agreement with their reported slightly increased proliferation rate [7].  
BCG challenging resulted in the modulation of a larger number of genes in HT1376 cells 




BCG modulation, confirming that the presence/absence of sialylated TF-related glycans on 
the cell surface affects the development of the genetic program triggered by BCG contact. 
Even though genes involved in inflammatory and immune response were found modulated by 
BCG challenging in both HT1376 cell variants, little or no changes were observed in genes 
encoding MHC molecules and cytokines. This could depend on the sensitivity of the 
microarray technology, which is lower that other techniques, and/or on the role played by 
post-transcriptional mechanisms of control. This possibility is supported by the strong and 
consistent modulation of genes involved in post-transcriptional regulation. In particular, in 
both MCR cell variants the surprisingly low number of protein coding genes which were 
modulated was in sharp contrast with the high number of non-coding RNA genes which were 
up-regulated only in the MCRsTn variant. The majority of these RNA genes belonged to the 
group of small nucleolar RNAs, which guide the methylation or pseudouridylation of other 
RNAs [45, 46], regulating protein expression. Through this mechanism, BCG could 
profoundly alter the pattern of protein expression of bladder cancer cells through a gene-
expression independent mechanism. 
 
Conclusions 
In this study we have shown that the expression of sT and/or sTn antigens in BC cells induces 
changes of gene expression putatively affecting multiple cellular functions associated with 
increased malignancy. In particular, the down-regulation of genes responsible for genomic 
stability results in alterations of the cell cycle. However, the expression of sT and/or sTn 
antigens by BCG-challenged BC cells strengthen the inflammatory response of macrophages, 
indicating that the presence of these antigens can be a key factor for a successive BCG 





Materials and Methods 
Cell lines  
Both cell lines were from invasive transitional cell cancer of the bladder: HT1376 was from a 
primary tumour [47], while MCR was from a subcutaneous metastatic lesion [48]. Cells were 
grown in DMEM (4.5 g/L glucose, Sigma), containing 10% Foetal Calf Serum (FCS, Sigma), 
2 mM L-glutamine (Sigma) and 100 µg/mL penicillin/streptomycin (Sigma).  
 
Sialyltransferase-expressing cell lines  
HT1376 cells expressing ST3GAL1 and MCR cells expressing ST6GALNAC1 were generated 
through lentiviral transduction, as described [7]. The transduced MCR cells were enriched in 
their sTn positive population (MCRsTn), by magnetic-activated cell sorting (Miltenyi Biotec), 
using 1:50 diluted anti-sTn antibody (HB-STn1 clone, Dako) and magnetic sorting as 
recommended by the manufacturer.  
HT1376 cells homogeneously negative for T antigen, according to negative reactivity to 
Arachis hypogea (PNA) lectin, (HT1376sT) were obtained by selection of individual clones. 
About 100 transduced HT1376 cells were seeded in a 10 cm Petri dish and after one month 
nine colonies were randomly selected and the loss of the T antigen was detected by PNA-
FITC staining by flow cytometry (FACS) analysis.  
 
Flow cytometry 
Cells were stained with the following lectins or antibodies. PNA was conjugated with 
fluorescein isothiocyanate (FITC) as previously described [49]. The anti-sTn antibody (TKH2 
hybridoma clone) was kindly provided by Professor Celso Reis, University of Porto, Portugal. 
For anti-sTn staining, cells were incubated with 1:50 diluted TKH2 supernatant. , for 45 min 
at 4 ºC, and then with 1:100 diluted polyclonal anti-Ig-FITC (Dako). For PNA staining, cells 
were incubated with 1:20 diluted PNA-FITC.  Cells were then washed and FACS analysed. 
For the analysis of the cell cycle, cells were washed twice with PBS, gently suspended in ice-
cold 70% ethanol and kept at 4 °C 16 h. Then cells were washed once by centrifugation, 




0.08 mg/mL propidium iodide and incubated at 30 min at room temperature. Samples were 
FACS analyzed in linear scale. 
 
Real time RT-PCR 
Total RNA was isolated using the GenElute Mammalian Total RNA Purification kit and 
DNase treatment (Sigma), according to the manufacturer's instructions. One microgram of 
total RNA was reverse transcribed, using the random-primers based High Capacity cDNA 
Archive Kit (Applied Biosystems). The expression level of sialyltransferases ST3GAL1 and 
ST6GALNAC1 was evaluated with the TaqMan assay system (Applied Biosystems) in a 7500 
Fast Real-Time PCR System (Applied Biosystems) using the TaqMan Universal PCR Master 
Mix Fast as described previously [11, 14, 50]. The assay identification and the detected 
reference sequences were the following: ST3GAL1 (Hs00161688_m1; NM_173344.2; 
NM_003033.3); ST6GALNAC1 (Hs00300842_m1; NM018414.2). The efficiency of the 
amplification reaction for each primer-probe was above 95% (determined by the 
manufacturer). The normalized mRNA expression was computed as ‰ of the endogenous 
control β-actin gene expression, calculated by using the 2-ΔCT×1000 formula [51]. 
 
Sialyltransferase activity assays 
Cell pellets were homogenized in water and the protein concentration of the homogenates 
was determined by the Lowry method. The activity of the two sialyltransferases was 
measured in the homogenates in the range of linearity with regard to time and substrate 
concentration as follows. ST3GAL1 activity was assayed as previously described [52] with 
some modifications. The reaction mixture contained in a 25 µL volume: 50 mM of 2-(N-
morpholino)ethanesulphonic acid (MES) buffer pH 6.5, 0.5% Triton X-100, 23.5 µg of 
Galβ1,3GalNAcα1-O-benzyl (benzyl-T; Sigma) as acceptor substrate, 15 µM (640 Bq) of 
CMP-[14C]Sia (Amersham) and 50 µg of homogenate proteins. The enzyme reactions were 
incubated at 37 ºC, for 2 hours and the products were then isolated by hydrophobic 
chromatography in SepPak C18 Classic Cartridge (Waters). The columns were washed with 
water and eluted with 1 mL acetonitrile, which was counted in a liquid scintillation counter. 





ST6GALNAC1 activity was assayed as previously described [53] with some modifications. 
The reaction mixture contained in a 50 µL volume: 80 mM sodium cacodylate buffer pH 6.5, 
0.5% Triton X-100 (Sigma), 0.3 mg of asialo bovine submaxillary mucin (asialo-BSM, 
prepared by acid desialylation of BSM as acceptor substrate, 30 µM (1280 Bq) of CMP-[14C] 
Sia and 0.1 mg of homogenate proteins. The enzyme reactions were incubated at 37 ºC, for 2 
hours, then the acid-insoluble radioactivity was measured in a liquid scintillation counter. The 




Cells were treated with 20 mU of Clostridium perfringens sialidase (Roche Diagnostics), for 
90 min at 37 °C and after washing with PBS by centrifugation, they were stained and FACS-
analyzed as above. 
 
BCG internalization by cell lines 
Commercial Connaught strain BCG (ImmuCyst, Sanofi Pasteur SA, France) was suspended 
in PBS containing 0.05% Tween 80 and stored at -80 ºC. Before each assay, BCG aggregates 
were discarded by centrifugation (300 × g for 5 min). When required, about 1 O.D.600nm unit 
of single cell BCG was labelled with 2 µg/mL of orange cell tracker dye 5-(and-6)-(((4-
chloromethyl)benzoyl)amino)tetramethylrhodamine (CMTMR, Invitrogen) for 2 hours in 
growth conditions, and incubated for other 2 hours in one volume of growing medium. BCG 
internalization by BC cell lines was accomplished by co-incubating cell lines with stained 
BCG in a BC cell:bacteria proportion of approximately 1:10. Cell lines, seeded in 24 wells 
plates, were incubated with 0.25 O.D.600nm units of BCG, at 37 °C for 2 hours. Internalization 





Preparation of monocyte-derived macrophages 
Macrophages were obtained by differentiation of human monocytes from peripheral blood as 
follows. Blood from the Blood Collection Service of the Pizzardi Hospital of Bologna was 
diluted one fold with PBS and centrifuged at 200 × g, for 30 min at 20 ºC. The interface, 
containing the majority of the white blood cells, was diluted two folds with PBS and gently 
stratified in Ficoll-Hypaque (GE Healthcare) in a proportion of 5:3.7. Stratified preparations 
were centrifuged at 1200 × g for 30 min at 20 ºC and the white interface was carefully 
collected. This phase, containing the mononuclear cells, was washed abundantly with PBS, 
and cultured in RPMI 1640 (Sigma) medium supplemented with 20% FCS, 2 mM L-
glutamine (Sigma) and 100 µg.mL-1 penicillin/streptomycin (Sigma). Medium was daily 
renewed. After 7 days, monocyte-derived macrophages were detached with a cell scraper and 
dispensed in 24 well plates at approximately 50% of confluence for further assays. 
 
Macrophage stimulation  
BC cell lines were incubated with BCG as described above. Then the medium was removed, 
cells were washed twice with PBS and incubated with fresh medium without BCG. After 16 h, 
the conditioned media were collected and stored at -80 ºC, for further analysis. BC cells were 
washed, harvested and used for gene expression analysis. The media and cells mock treated in 
parallel without BCG were used as controls. The response of macrophages to components 
secreted by BCG-treated cell lines was assessed by incubating macrophages with conditioned 
media from BCG-challenged or unchallenged cell lines obtained as described above. After 2 
hours, the media were changed and 24 hours later collected and stored at -80 °C for further 
analysis. 
 
Detection of secreted cytokines 
The content of cytokines was measured by enzyme-linked immunosorbent assay (ELISA) and 
multiplex immune-beads assay (MIBA). IL-6 was detected with a commercial 96 wells 
ELISA kit Raybiotech) as recommended by the manufacturer. After evaluation of IL-6, ten 
cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, IFNγ and TNF-α) were 




manufacturer’s instructions. In short, a mix of colour-coded micro beads coated with each 
specific antibody recognizing each cytokine were incubated with supernatant sample in a 
filtered bottom 96 wells MIBA plate, for 30 min at room temperature. Further steps of 
incubation with a mix of antibodies for 30 min and with Phycoerythrin-streptavidin (PE-
streptavidin) for 10 min at room temperature were performed. Fluorescence was read in a 
Luminex 100 Bio-Plex Liquid Array Multiplexing System reader (Bio-Rad) and the data were 
analysed with the Bio-Plex Manager v5 software (Bio-Rad). 
 
Whole transcriptome analysis by expression microarray 
Total RNA was isolated by the guanidinium thiocyanate-method [54]. RNA was then 
converted to labelled single strand cDNA (ssDNA) by the commercial Whole Transcript 
Expression kit (Ambion), according to the manufacturer’s instructions. Labelled ssDNA 
fragments virtually covering the whole transcriptome of transduced BC cell lines were then 
hybridized in a Human Transcriptome Array 2.0 overnight. Arrays were then washed and 
stained with phycoerythrin-streptavidin and fluorescence was read in a GeneChip Scanner 
3000 7G (Affymetrix). Raw data were background-subtracted, normalised and summarised 
with the robust multi-array average (RMA) algorithm implemented in the Affy package of 
Bioconductor (http://www.bioconductor.org). Differential genes between query and control 
assay were selected by application of the t-test with a p ≤ 0.05 cut-off and by the log2 
expression ratio, considering only variations ≥0.5. Array data were analysed by the ArrayStar 
v2.0 software (DNASTAR) and through a literature search of the biological roles of 
modulated genes. Genes herein approached follow HUGO Gene Nomenclature Committee 
roules (http://www.genenames.org/), being represented in italic uppercase letters. With 
exception for cytokines, proteins herein discussed have the same name as the gene and are 
represented in regular uppercase. 
 
Abbreviations: BC: bladder cancer; BCG: Bacillus Calmette-Guérin; BSM: bovine 
submaxillary mucin; CMTMR: 5-(and-6)-(((4-
chloromethyl)benzoyl)amino)tetramethylrhodamine; DMEM: Dulbecco’s modified Eagle 
medium; FCS: foetal calf serum; FITC: fluorescein isothiocyanate; Gal: Galactose; GalNAc: 




morpholino)ethanesulphonic acid;  MIBA: multiplex immune-beads assay; PE: phycoerythrin; 
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Table 1. Genes involved in maintaining chromosomal stability and/or DNA repair showing down-
regulation in HT1376sT and/or MCRsTn cells.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
“Caretaker” genes showing downregulation in either cell line or in both are grouped in 3 functional 
categories. In bold are indicated genes identical or closely homologues showing parallel down-
regulation in both HT1376sT and MCRsTn. Genes in parenthesis displayed a fold change down-
regulation between 1.4 and 1.9. The other genes displayed a fold change down-regulation ≥ 2.  
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Table 2. Modulation of gene expression by BCG challenging. 
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Genes showing a fold change ≥  2  upon  BCG  challenging  were classified in broad functional 
categories. Each square represents a modulated gene according to this code:  up-regulation by 
BCG  ≥  4  (fold  changes);;    up-regulation  by  BCG  ≥  3,  <4;  up-regulation  by  BCG  ≥  2, <3;  
down-regulation  by  BCG  ≥  4;;    down-regulation  by  BCG  ≥  3,  <4;;    down-regulation  by  BCG  ≥  
2, <3 
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